Development of a patient reported experience measure in chronic obstructive pulmonary disease (COPD) by Hodson, Matthew
  
 
Development of a Patient 
Reported Experience 
Measure in Chronic 
Obstructive Pulmonary 
Disease (COPD) 
 
'The thesis is submitted in partial fulfilment of the 
requirements for the award of the degree of Doctor of 
Nursing of the University of Portsmouth' 
 
 
 
 
Matthew Hodson  
September 2014  
 
 
 
 
 
 
 
 
1 
 
 Abstract  
The experience of patients living with chronic obstructive pulmonary disease 
(COPD) and their views on the quality of healthcare they receive is not currently 
captured in patient reported measures.  
Aim: To develop and validate a patient reported experience measure to assess 
experiences of living with COPD and perceived quality of healthcare provision.  
Method: Previous work with 83 COPD patients identified 38 items for inclusion in 
a patient reported experience measure. These, together with the COPD 
Assessment Test and Hospital Anxiety and Depression Scale were administered 
to patients with COPD. Items demonstrating significant gender or age bias 
(p<0.05), floor or ceiling effects (set at 40%), missing data >15%, or high item to 
item correlations (r>0.8) were removed. Rasch analysis was applied to the 
remaining items.  
Results: 174 patients (Mean age 71 years, SD 9; 91 female; Mean Forced 
Expiratory Volume1 59%, SD 21.9) were studied. 29 items were removed, 
providing a 9-item unidimensional scale (chi-square p=0.33) with a wide scaling 
range (logits from -0.1 to +0.2). These cover experiences of living with COPD (e.g. 
I feel that I am in control of my condition) and health care (e.g. I am concerned that 
my GP won't listen to my point of view). Internal consistency was good (PSI= 0.77) 
and correlations between the COPD PREM-9, COPD Assessment Test and 
Hospital Anxiety and Depression Scale were moderate (r=0.42 and r=0.30, 
respectively).  
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Conclusions: The  COPD PREM-9 demonstrated good internal reliability and 
showed a wide scaling range suggesting, regardless of severity, people with 
COPD can have good or bad experiences. There were low to moderate 
correlations with the COPD Assessment Test and Hospital Anxiety and 
Depression Scale, which suggests the PREM COPD-9 is measuring a different 
concept. The COPD PREM-9 may be a useful measure of quality of care that 
complements measures of health status and mood. 
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CHAPTER ONE 
1. Background context 
1.1. Introduction 
Chronic Obstructive Pulmonary Disease (COPD) continues to be a significant 
disease. It is growing globally, estimated to affect between 2–5% of the adult 
population and is responsible for about 5% of all deaths in England (National 
Institute of Clinical Excellence [NICE], 2010). It is the second most common cause 
of emergency admission to hospital. Approximately 14% of patients admitted to 
hospital with COPD will have died within 90 days, and a further 32% will have 
been readmitted within the same time span. The 2003 National COPD Audit has 
shown significant deficiencies in both acute hospital and community care for 
COPD patients, when measured against guidelines or top quartile performing 
Trusts (Price et al., 2006). In response to these alarming statistics, the Department 
of Health has created a National Service Strategy and Framework Document  
(DoH 2012) with suggests the measurement of patient outcome metrics.  
These metrics recommend the recording of both Patient Reported Experience 
Measures (PREMs) and Patient Reported Outcome Measures (PROMs) but 
currently there are no disease-specific PREMs for COPD (Hodson, Andrew, & 
Roberts, 2013) that could be used by clinicians to measure the experience of living 
with COPD. There are, however, a number of PROMs used routinely and 
extensively within the respiratory community to capture data (Jones et al., 2001). 
Therefore, this study will seek to develop a validated and reliable new PREM 
instrument that can be used specifically with patients with COPD to complement 
the existing PROMs.  
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This first chapter will introduce COPD as a global disease and its impact on the 
quality of patients’ lives, as well as seek to understand the burden the disease 
imposes upon patients and the frequent need for people to access healthcare.  
The reasons for collecting patient data in healthcare will also be discussed 
defining the national direction. There will be an emphasis on the many different 
aspects of patient experience, drawing upon the national polices which link 
together the concept of safety, patient experience and clinical effectiveness which 
formulates a recipe for quality patient care (Dazi et al., 2008).  
This chapter will also discuss the programme of previous work undertaken by the 
North East London, North Central London and Essex Health Innovation Education 
Cluster on the initial stages of the development of a new preliminary PREM 
instrument know as Study One. Chapters Two and Three will explore the current 
literature behind experience moving to its relationship with COPD and other forms 
of healthcare measurement. Chapters Four, Five and Six introduce  
the methodology, the methods and the results of the formation and subsequent 
development and validation of the new COPD PREM instrument (known from now 
on as Study Two). The final two chapters, Seven and Eight discuss the findings  
of the PREM instrument and its proposed and future use within the clinical 
respiratory field.  
1.2. Chronic Obstructive Pulmonary Disease (COPD) 
COPD is a complex, long-term condition leading to both high mortality and poor 
morbidity (Rabe et al., 2007). For people living with the disease it places a heavy 
burden of symptoms which are often made worse in acute exacerbations or flare-
ups of symptoms leading to reduced quality of life. For many people, managing to 
live with the disease can be isolating and frightening, and can induce high anxiety 
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and depression (Roche, Chavannes, & Miravitlles, 2013) both on the patient  
and his or her carers. 
1.3. Defining Chronic Obstructive Pulmonary Disease (COPD) 
COPD is defined as a disease characterised by the presence of airflow 
obstruction, which is generally progressive, not fully reversible, and not changed 
markedly over months (NICE 2010). COPD is a universal umbrella term used 
internationally to describe the irreversible effects of chronic bronchitis, 
emphysema, and chronic asthma (Calverley, 2013). Although different conditions 
themselves, there is wide consensus (Global Obstructive Lung Disease [GOLD], 
2014), that they are related terms which describe airflow obstruction due to a 
combination of airway and parenchymal damage. The chronic inflammatory 
damage in the airways and alveoli results in a loss of elastic recoil, bronchospasm 
and an increase in sputum production and coughing. Long-standing asthma can 
also lead to irreversible airflow obstruction (Lange, Parner, Vestbo, Schnohr, & 
Jensen, 1988, p.1194) and there is, therefore, a clinical overlap between Asthma 
and COPD (Pauwels & Rabe, 2004, p. 613) in both its chronic and acute forms. 
1.3.1. Prevalence 
 
The prevalence of COPD continues to grow due to the growing rate of tobacco use 
worldwide. However, the disease continues to be mis-diagnosed and its true 
prevalence is therefore understated. A cross-sectional study of GPs demonstrated 
that both an observed and modelled COPD prevalence in England ranged from  
a ratio from 0.20 to 0.95 (Mean 0.52), suggesting, therefore, that this ratio  
of observed to expected new cases of COPD is low (Nacul et al., 2011). 
Worldwide, respiratory disease including COPD is the cause of approximately  
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4.2 million deaths yearly (Wagner & Brath, 2012), and is the fifth leading cause of 
death in Great Britain (British Lung Foundation [BLF] 2007). Recent research 
(Shahab  et al., 2006) suggests there are 3.7 million people living with COPD  
in the UK, yet only 900,000 people have been diagnosed with the lung disease 
(NICE 2004). The World Health Organisation suggests that globally there are  
64 million people living with the disease. COPD therefore continues to be a 
significant burden placed on society across the globe, however exact figures on 
prevalence of COPD are underestimated and difficult to predict from the literature 
(Halbert et al., 2003, p.523). In 2010-11 the NHS spent £720 million of its £4 billion 
respiratory budget (Department of Health [DoH], 2012) on COPD alone with 
clinical commissioning groups (CCGs) spending an average range of £12m  
to £40m a year on respiratory disease depending on the CCG’s demography and 
population size. 
1.3.2. Clinical Features 
 
COPD is a heterogeneous disease that affects different people in different ways. 
 It is, however, a respiratory disease that can be very disabling due to the 
symptoms of dyspnoea, fatigue and social isolation caused by embarrassment 
over chronic sputum production or coughing because of a perceived general lack 
of understanding over this long-term condition. The disease is predominantly 
caused by smoking. There are also a number of other factors associated with 
COPD such as air pollution, socio-economic background, and occupation 
exposure such as coal miners (NICE 2010). Other respiratory diseases and 
malnutrition have also been linked to the onset of COPD (World Health 
Organisation [WHO], 2002).  
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COPD is diagnosed by clinical judgement including a clinical history of cough, 
exertional breathlessness, wheeze, winter bronchitis and exposure to risk factors 
in patients over 35 years (NICE 2004). Objective measurements to confirm the 
diagnosis of airflow obstruction can be recorded using a spirometer. Airflow 
obstruction is defined as a reduced Forced Expiratory Volume (FEV1) in one 
second and a reduced FEV1/FVC ratio (Forced Vital Capacity) of less than 70% 
(NICE 2010). There are now widely accepted pharmacological approaches to 
optimise the management of COPD in both its acute and chronic setting with the 
use of inhaled and oral medication (GOLD 2014) along with smoking cessation 
interventions. More non-pharmacological approaches to COPD care are also 
recognised, for instance intervention such as Pulmonary Rehabilitation (PR) and 
breathing control groups. 
1.4. National Context of Patient Experience  
 
The national drive to improve the quality of care for patients by putting people at 
the heart of their own care is not just about being involved in the decisions around 
care, but also being involved in the experience of healthcare. Being able to record 
and report the experience alongside the experience of living with the illness or 
disease is a key factor. But how does the National Health Service (NHS) capture 
this and what does the bigger picture look like? These are questions that 
healthcare professionals including nurses need to explore further to generate  
a greater understanding of why the measurement of patient experience is key  
to improving and driving quality change in the NHS.  
The much-needed national refocus on ensuring that patients remain at the heart of 
healthcare and reporting patient experience is now becoming an integrated part of 
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nursing and trust strategies. An historic example of poor experience and care is 
the high profile case of care at Mid-Staffordshire Hospital. The Francis Report 
(Francis, 2013, p.41)  clearly identified a vast number of systemic failings which 
led to serious patient harm and where quality and patient experience were not 
measured or, if they were, the findings were not acted upon. The report also 
highlighted that patients were not listened to either in a proactive way through 
feedback or through reactive means such as complaints. This widely publicised 
report was highly influential, and has led to some of the recent widespread 
changes in key areas such as Trust values being built upon the expectation of 
providing quality services. Much of this has been driven by the national focus on 
and subsequent shift towards listening to the patient voice as a key driver for 
change, moving away from the traditional NHS focus on activity, waiting times and 
targets (Raleigh & Foot, 2010). A key recommendation from the Francis report 
(2013) was recommendation 254: 'the gathering of patient comments and the use 
of patient feedback.' 
In April 2013, changes in the National Health Service and Department of Health 
refocused on the ‘new NHS’ with the creation of NHS England and many other 
authoritative bodies responsible for the patient voice such as Healthwatch and 
clinical commissioning groups. Within the many new changes in the NHS structure 
and formation of health policy a domain lead for patient experience along with  
a further four domains within the newly created NHS England were created. The 
vision of the new NHS (2013) is that:  
Everyone has greater control of their health and their wellbeing, supported 
to live longer, healthier lives by high quality health and care services that 
are compassionate, inclusive and constantly improving 
 
22 
 
The main focus for healthcare providers in delivering this vision is that of a ‘high 
quality̕ service, and built into this is the need for a p̔ositive patient experience’  
The biggest concept at present by NHS England (2013) is the introduction of the 
Family and Friends Test by simply asking patients whether they would recommend 
the hospital, ward or accident and emergency department to a friend or relative 
and through a transparent NHS this data is published and shared in the public 
domain. But this doesn’t go far enough. Firstly there is little published data on the 
outputs from the family and friends test. In a study of 142 hospitals, results 
showed only mild to moderate correlation with other quality indicators such as the 
NHS inpatient survey (0.46 p<0.001) & hospital mortality indicators (0.21 p =0.01). 
(Greaves, Laverty, & Millett, 2013, p.396). And if we look further at disease-
specific areas, asking such a question has caused distress and anxiety,  
as demonstrated by a recent letter to the editor of the BMJ which suggested such 
among inpatients living with cancer and receiving chemotherapy (King, Eyre, & 
Bruce, 2013, p.346). In 2009, a systematic review by Naidu, (2009, p.366)  
of patient satisfaction made suggestions that friends and family are the observer 
groups that potentially represent future patients who therefore could become major 
influencers of patient healthcare choices. The NHS therefore must ensure that 
patient experience is captured, while not confusing the terminology (between 
satisfaction and experience).  
As well as the previous reports, The NHS Constitution (2013) also makes it clear 
that ‘high quality care is for all’ and is key to the success of quality in the NHS by 
building on the previous work undertaken by Professor Lord Darzi (DoH 2008).  
He recognised the enduring principles and values of the NHS; the constitution 
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gives readers clear signposting to the rights and responsibilities for patients, public 
and staff. Key aspects of this important legislation are: 
• Empowering all patients and the public;  
• Creating shared purpose, values and principles;  
• Strengthening accountability through national standards for patients.  
In a subsequent follow-up report in 2009, (High Quality Care for All – Our Journey 
So Far), three defining components which mattered to patients were identified: the 
effectiveness of care interventions, the experience of the patient and the safe 
delivery of healthcare (Figure 1.1). 
 
Figure 1.1 Key components to healthcare, according to patient experience 
 
It is these three guiding principles around which quality of care and nursing 
strategy is now built in many healthcare providers. In 2011, the Department  
of Health produced the NHS Patient Experience Framework which clearly defines 
the concepts of healthcare critical to the patient experience, as defined  
by patients, and will be discussed further within Chapter Two.  
The National Institute of Clinical Excellence also worked on the need to develop 
quality in healthcare and continues to develop the introduction of NICE Quality 
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Standards which cover diseases and complex health areas from stroke to cancer 
care. This is aimed at achieving a range of national standards with a central focus 
on improving quality care in a specific field. To help achieve this, NICE published, 
in 2012, a quality standard for the patient experience. These are a set of fourteen 
priorities aimed at improving quality, which would be benchmarked against quality 
indicators (NICE 2012). These support previous work ensuring that patients are 
central to care and ensuring the best possible experience of care provided by the 
NHS. Other countries are also developing government policy in response  
to growing need. In Australia, for example, the federal policy for long-term 
conditions is based upon patient experience, and as discussed in the paper by 
Corcoran et al., (2013, p.19), who emphasise that understanding the patient 
experience can help influence healthcare providers deliver services based and 
tailored upon individual patient needs.  
The USA, for many years, worked to develop ‘patient-centeredness’ and improve 
the patient experience throughout the US Health system. The Picker Institute led 
the way in programmes of work to capture this through survey design, 
questionnaires and dissemination of work across the US and the US Department 
of Health by developing the Human Services National Quality Agenda (Picker 
Institute, 2013a). 
The national UK mandate and focus on experience is complex. There has been  
a real clear shift within the National Health Service and NHS England to ensure 
that services, staff and patients play an integral role in the future of the NHS and 
that patient experience is central to the measurement of quality alongside patient 
safety and clinical effectiveness. 
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1.5. Quality Measurement in Healthcare 
 
An appreciation of why we measure in healthcare is an important aspect of 
ensuring that quality care is being commissioned and delivered. The evaluation of 
healthcare is continuously evolving with the patient perspective increasingly 
sought to provide high-quality care for patients at the centre of their own 
healthcare. The concept of collecting patient data in healthcare will now be 
explored drawing upon the national direction, and making the association further 
between quality and patient experience.  
‘Self-report’ questionnaires are increasingly being used to gather information about 
patients’ health-related quality of life. The actual outcomes of the treatment, along 
with their experience, and the recorded perceptions of care delivered by their own 
healthcare team are all considered. Patient satisfaction measures may be familiar 
to clinicians and researchers as they are used routinely in many clinical settings as 
a benchmark of quality (Crocker, Lewandrowski, Lewandrowski, Gregory, & 
Lewandrowski, 2013;  Wiebe et al., 2014). Patient satisfaction measures, however, 
have a ceiling effect, a point at which scores for the measurement have reached 
their highest point, potentially masking the negative health care experience             
(Hodson et al., 2013, p.359). In many cases, patient satisfaction questionnaires 
are generic and loosely constructed thereby not supporting any change or adding 
to the richness of patient experience or disease specific measurement. 
1.6. Patient Reported Experience Measures (PREMs) in Context 
 
The main objective of this study is to understand the complex experience  
of people living with COPD, and the disease’s effect on their daily life, as well as 
their experience of interacting with the healthcare system, for example the 
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interaction between patients and their General practitioner or COPD team.  
How this is measured and the descriptors in which patients describe this 
experience will be a focus of this study. 
The strategic development of an overarching programme of work in COPD was 
begun by the North East London, North Central London and Essex Health 
Education and Innovation Cluster (NECLES HEIC), in partnership with Anglia 
Ruskin University of which the author was a fellow. One strand of this work was to 
measure the patient experience in COPD. The first programme of this work (‘Study 
One’) was to develop a set of descriptors and eventually items (a set of questions) 
to formulate a preliminary instrument to describe the experience of living with 
COPD and patients’ experience of interaction with healthcare professionals.  
In summary, Study One was a qualitative study resulting in the generation of  
52 items using a number of descriptive terms to describe COPD experience, of 
which further detail is provided in Chapter Two. This work fed into Study Two  
(this thesis) in which the author led on all aspects of its development with the aim 
of creating a disease-specific PREM instrument to be used by healthcare 
professionals aimed at benchmarking and improving the overall quality of care and 
services for patients living with COPD. 
An understanding of different dimensions in COPD care through experience 
developed from the language and descriptors used by patients to validate and test 
this PREMs questionnaire in COPD. This questionnaire may help to generate  
a greater understanding of the patients perspective in providing quality services for 
people living with COPD in the future, through its potential use in clinical audit  
or patient assessment. A definition for patient experience is varied (Cornwell, 
2012, p.1; Pemberton & Richards, 2013, p.19) and widespread according to its 
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meaning and measurement in the context of healthcare (Hodson et al., 2013). 
Currently, measurement of the experience in COPD is by generic instruments and 
a more disease-specific instrument is needed rather than focussing current 
assessment around the objective measurements recorded through PROMs, for 
example walking distance or health-related quality of life. Other PROMs also tend 
to focus more on areas such as the patient’s breathlessness, physical activity and 
patient reported symptoms such as cough and sputum. PREMs, however, are not 
only measures, but also provide a more patient-centric view of overall healthcare, 
but are often confused and used together with no clear definition or are simply 
measures of patient satisfaction or a form of a PROM. 
This study will also make further distinctions between patient satisfaction, PROMs 
and PREMs as measures of healthcare detailed in Chapter Three. An appreciation 
of the relevant literature is presented with a clear focus on the need for a definition 
of experience in healthcare and its relation to the experiences of people living with 
COPD. The primary objective of this thesis was to develop a new instrument for 
use to measure the experiences of people living with and their utilisation  
of healthcare, specifically with those living with COPD. 
1.7. Following Chapters 
 
The concept of measuring and generating new ways of recording patients’ 
experience is not a new phenomenon in healthcare, and the Literature Review 
(Chapter Two) explores this concept, drawing upon the evidence and premise 
undertaken in Study One that there is currently no published PREMs in COPD and 
will be discussed further alongside a demonstration of how other instruments for 
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long term conditions have captured and recorded the patient experience and other  
measures of quality of life and recording outcome measures (Chapter Three).  
Chapters Four to Six convey the original research work conducted in Study Two, 
with the research plan presented in Chapter Five. The method of reducing items to 
formulate the final PREM COPD-9 (Figure 7.1), which is a reliable and validated 
measurement of experience through the application of hierarchical methods of 
item reduction and Rasch analysis, is discussed further in Chapter Five. Chapter 
Six explores the preliminary results of reliability testing and the primary structure  
of the newly created instrument. Chapter Seven discusses testing the instrument 
with other widely validated instruments in COPD to measure health related quality 
of life, in discussion with current literature and reported experiences of living with 
COPD. Finally, Chapter Eight will provide a summary of the study and the 
implications for clinical practice, personal reflection and suggestion for further 
research.  
It is clear that the focus and shift of the measurement of quality healthcare has 
moved at a rapid pace and therefore the need to measure the experience  
of people living with COPD is paramount given the global prevalence the disease 
imposes on society and the heavy burden of symptoms placed on individuals living 
with the disease. Developing this instrument can help to evaluate effectively the 
services that are commissioned using the most appropriate disease-specific tools. 
Therefore, the COPD-PREM 9 may be a useful measure in clinical audits of quality 
of care, as well as being useful for patient assessment, and may complement 
other measures used in COPD care such as health related quality of life 
questionnaires (Roberts, Andrew, Walker, Hodson, & Hudson, 2012) 
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CHAPTER TWO 
 
2. Literature Review 
 
2.1. Introduction 
 
In the opening chapter, COPD was introduced as a long-term condition with  
a heavy burden of symptoms on the patient’s quality of life and healthcare. The 
national context of NHS healthcare and the need to measure patient experience 
was also introduced and discussed along with the further need to explore the 
development of a disease-specific instrument to measure COPD patient 
experience, known as a PREM.  
In Chapter Two we start to examine existing literature around patient experience, 
discovering what the most important aspects about living with COPD we need  
to understand, mainly through qualitative methods of data collection and analysis. 
There are a number of key issues and themes which are important to explore 
further in the rigorous literature review on experience and COPD. Firstly, however, 
it is important to understand further the concept of experience and what we mean 
by it, how we define it, and then drawing the link between quality care and patient 
safety. 
2.2. Experience 
 
There can now only be a general consensus that patient experience  
is fundamental to the delivery of high quality patient centred care in the NHS and 
is central to the evaluation of healthcare services and the delivery of quality care, 
as there is now good evidence (Doyle, Lennox, & Bell, 2013, p.1) that there is  
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an important and positive relationship between patient experience, effectiveness 
and safety as outlined in the introduction to this thesis. Black et al., (2014, p.534) 
found that there was a weak correlation between experience and outcome after 
knee surgery and therefore, it could be argued that the measurement of clinical 
outcomes and the views and experiences of patients must be seen as discrete 
concepts (Graham & MacCormick, 2012). 
It is therefore important that the assessment of quality services should potentially 
include measures of both clinical performance and the experience of patients 
where possible, the measurement of which will be discussed in more detail in 
Chapter Three. The definition of experience and the understanding of the basic 
principles of what we as clinicians mean by experience has become confused in 
the last twenty years (Hodson et al., 2013, p.359). A simple definition of 
experience comes from the Oxford English Dictionary (2013, p.214) is an event 
from which ‘you learn, or gain knowledge and skill through practical involvement’   
Experience, however, can be broadly categorised in two main areas: firstly, 
experience which consists of knowledge or skills learnt, for example in a job, 
or activity such as learning a musical instrument; secondly (and this is closer to the 
dictionary’s definition) experience which is gained through exposure to an event 
that leads you to make a judgment about part of your life. Therefore,  
the experience of quality healthcare should be a positive experience and it is 
critical to ensure that the NHS provides quality, compassionate care, as many 
people will experience different journeys and come in to contact with healthcare 
professionals and services, all adding to the creation of 'new knowledge' which 
leaves an impression long afterwards. The Beryl Institute, an American global 
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leader of patient experience, cited in LaVela & Gallan (2014, p.29), defines  
the patient experience as: 
the sum of all interactions, shaped by an organization’s culture, that 
influence patient perceptions across the continuum of care. 
 
They also suggest that this is a wide definition, but despite this uncertainty of what 
to measure or which underlying construct to focus on, there is general consensus 
that patient experience in a health care framework incorporates the patient’s 
journey as a whole and that it is a significant aspect to measure: clinically, 
practically and managerially (LaVela & Gallan, 2014). 
2.3. Customer experience – has business shaped measurement in health? 
There have been a number of publications (Health Foundation [HF] 2013) 
discussing the different concepts of experience, not just in healthcare, but in many 
areas of life. The need for consumer feedback is important and has been 
measured in many different ways such as star ratings, online questionnaires 
and ̔smiley face̕ rating your experience of service. But exploring further the 
concept of ‘customer experience’. Harvard Business School’s suggestion is that 
customer experience is the internal and subjective response customers have to  
a direct or indirect contact with a specific company (Meyer & Schwager, 2007, 
p.2).  Direct contact is your experience of interaction with a customer assistant 
while discussing a product or in the purchasing of goods for example; indirect 
contact is interaction you have remotely, maybe with a website or an unplanned 
encounter for example a review of a company in a magazine which talks about 
others’ experiences. But, ultimately, the direct and indirect relationships  
in consumer markets make a direct impact on the positive or negative experience 
of an encounter. It is also clear that in customer experience people have 
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expectations around the service being delivered and these experiences can be 
instinctively compared either positively or negatively, but it is imperative that these 
judgments are managed and effectively thought through. It is clear, however,  
that interest in customer experience has developed over the last five years,  
as Verhoef et al. (2009, p.31) would argue that in 2009 the current literature, much 
like the health service, did not see the ‘customer experience’ as a separate 
construct or priority and had focussed much more on the satisfaction and service 
quality in the marketing, retail or service organisation. 
For a long time, the US market, for example, have been working hard to develop 
their customer satisfaction strategy, focusing on two main aspects: high customer 
satisfaction for service quality; and financial stability, ensuring that companies 
retain customers (Hayes, 1998). Thus the application of the principles 
underpinning satisfaction within healthcare were borrowed from the service 
industry, backed by a tenet of consumerism, and an increasing recognition of 
service user opinion (Darzi, 2008; Oliver, 1993; Sitzia & Wood, 1997). This 
concept of improved satisfaction in local services and the growing previous need 
to evidence positive feedback is even more apparent with healthcare regulators 
such as the Care Quality Commission (CQC). A growing body of evidence 
(Fornell, 1992; Narver & Slater, 1990) outside public services suggests that the 
long-term success of an organisation is undoubtedly based on its capability  
to react quickly to changing customer needs, preferences and the ability to support  
a higher competitive position (Bayraktar, Tatoglu, Turkyilmaz, Delen, & Zaim, 2012 
pp.99-104).  
Taking these concepts further, in the NHS there has been a large number  
of patient satisfaction scales (Jennings, 2013; Wiebe et al., 2014) developed and 
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used in practice today which include measurement in specific diseases. 
Satisfaction tools may be generic, measuring satisfaction with care given by  
a healthcare professional or service (for example by asking ‘would you 
recommend this GP to others?’) or condition specific (‘Did your respiratory doctor 
give you sufficient information about how to manage your COPD?’). A systematic 
review of factors affecting patient satisfaction and quality by Naidu, (2009, p.367) 
claims that patient satisfaction is multi-dimensional, affected by a number of 
variables which affect healthcare quality:  
Healthcare quality affects patient satisfaction, which in turn influences 
positive patient behaviours such as loyalty. Patient satisfaction and 
healthcare service quality, though difficult to measure, can be 
operationalised using a multi-disciplinary approach that combines patient 
inputs as well as expert judgement (Naidu, 2009, p.366). 
 
Ware et al., (1977, p.2-5), through a review of 111 articles on patient satisfaction 
and healthcare published between 1951 and 1976, identified the main themes as: 
the technical quality of care, accessibility/convenience; finances (an American 
study), physical environment, availability, continuity, and outcomes of care. 
Subsequent summaries (Tucker & Adams, 2001, pp.272-273) of the measurement 
of satisfaction in healthcare continue to relate to a number of key areas such as 
the patient’s satisfaction in interactions with providers, the ease of access,  
the burden of costs, and the environmental issues such as cleanliness of the 
health care facilities. These, of course, remain the foundation of current patient 
satisfaction with healthcare, and continue to be measured and developed  
in current healthcare design and structures. For example Weston et al., (2010, 
p.584) concluded from their systematic literature review that there were  
no published patient satisfaction questionnaires in sexual health, so used a 
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qualitative design method to develop and validate an instrument. The results 
generated by the questionnaire continue to reflect the traditional approach to 
patient satisfaction, focusing on themes identified back in 1951 such as whether 
the nurse was ̔friendly̕ and ̔approachable̕ with a scale of ̔yes̕, 'to some extent' 
and ̔no̕.  
Patient satisfaction scales, however, have a ceiling effect, in that most patients 
score their care highly, and therefore there may be very little discrimination 
between items (Andrew, Salamonson, Everett, Halcomb, & Davidson, 2011; 
Cappelleri, Gerber, Kourides, & Gelfand, 2000) and give very biased results.  
In clinical circles they are irreverently referred to as the ̔happy scale̕ as illustrated 
in Figure 2.1 and can only reflect satisfaction in comparison to scales such as the 
visual pain assessments commonly used in healthcare. 
 
Good                                                                   Bad 
Figure 2.1 Happy scale  ̶  example 
 
Clearly, however, not all patients are ‘happy’ with their care and satisfaction scales 
may mask negative experiences (Andrew et al., 2011; Williams, Coyle, & Healy, 
1998). A study of 21 EU countries (Bleich et al., 2009, p.271) stresses that 
satisfaction is also linked to much ‘broader societal factors’ such as the wealth  
and prosperity of a country. Frustration with patient satisfaction surveys (Bleich et 
al., 2009; Cleary, Edgman-Levitan, McMullen, & Delbanco, 1992;  Cleary, 2009) 
led to recommendations that the focus should shift from satisfaction with care  
to patient experience of care. Williams et al., (1998, p.1358) recommended that   
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High satisfaction ratings do not necessarily mean that patients have had 
good experiences in relation to that service. If the underlying policy purpose 
of satisfaction surveys is to provide patients with a voice in the assessment 
and continuing development of services then it is not adequate to utilise 
satisfaction survey results. Effort must be put into designing methods of 
assessing patients’ experiences of services and the meaning and value 
they attach to them, whether these are positive or negative and whether 
they can be improved.  
 
This is where healthcare professionals’ understanding of patient satisfaction and 
experience is confused by the inconsistent use of terminology. Delnoij (2009, 
p.354) claims that one of the major problems with patient satisfaction is its 
indistinctness, being ill defined or not clear in its measurable outcome.  
And therefore other methods of reporting and collecting data such as the use  
of PROMs and the further development of PREMs are currently considered 
alternative ways of collecting, reporting and recording a richer and more relevant 
set of information than patient satisfaction surveys (Whelan, Reddy, & Andrews, 
2011). 
Drawing upon previous papers, Tynan & McKechnie (2009, p. 501) claimed the 
idea of ‘customer experience’, as holistic – building on the experience  
of consumers as ‘individuals’  and as a single voice. This relates well to the holistic 
needs of individual patients and the concept of patient-centred care, moving away 
from the traditional patient satisfaction approach. Gentile et al., (2007, p.397) 
describe the consumer experience as an: 
Experience which is strictly personal and implies the customer’s 
involvement at different levels (rational, emotional, sensorial, physical, and 
spiritual) 
 
Therefore, reflecting back on the overview of constructs of the consumer 
experience and building up the need for the customers’ view point of generating  
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a customer friendly image, the need for promoting the right patient-centred 
healthcare is fundamental to all those who are delivering healthcare services such 
as nurses and allied health professionals. This has been strengthened by the 
commitment made by the Department of Health and NHS England to embrace and 
strengthen the need for the ‘customers’ involvement’, if we reflect on the definition 
by Gentile et al (2007). 
Creating and promoting new ways to capture and collate patient experience has 
evolved over the last ten years (NHS 2013). This evolution has stemmed from the 
plethora of national policies (NHS Constitution; NICE 2012) and drivers aimed  
at focusing health service organisations to embed patient experience into 
organisational strategy, promoting a continued positive patient experience for now 
and the future. Specifically, the Operating Framework for the NHS 2012/13 states 
clearly that patient experience should be collected in real time and used to 
improve local services; whereas, the NHS Outcome Framework, designed to be 
the overarching strategy for the NHS England, has patient experience as one  
of five domains aimed at set high-level outcomes to be disseminated throughout 
the NHS (NHS 2013). 
2.4. Patient Experience Overview 
 
We have so far discussed how patient satisfaction and how the business principles 
of customer satisfaction are linked and the importance of where experience  
in business has started to influence the direction of quality in this area and 
therefore underpinning the development of polices and drivers within the NHS as  
a theme. One milestone in the development of the understanding of patient 
experience in general was achieved in 2010, in a literature review commissioned 
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as part of a wider project by the Department of Health and King’s Fund called 
‘What Matters To Patients? Developing the Evidence Base for Measuring and 
Improving Patient Experience’ (Department of Health and Kings Fund, 2010). This 
report states a number of important aspects to the understanding of patient 
experience: the clearest is that the number of studies that had been undertaken in 
patient experience – whether it be a systematic review or results from the NHS 
national patient NHS survey (Coulter, 2005, p.1119), or more discrete (Cunnett, 
2010) trust-wide reports. These findings draw together a common number of 
similarities in views or opinions by patients in connection with their experience or 
‘satisfaction’ of NHS care. These similarities are evident in ‘reports’ or research 
whether their data collection was from a focus group or through postal surveys.  
The 'What Matter to Patients’ (Kings Fund,2010) report and subsequent work by 
Coulter et al. (2014 p.119) and Cunnett (2010) now conclude that we have rich 
data to understand what is important to patients and its relationship is key to the 
connection that patients expressed in their aspects of care like dignity, empathy 
and emotional support which are incredibly important in terms of reflecting on the 
overall patient experience’ together with more functional features such as access, 
waiting, food and noise (Glenn & Cornwell, 2010, p.20). These features  
of experience are also not dissimilar to the findings of the COPD PREMs Study 
One work which is picked up later in the second section of this literature review 
(p.124). The initial definition of experience simply suggested that experience was 
based upon an impression that the event leaves on ‘someone’, of course in this 
context, the ‘patient’. The NHS institute for Innovation and Quality have stated that 
there are a number of different aspects and policy drivers of experience captured 
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by the health service and that a focussed report from the King’s Fund led to the 
development of a National Patient Experience Framework (Appendix Two). 
2.4.1. NHS Patient Experience Framework 
 
So it is clear that these policies (NHS Operating Framework, The NHS Outcomes 
Framework & NHS Constitution) has focused a more detailed approach  
to experience and in 2011, the NHS made a commitment to putting patient 
experience at the centre of its evaluation of the quality of care by developing the 
NHS Patient Experience Framework (Figure 2.2). The Department of Health made 
the commitment to develop this framework which was agreed by the NHS Quality 
Board (NQB) which is a multi-stakeholder board within NHS England to champion 
quality and ensure alignment in quality throughout the NHS. The aim of the NQB  
is to bring together all those with an interest in improving quality and embedding 
this in everything within the NHS, of which patient experience is a driver.  
The framework is designed to help guide the measurement of patient experience 
and clarify the critical elements as the guiding principles within the NHS. This 
framework was based upon the previously discussed research published by the 
King’s Fund and King’s College London. A final aspect of this research proposed 
that it is possible to apply a unified generic framework for patient experience to  
a large number of health-related conditions and settings, and thus finally 
recommended that the Department of Health adopted a common single framework 
for this purpose (DH 2012). The framework however, was modified and is based 
upon a version of the Picker Institute Principles of Patient-Centred Care, an 
evidence-based definition of a good patient experience (Picker Institute, 2013b). 
However, the founding principles remain the same by asking and collecting patient 
data and utilising these values. The Department of Health (2011) NHS Patient 
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Experience Framework has eight core concepts to it as outlined in Figure 2.2 
which cover a range of different aspects of patient experience. 
Figure 2.2 The NHS Patient Experience Framework (DoH 2011) 
 
 
This framework enables the NHS to meet public expectations by providing 
concepts which are critical to meet effectively, in a timely manner by clinicians who 
are skilled and knowledgeable about healthcare. Healthcare should, then,  
be delivered by workforces who are professional with customer services skills  
 
Respect for patient-centred values, preferences, and expressed needs, 
including: cultural issues; the dignity, privacy and independence of patients and 
service users; an awareness of quality-of-life issues; and shared decision 
making; 
 
Coordination and integration of care across the health and social care 
system;  
 
Information, communication, and education on clinical status, progress, 
prognosis, and processes of care in order to facilitate autonomy, self- 
care and health promotion;  
 
Physical comfort including pain management, help with activities of daily 
living, and clean and comfortable surroundings;  
 
Emotional support and alleviation of fear and anxiety about such issues  
as clinical status, prognosis, and the impact of illness on patients, their families  
and their finances;  
 
Welcoming the involvement of family and friends, on whom patients and 
service users rely, in decision-making and demonstrating awareness and 
accommodation of their needs as care-givers;  
 
Transition and continuity as regards information that will help patients care 
for themselves away from a clinical setting, and coordination, planning, and 
support to ease transitions;  
 
Access to care with attention for example, to time spent waiting for admission 
or time between admission and placement in a room in an in-patient setting, 
and waiting time for an appointment or visit in the out-patient, primary care or 
social care setting. 
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to match.  Acknowledging that quality and patient-centred care must work together 
to provide effective healthcare services is vital to ensure appropriate measurement 
with new ideas and instruments. As has previously been mentioned, patient 
satisfaction has for too long been measured by weak methodologies (Coulter, 
2002). Often, many patient satisfaction surveys have focussed on operational 
aspects of hospital care and failed to explore patient-centred aspects – as 
highlighted in the patient experience framework (Holmes-Rovner, 2001) – such as 
communication and co-ordination of care which was evident in the English 
National Adult Inpatient Survey data. But DeCourcy et al. (2012, p.71),  
who undertook a systematic search of the English inpatient surveys and grey 
literature (published work such as specific reports) from 2002 to 2009, conclude  
that the results of these surveys alone are not adequate to create change  
to patient experience.  
The need for change in the management and assessment of patient experience 
has, for many decades, been central to health policies and healthcare 
developments. However, even though it is evident that the patients’ experience 
can bring about improvements in NHS healthcare, the pace of change seems 
slower than expected with additional pressures on the NHS system such as 
finance concerns. Budgetary pressures, staffing and an increase in patient 
demand has compromised quality of care as reported by patients’ experience over 
time (Coulter, 2002, p. 1200). The measurement of experience however, needs to 
focus more on the individual care and living with diseases rather than the more 
overarching response to healthcare.  
The definition of patient experience is translated across the eight different 
concepts within the NHS patient experience framework. This allows for a broader, 
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more personalised view of patient experience, ensuring that, patient centred care 
is fundamental to the experience and future design of NHS services. Previous 
work undertake by Hughes, Bamford, & May, (2008); and Mead & Bower, (2000) 
on patient-centred care has yielded similar constructs to that of the NHS patient 
experience framework. A recent study by Luxford et al., (2011, pp.510-515) who 
used semi-structured interviews with senior clinicians and directors to investigate 
the facilitators and barriers to patient-centred care in the US, renowned for 
improving the patient care experience, explained that the ‘delivery’ of healthcare 
was a shift towards a ‘patient-centred healthcare system’ to that of current 
‘provider-focus’ system,  but argued that the length of time it took to transition 
towards such a patient focussed approach relied on key deliverables such as a 
lack of commitment and clinical leadership, communication and organisational 
culture. These where perceived as barriers towards providing a more patient 
centred healthcare focussing on the needs of patients experience and not that of 
the organisation. Although this is a US study, these are not dissimilar findings to  
a postal survey of nurses in 20 London hospitals undertaken by West et al., (2005, 
p.435) who explored the barriers to delivering high quality patient-centred care. 
West et al. showed time, tools and training were identified as common barriers to 
providing patient centred care which, of course, leads to poorer patient experience 
of healthcare. It is clear that experience is captured globally in every setting from 
retail and marketing to those recorded by health services and the principles 
discussed regarding how experience is reported and evidenced using different 
approaches help to understand how experience is seen within healthcare.  
There are many similarities that can be learnt and shared between business and 
healthcare. This section gave an overview for the national picture of why the NHS 
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has become more enriched in patient experience and how experience can drive 
change if used appropriately and inspired by the NHS patient Experience 
Framework.  
The next step in the development of any new instrument is to explore the existing 
literature in relation to the disease in question and to gain a greater understanding 
of its effects on the patient experience. For this study, it was important to identify 
papers which present the results relating to the measurement of Patient Reported 
Experience Measures (PREMs) in COPD either as a measure of experience of 
living with COPD or through utilisation of healthcare services and the appropriate 
papers to explore the concept of patient experience in COPD. 
2.5. COPD Literature review 
 
This next section will include a rigorous literature review to ensure a wide range of 
literature was searched for existing disease-specific literature relating to COPD 
and experience. This included English language literature reviews, primary 
qualitative and quantitative papers and grey literature of high relevance, as well as 
items with certain keywords in the title or abstract such as ‘experience’ and 
‘measure’ (Table 2.1). Undertaking a rigorous literature review was fundamental to 
providing a comprehensive understanding of the experience of people living with 
COPD and the availability of current patient reported experience instruments  
in COPD. 
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2.5.1. Aim  
 
The main aim of this literature review was to explore the current understanding, 
landscape and practical concepts in PREMs for patients with COPD. The review 
initially looked at scoping search for both qualitative and quantitative literature that 
has explored, published or made reference to the development of a COPD PREM 
instrument or of measurement of experience used in clinical practice. The main 
search focuses on a rigorous review of the literature that describes the experience 
of living with COPD, or of healthcare.  
The following objectives drove these two approaches: 
A. Is there a disease specific measure of experience and COPD? 
B. What is the current understanding of experience in relation to COPD? 
C. What are the descriptors used in experience to describe living with 
COPD? 
D. Do the themes and descriptors used in the preliminary PREM-COPD 
instrument differ to that of the current literature? 
2.5.2. Design  
 
Tangible literature was explored in relation to PREMs in COPD, and the current 
understanding of experience of living with COPD and the language used to 
describe COPD experience. The literature review design was intended to be 
broad, to gather work from a number of sources that included studies using the 
qualitative and quantitative paradigms, while seeking to explore and review new 
information in relation to COPD and experience. This was undertaken following 
PRISMA principles. PRISMA is used as an evidence-based systematic approach 
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to searching the literature and enables a transparent approach to the design 
(Disler et al., 2012, p. 8).    
The individual steps of this review are outlined over the following pages.  
2.5.3. Searching and Selection Criteria  ̶  Initial Scoping Search 
 
It was also important to narrow the search to patients with COPD to ensure 
relevance to the study. Probing and reading existing literature enabled the 
reviewer to identify previous literature relating to other similar concepts such as 
PROMs and patient satisfaction in the subject field and therefore this enabled  
a more focused approach on relevant recent published literature in PREMs.  
Generating an understanding of PREMs in other disease areas enabled the 
scoping search of PREMs in COPD to focus on the methods and instruments 
under a PREM heading. There were a number of databases were reviewed and  
inclusion and exclusion criteria are presented on pp.47-48. 
The scoping search strategy included a rigorous search of the following eight 
computerised databases from 1999 up to May 2013: 
1. Allied Medicine and Complementary Database; 
2. British Nursing Index;  
3. Cumulative Index to Nursing and Allied Health Literature (CINAHL); 
4. Embase;  
5. Health Management Information Consortium;  
6. Health Business Elite Medline;  
7. Medline; 
8. Psychinfo.  
46 
The Nursing Times and Nursing Standard were also searched to ensure that 
particular non-specialist nursing journals not included in the British Nursing index 
were not omitted including a hand search of the literature to ensure a wide range 
of both clinical and non-clinical journals were captured.  
Specific search terms were used and a combination of search terms to ensure  
a wide range of indexed and non-indexed synonyms was captured.  
The combination of specific search terms used are shown in Table 2.1. As the 
terminology of measurement is so varied and the meaning of the measurement of 
experience is also varied (Health Foundation, 2013), the literature search was 
extended to include papers specifically on the three main ‘measurements of 
health’; these being outcomes, experience and satisfaction. These are widely used 
terms within the NHS. Broadly the search strategy included the terms ‘patient 
reported experience’, ’outcome’, ‘satisfaction’ AND/OR ‘COPD’ and other 
descriptions of COPD as shown in Table 2.1.The word measurement was 
deliberately omitted due to the construct of measurement which can lead to many 
different concepts. 
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Table 2.1 
Search terms 
Key search words and phrases 
Experience 
PREM OR PREMs 
PROM OR PROMs 
Patient reported outcome 
Patient reported experience 
Patient related outcome 
Patient related experience 
Patient satisfaction 
Patient experience 
Patient outcome 
National health Programmes 
NHS 
National Health Service 
 Lung diseases, obstructive 
COPD 
Pulmonary disease 
Respiratory disease 
 
Papers from the scoping exercise were then categorised into the four main 
themes: 
1. Not relating to COPD  
2. COPD related but not a measure of experience  
3. COPD related on experience but does not measure the experience using 
an instrument 
4. Related to children 
48 
Papers were included if: 
• they referred to COPD experience and a measurement of experience was 
recorded;  
• the language of publication was English; 
• they were published in a journal (no grey literature). 
 
The search for included papers was conducted in May 2013 prior to submission  
of the project’s proposal for ethical approval of this thesis (study two). 
A full search outcome is shown in the PRISMA chart Figure 2.3 
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Figure 2.3 PRISMA ̶  Scoping Literature for PREMs in COPD
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As the PRISMA flow chart suggests there were no current published papers on the 
measurement of COPD which described using an instrument to measure patients' 
experience (objective A). However, it did highlight a number of papers concerned 
with the recording of people's experience's of living with COPD using qualitative 
methods of experience descriptors. Therefore a further rigorous search of the 
literature was undertaken to explore further the meaning of 'experience in COPD' 
and it's context (objectives B and C). The literature was also then reviewed in 
relation to the themes and descriptors used to describe experience in COPD from 
study one on the COPD PREM development (objective C), of which the items and 
descriptive words were used to formulate the preliminary COPD PREM-38 
instrument. 
2.6. Main COPD and Experience Search  
 
The scoping search identified a number of papers on the lived 'experience of 
COPD' but not on its measurement. This main search then focused on ensuring  
a more recent review of the literature and a manual search of the grey literature 
was also undertaken. An identical search using the same electronic databases 
and search terms as in Table 2.1 (p.47) was used.  This search was now primarily 
exploring the patient experience in COPD to include papers on both the qualitative 
and quantitative paradigms in relation to COPD and experience. The search date 
was extended from 1990 until July 2014.  
This search identified that there had already been two published systematic 
reviews on the experience of COPD: Giacomini et al., (2012); & Disler et al., 
(2014). Therefore papers were included if: 
51 
• they were qualitative studies that explored the experience of COPD and 
contained words or descriptors that reflected the experience of living with 
the disease; 
• language of publication was English; 
• appeared in the grey literature if applicable to experience of living with 
COPD, or of healthcare. 
Papers were excluded if: 
• the paper appeared in the systematic reviews of patient experience by 
Giacomini et al., (2012); or Disler et al., (2014) over the timeframe; 
•  the paper measured experience of a specific intervention or treatment  
in COPD such as palliative care, pulmonary rehabilitation or valve implants 
(though examples of these would be used within this literature review). 
The outline of the rigorous literature review is shown in Figure 2.4 using PRISMA 
flow chart.   
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Figure 2.4: PRISMA  ̶  rigorous literature experience and COPD search
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The results of the computerised search process returned 507 abstracts for review, 
of which 281 were removed as duplicates. This highlighted 226 records to be 
screened. When abstracts were reviewed, 164 were excluded for a number of 
reasons such as ‘not COPD’, ‘not experience’ and ‘not a discussion on 
experience’. Initially, to manage the abstracts, including the screening for 
relevance and suitability according to the articles, they were separated into three 
groups which comprised: ‘review’, ‘duplicate’, and, ‘not for review’ when applying 
the inclusion and exclusion criteria outlined on pp.47-48. A total of 62 papers were 
then identified and fully reviewed. After a further reduction due to relevance to the 
subject a total of eight papers were included plus the inclusion of the two 
previously published systematic reviews and the report from Study One by Andrew 
(2012). 
2.6.1. Quality Appraisal 
 
While searching the literature it was apparent the research methodologies were 
appropriate for this subject matter, many of the articles used qualitative methods 
exploring different aspects of COPD care in either focus groups or one-to-one 
interviews. A limitation, however to the scoping review identified that there were  
a number of papers that did examine patient experience, but these were 
qualitative designs using interview techniques which did not use any formal 
‘instruments' to measure experience, only comment on themes generated. 
Therefore, it was difficult to make any definite conclusions on positive or negative 
experience as a formal measure of COPD experience. These articles however, 
were used in the main search to decide on emerging themes and descriptors of 
experience.   
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A number of the articles had appeared in peer reviewed journals which suggests 
there has been some quality checks but adding credibility and an assurance of 
quality and accuracy a systematic approach to review is critical through appraisal. 
This is undertaken to enable the evaluation of an article and assess its validity and 
clinical usefulness (Burns & Grove, 2011). To assist the critical appraisal of the 
chosen articles identified in this literature review the underpinning principles of the 
Critical Appraisal Skills Programme tool (CASP, 2006) were used to guide article 
evaluation. The appraisal tool uses ten questions to help make sense of literature 
and has been adapted to support literature reviews (Guyatt, 1993, p.2598) and 
findings are presented in Tables 2.2 and 2.3. 
In summary, this rigorous literature review focuses on the literature concerning 
patient experience in COPD under a number of different themes that focus on the 
four domains that were highlighted in Study One (COPD PREM development).  
The current literature on COPD and experience is discussed alongside  
a presentation of a wide range of additional literature is presented. 
2.7. COPD and Experience 
 
An exploratory study by Williams et al. (2007, pp.77-78) emphasised that there 
had been very limited published research on what really mattered to those people 
living with COPD, and that research had focussed much more on the reporting of 
symptoms rather than their impact on living with COPD. However, the lived 
experience has subsequently been systematically recorded through a number of 
qualitative means, continuing to focus on the impact of the experience of reported 
symptoms, daily living, diagnosis, exacerbations and healthcare interventions. Two 
systematic reviews of qualitative papers (Disler et al., 2014; Giacomini et al., 2012) 
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were included in this literature review. They were included as they had focussed 
on systematic searches of the relevant literature in relation to COPD and 
experiences of living with the disease and of people’s experience of healthcare 
use, over a twelve-year period up until 2012. Both papers have identified a number 
of correlating themes which have emerged from the literature.  
The study by Giacomini, M., et al, (2012) was critiqued using the CASP systematic 
review tool, of which further details can be found in Appendix Eleven. In summary, 
this paper was a systematic review of 101 papers and formulated part of a national 
series of Health Technology Assessments (Giacomini, 2012). The process for 
systematic review used the GRADE system, which provides a transparent and 
explicit framework for the judgments involved in quality assessment of papers. It 
was also subject to external expert peer review. The review had an appropriate 
research question and used a structured approach to its methodology, with clear 
inclusion and exclusion criteria. Five themes were identified relevant to the 
research question and the thematic analysis was robust using two separate 
reviews. Clear narratives within the themes demonstrated the clear experience of 
patients and carers of COPD, and the results could be extrapolated across the 
population. However, the systematic review only reviewed articles written in 
English and made no attempt to give an overview of the actual studies reviewed, 
i.e. total number of subjects, severity and/or other patient demographics therefore 
results were generalised but appropriately documented.   
The study by Disler, R., et al, (2014) was also critiqued using the CASP systematic 
review tool and further analysis is summarised in Appendix Eleven. In reviewing 
the Disler., et al. (2014) work, the authors undertook a metasynthesis of qualitative 
research on the experience of advanced COPD. This was an appropriate 
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methodology to use and explored a breadth of articles relating to the subject 
matter. Though a research question was not evident, a sound objective with a 
rigorous search of the literature was undertaken using the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA). The analysis of the 
chosen articles were also systematically scrutinised using independent 
researchers, and the results of the review were narrowed to three clear and 
focused approaches to living with COPD. Though the review did make reference 
to this as a limitation of this review, it was a broad generalisation of the term 
‘advanced COPD’. However, the systematic review was clear, concise and added 
value to the synthesis of qualitative evidence on living with COPD, which can be 
generalised to a local population.  
These two systematic reviews (Giacomini, M., et al. 2012 and Disler., et al. 2014) 
were critiqued in this approach as they formulate the main focus to the rigorous 
literature review, as both identified literature that was historical and highly relevant 
to COPD experience dating back over a combined 12-year period. As the focus of 
the thesis, however, was on the ‘measurement’ of patient reported experience (as 
identified, there were previously no COPD PREMS) then the further rigorous 
search of the literature focused on COPD experience themes identified with Study 
A. These two systematic searches would underpin this literature review as these 
were two comprehensive reviews already giving rich data which, over this period, 
had not changed significantly. Critiquing all these papers within these two 
systematic reviews would have lost focus of the thesis concentrating on the 
themes of experience rather than its measurement. The findings are summarised 
in Table 2.2 which gives a clear overview of the study aims, analysis of methods 
and quality overview. 
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The remaining eight papers are shown in Table 2.3 which were published between 
2012 until July 2014. They were not included in the previous two systematic 
searches. Table 2.3 gives a clear overview of the study aims, analysis, limitations 
and quality overview of the papers. The literature identified in Table 2.3 explores 
more recent published papers focusing on experience and COPD; they were 
published since the two systematic reviews inclusion dates (objective B). The 
review will also explore the descriptors used for experience (objective C). And 
finally it will evaluate any similarities to Study One (COPD PREM development) on 
the descriptors used to generate the items within the preliminary PREM 
instruments (objective D) included in Table 2.4. 
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Table 2.2 Systematic literature reviews of COPD and Experience  
Study Study Aim 
Patient 
Group 
Analysis of 
Methods 
Limitations 
of Study CASP Evaluation 
1.Giacomin
i et 
al.(2012)** 
To review the 
empirical 
qualitative 
research on the 
experiences of 
patients with 
COPD and 
informal 
caregivers from 
diagnosis to end 
of life care. 
COPD  Qualitative 
Empirical 
Literature  
Search 
101 Papers  
Large 
number of 
articles 
covering very 
similar 
themes 
Difficult at 
times to 
understand 
the full 
meaning of 
the themes 
as lots of 
information 
condensed 
into small 
themes.  
 
 
This was a large qualitative empirical literature search 
with aim to develop a ‘synthesis to relate the findings 
to the clinical trajectory of COPD care.’ A clear 
research question is presented in this paper, with an 
excellent range of qualitative descriptors and 
interpretations of COPD experience through a vast 
literature search using a number of recognised 
databases. The empirical systematic review, 
however, only includes English language reports 
which may have discriminated some literature given 
the global prevalence of COPD; it also excludes 
quantitative research which also poses the question 
that research which has a mixed method approach 
would have also been excluded. There was, however, 
a rigorous process using an expert in COPD to review 
a final report, but no evidence of any quality 
assessment used to select articles. The results 
presented give the reader a clear and good 
understanding of the needs of the COPD patient’s 
experience and identify clear themes and descriptors 
for COPD. The results can provide a useful 
correlation of empirical evidence in COPD across a 
number of different aspects of a patient’s pathway. 
2. Disler et To increase the COPD Metasynthesis Mismatch The paper is well thought through giving a clear 
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Table 2.3 
CASP overview of experience literature 
al. 
(2014) 
understanding of 
the experience 
and ongoing 
needs of 
individuals living 
with COPD  
22 Articles   between title 
of study and 
purpose of it  
Identified 
moderate 
papers but 
explore 
advanced 
disease  
Missing 
participant 
data  such as 
age / FEV1 % 
 
 
objective to understand the experience and ongoing 
needs of patients with COPD. The method uses a 
metasynthesis aimed at generating new insights and 
understanding of a topic area. However, the objective 
does not match the title, as the title uses the word 
‘advanced’ but this was only described within the 
introduction; the characteristics of the majority of 
papers reviewed suggest that patients had were 
'advanced' COPD, however, some papers reviewed 
do not mention severity, and papers  discuss 
moderate COPD, therefore assumptions been made 
and generalised within the article. The paper 
however, does highlight and report on 22 articles in 
relation to experience of COPD and draws upon 
trying to generate a 'synthesis' of the literature 
reported. It has a different context to the previous 
systematic reviews by challenging the understanding 
of the varying dimensions of COPD care. 
3. Andrew 
(2012)* 
 
To develop a set 
if item 
descriptors to 
formulate a 
proposed PREM 
instrument in 
COPD 
COPD Report of 
Study One 
Qualitative 
Design 
(n=89) 
Discovery 
Interviews  
Missing 
participant 
data  such as 
age / FEV1 % 
 
 
A report that was published from the outcome of 
Study One (COPD PREM development) 
Identifies four themes and a range of descriptors 
used to describe the experience of living with COPD.  
Collaboration project identified in Appendix One.  
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Study Study Aim 
Patient 
Group 
Analysis of 
Methods 
Limitations 
of Study 
highlights CASP Evaluation 
1. Powell et 
al. (2013)** 
To better 
understand the 
patient 
experience of 
COPD care in 
order to educate 
clinicians.   
COPD Qualitative 
Discussion 
Focus 
Groups  
(n=75) 
Not a rigorous 
research 
study but 
written up as 
one. 
No ethical 
consideration 
or clearance 
noted  
Participants’ 
demographics 
sparse  
No specific 
COPD data 
i.e. FEV1% 
Participants 
asked to scale 
their health on 
1-5 (open to 
wide 
variation) 
No clear 
analysis of 
This study had 3 key areas that it wanted to 
address, but there was not a clear research aim. 
The paper identifies methods and presents results 
and discusses them, but this does not demonstrate 
sufficient rigor in the design process. For example 
there were no clear methods, research aims or 
goals, or classification of COPD. Patients were 
asked to rate their COPD from 1-5 (mean 3.3); 
however, this type of rating adds no value as it not 
validated. However, the paper does identify some 
common themes: there are a number of areas 
related to people experience in healthcare. 
However, there is no formal approach to how 
themes where collated or reviewed, just 
summaries given. The conclusion however, does 
identity this as a ‘qualitative exercise’ for feedback. 
But overall it provides useful information of 
people’s understanding and experience of living 
with COPD.  
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theme 
generation  
2. Rocker 
et al. 
(2013)** 
Understand 
patients’ 
experiences 
when opioids are 
added to usual 
conventional 
treatments in 
advanced COPD 
patients.  
COPD Longitudinal, 
observational 
interventional 
study  
(n=44) 
Sample group 
numbers 
acceptable  
Possible 
participant 
bias as 
researchers 
knew sample 
well  
Possible 
placebo effect 
of drug 
Results may 
not necessary 
be 
representative 
of the whole 
COPD 
population  
This is a very well thought through and well-
executed study that really explores the use of 
opioids in COPD. Though an exact research 
question wasn’t documented, the ‘background’ 
gave the reader a good understanding of the aim 
of the study. A mixed method design, which is 
appropriate to understanding the experience, as 
well as objective measurement was a strength of 
the study, (n=44).  
The characteristics of the participants were well 
reported, with a mean FEV1% 26.8 (very 
severe).The patients however, were well known to 
the site where the researcher worked, and 
therefore could have added some sampling bias. 
This is acknowledged in the limitations as is the 
small sample group which suggests results are not 
necessarily representative of the wider population. 
However, there is only minimal literature or 
presentation of the previous literature on the 
subject. 
Overall a well-structured article adding to the 
experience data and to the literature on this critical 
and controversial area.  
3. 
Corcoran 
 To describe the 
disease specifics 
COPD Qualitative 
semi-
Results broad 
so may not 
The aim of the study was clear, using appropriate 
interview techniques, and the use of QSR Nvivo8 
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et al (2013) of patients living 
with a number of 
long term 
conditions 
HF 
Type 2 
Diabete
s  
structured 
interviews 
(COPD n=15) 
(HF=9) 
identify as a 
whole COPD 
population. 
qualitative data software to support results. 
Although a literature a review is not present, an 
understanding and appreciation of previous 
literature is acknowledged and well referenced. 
Characteristics of the participants were 
acknowledged. However, in the COPD group there 
was no reference to severity, or even an 
acknowledgement of how unwell these patients 
were (i.e. exacerbation history or MRC scale).  
The results are clearly grouped and good themes 
identified, however, there is no relation to be made 
in terms of severity. Therefore, broad results which 
reported for the ‘whole COPD’ population rather 
than a specific group, have been reported using a 
small sample group, with participants who also 
have other co-morbidities (though this is 
acknowledged in the limitations of the study).  
4. Lowey et 
al. (2013) 
To describe the 
experiences and 
goals for care of 
patients with end 
stage HF and 
COPD who were 
recently 
discharged from 
hospital.  
COPD 
HF 
Qualitative 
descriptive 
design 
Semi-
structured 
interviews  
(n=20)  
Population of 
participants 
varied  
No 
characteristics 
to determine 
severity of 
participants 
(no FEV1% 
An appropriate methodology was chosen that 
sought to find out the experiences of people living 
with advance COPD, nearing end of life; however, 
the inclusion criteria for the study was oxygen-
dependent, home care with hospital admission, 
whilst good indictors of advanced disease, no 
severity or other indicators were included in the 
inclusion criteria and no use of FEV1% (a marker 
of severity). However, robust data collection was 
utilised to determine those nearing end of life. The 
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 recorded). 
Indicators of 
advanced 
COPD good 
but not always 
true. 
semi-structured interviews gave a good overview 
of the key aspects but were not condition specific. 
The results gave clear themes and identified 
appropriate themes relevant to the subject.  
5. 
McDonald 
et al. (2013) 
To explore older 
people’s 
experience of 
asthma or COPD 
with reference to 
their journey in 
healthcare.  
Asthma 
COPD 
Both 
Qualitative 
descriptive 
design  
Semi-
structured 
interviews  
(n=21) 
Small 
populations  
Older 
population 
questionable 
(mean age 
68)  
Gender 
imbalance  
Mean FEV1% 
51%  – 
therefore 
matches a 
moderate 
picture.  
 
This was a sub study of a larger cross sectional 
study. A good introduction addresses the question 
and objective of the study. Gives a rationale for 
why this was undertaken, and also why people did 
not take part. A list of questions were used for data 
collection, appropriate to the initial question asked 
though a couple may introduce bias into the 
conversation as they use questions such as 
‘describe any fears’ which influence the direction of 
the questioning, but open-ended questions were 
also used. A software package was used to code 
and categorise potential themes from the data. A 
good sample size was obtained, though the age 
range was from 59-82; I wouldn’t class 59 as 
‘older’, but the mean age was 68.6. Ethical 
considerations have been explored and 
documented. The uses of patient quotes have 
supported the themes identified. There are 
concerns however, that the paper examined 3 
different lung conditions, but does not specifically 
address these separately within the paper. 
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Therefore, for the reader, it is difficult to 
understand if this was pertinent to a COPD or 
asthma patient for example. But overall this paper 
does add insights and to the growing body of 
knowledge in respiratory disease.  
6. Lindgren 
et al. (2014) 
To illuminate 
patients’ lived 
experiences of 
going through the 
process of being 
diagnosed with 
COPD 
COPD Phenomenolo
gical- 
hermeneutic  
(n=8) 
Recruitment 
of participants 
varied and 
therefore 
results not 
necessarily 
representative 
of the whole 
COPD 
population. 
 
Wide variation 
from time of 
diagnosis of 
COPD to 
interview (4 
mths-8 yrs). 
All by 1 
participant, a 
non-smoker  
There is a clear ‘purpose’ proposed but uses the 
word ‘illuminate’ which I personally feel is unclear 
in the context or focus of the study. 
A phenomenological-hermeneutic analysis was 
applied to the interviews that were undertaken. 
This is an appropriate analysis as it sets out to 
explore and relate to the experiences of a personal 
significance, in this case the diagnostic process of 
COPD. The small sample size was acceptable 
(n=8), all of whom at mild/moderate COPD which 
was identified in the first stage, but not in the 
purpose as I feel this study should have been 
clearer to identify that it was only going to discuss 
this patient group, as the aim states that a 
‘variation’ of experiences was sought.  
The study should have explored further people 
with all severities as this would have added a 
richer understanding of what it is like to be 
diagnosed with severe or very severe COPD. 
However, the narrative and results gives the 
reader a comprehensive understanding using 
patient quotes to add richer data to the context, 
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giving themes and context. The conclusion of the 
study also does not match the purpose of the study 
in terms of informing the reader that there is a 
better understanding of the lived experiences of 
patients with COPD at the early stages. This was 
not the purpose of the study as stated in the 
abstract. 
7. Doos et 
al. (2014) 
To explore the 
experience of HF 
and COPD 
patients and their 
cares on hospital 
discharge.  
 
COPD 
HF 
Mixed 
Methods 
Questionnair
e & 
Structured 
interviews  
(n=14) 
Small sample 
group  
Saturation of 
data on 
discharge  
Only one 
area’s 
experience 
results cannot 
be 
generalised  
No disease- 
specific 
experiences 
noted – broad 
findings.   
 
This was a mixed methods study which set out 
clear objectives at the start of the paper exploring 
the experiences of hospital discharge in patients 
with COPD and HF. The secondary objectives also 
made clear. The study suggests the sample was 
29 eligible patients, gives justification for 5 pts who 
didn’t complete the survey, and 14 did which 
equals 19, but there is no record of what happened 
to the other 10 eligible pts. As participants were 
also recruited from the same hospital it will be 
difficult to make the findings broad as this is the 
experience of one hospital’s discharge process.  
The baseline characteristics give little 
understanding of the sample group i.e. no record 
of severity of COPD or HF. However, their analysis 
of the results and thematic review of the interviews 
give comprehensive review of the context of the 
subject answering the objectives set. However I 
am not sure the questionnaire used in the study 
adds value to learning about the experience of 
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these patients, the questionnaire is more 
‘satisfaction’ based. But overall the qualitative data 
adds value to this subject area but it would be 
unwise to make broad judgements from it. 
8. Hodson 
& Andrew 
(2014) 
Review piece 
discussion on 
capturing the 
patient’s 
experience of 
living with COPD. 
COPD Quality 
Review 
 
Peer 
reviewed   
Not research 
paper; 
comment 
quality piece  
 
This was a peer-reviewed quality piece written to 
highlight the different aspects of healthcare 
measurement. The paper addresses a number of 
different aspects, well written and identifies a need 
for further specific patient reported measures in 
COPD.  
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2.7.1. Living with COPD 
 
Though there is no measurement of patient reported experience in COPD, what 
has been documented in COPD care is concerned with the description of the 
measurement of quality of life (Powell, Spranger, Hartl, Roberts, & Fletcher, 2013). 
It was clear from the introduction that COPD impacts greatly on daily life through 
difficulties with physical activity and a heavy burden of symptoms, such as 
breathlessness and cough, with recurrent exacerbations, with some people 
requiring frequent hospitalisation reported (Annegarn et al., 2012; Janson et al., 
2013). Terminology regarding the description of a quality of life measure and  
a PREM is often confused. However, it has become apparent that measurements 
of outcomes and satisfaction are also being used to demonstrate a measure of 
experience. Terminology however to describe this is  becoming misunderstood 
among healthcare professionals as more data emerges in patient experience  
(M. Hodson, Jennings, & Martin, 2011).  
There remain still relatively few studies on the experience of living with COPD 
despite Giacomini et al., (2012) large empirical literature of experiences of living 
and dying with COPD. The study examines many themes which were generated 
from the findings (in Table 2.2) of the review. The study explored COPD from pre-
diagnosis through to everyday living and care, including end of life with associated 
themes with dying. The study clarified that living with COPD, was depressive, with 
a loss of independence routinely surrounded by the description of ‘good and bad 
days’. Making the most of the good, hibernating in the bad. An alternative 
approach to exploring living with COPD was by Disler et al., (2014) who focused 
on a broader meta syntheses interpreting and translating findings from the 
qualitative studies and integrating or comparing findings, to provide an overview 
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(Polit & Beck, 2012). Disler et al., (2014) chose to study specifically patients with 
'advanced COPD'. But the paper title suggests that advanced COPD is the focus, 
but gives no real clear definition of the description of this until much later in the 
paper. This paper also themes in connection with living with COPD and identifies 
similar themes to the previous Giacomini et al., (2012)  paper highlighting specific 
aspects of COPD care such as activities of daily living and describes the heavy 
burden of symptoms, as key sub- themes within living with COPD.  
To generate a better understanding of the themes and descriptors used in these 
papers and to describe the aspects of experience clearer in these two papers.  
The themes were mapped against Disler and Giacomini reviews and the data 
reported from Study One (COPD PREM Development) (Andrew, (2012).  This 
gives an overarching overview of the common experience themes and descriptors 
of experience used within these three main studies to describe the overall 
experience of living with COPD, including emerging experience themes and 
descriptors of experience outlined in Table 2.4. 
Table 2.4 
Summary of the three studies and their descriptors in COPD 
Article  Theme Sub-theme Descriptors 
Giacomini 
et al. 
(2012)1 
Experiences 
of diagnosis 
 
- Normal way of life 2,3 
- Limitations due to smoking or 
aging  
- Seek help for acute event not 
chronic  
- Not communicate a diagnosis 
clearly  
- Information in stages  
- Poor information and 
education 2 
Worry 2 
Normal 
Interpret 
mistakenly 
Incurable / fatal 
information 2,3 
Communication 3 
Unaware 
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Smoking 
 
- Different beliefs 
- Other exposures 
- Cause of COPD 
- Shame and self-blame 
Not enough 
Guilt 
Shame 
Regret 
Self-blame 2,3 
Stigma 
 
Experience 
of daily life 
2,3
 
 
- Good and bad days 
- Breathlessness and 
symptoms 2,3 
- Activities of daily living 
affected 2 
- Depression 2,3 
- Episodic emotions  
- Hospitalisation  
- Loss of independence 2  
- Multidimensional 
 
Relationships with others 
 
Challenges of smoking  
cessation 
- Complex  
- Understanding ve-/+ve 
benefits 
 
Interactions with the healthcare 
system3 
- Poor relationships  
- Access poor  
Exhausting  
Struggle 
Fatigue 2,3 
Loss of 
enjoyment  
Fear 2,3 
Panic 2,3 
Dread  
Struggle  
Relationships 
Anger 2,3 
Frustration 2,3 
Disruption 2,3 
Hastiness 
Compassion 
(lack of) 
Invisible  
Isolation 
 
Experiences 
of 
exacerbatio
ns 3 
 Recognition 
- Acute in nature 
 
Treatment 
- Management of one 
- Role of the HCP / Patient 
relationship 
 
Recovery  
- What does future hold 
Terrifying 
Acute 
Sudden death 
Recovery 
Frightening 3 
Terrified  
Distrust  
Uncertainty 3  
Prognosis 2,3 
Significance  
(of health) 
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Experiences 
of the end of 
life  
Understanding the prognosis of 
COPD 
 
Experience of dying  
- Take over every aspect of life 
- Daily challenge of living 
 
Communication with healthcare 
providers  
 
Palliative Care  
- language used by HCPs 
- lack of a definition among 
HCPs 
Fatal 
Uncertainty 
Poor 
Lack of 
understanding 2 
Death 
Social Isolation 2  
Imminent  
Suffocating 
Final attack 
Language  
Breathlessness 
2,3
 
Hope (dashing  
of) 2 
Disler et 
al. (2014) 
Better 
understandi
ng of the 
condition 
 
Sustained 
symptom 
burden 
 
Unrelenting 
psychologic
al impact of 
living with 
COPD  
Breathlessness 
Fatigue 
Frailty 
Anxiety  
 
Social isolation 
Loss of hope 
Maintaining meaning 
Debilitating  
Exhausted 
Frailty  
Hope (loss of) 
Andrew 
(2012) 
Journey to 
diagnosis 
 
Usual care 
 
Exacerbation 
 
My 
everyday 
life 
 
Hospital 
The limitations of living with 
COPD 
Going to hospital 
On arrival to hospital 
On the ward 
Discharge from hospital 
Follow-up care 
Shocked  
Frightened 
Frustrated  
Surprised  
Annoyed  
Confused  
Angry  
Embarrassing  
Motivated  
Gratitude / 
Respect 
Worry/ fear/ 
unknown 
1 Giacomini et al. (2012) 
2 Disler et al. (2014) 
3 Andrew (2012)* Report from Study One findings  (in development for publication) 
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Within the three studies there are a number of similarities used to support the 
development of items and descriptors in Study One (COPD PREM development). 
This is partly due to the fact that both Disler and Giacomini review many of the 
same papers, though Disler makes greater use of experience descriptors and 
'quotes' from papers reviewed to describe meaning behind themes, whereas 
Giacomini explores developing the themes and draws on a variety of papers and 
sources, so descriptive words are used but the literature source for these words is 
unclear. But what is evident is that the COPD journey is unclear and the pathway 
is complex with a mixture of conceptual descriptors which are common on both the 
positive (happy, respect, gratitude) to subjective poor (frightened, fear, shocked) 
descriptors, clearly stressing that living with COPD has a massive impact from 
diagnosis to end of life. 
The subsequent discussion of this literature review will fall under the four main 
themes identified within the thematic review of Study One (COPD PREM 
Development) which includes: 
1. History and COPD; 
2. Usual care in COPD; 
3. Everyday life with COPD;  
4. COPD exacerbations. 
These four themes are identified in relation to describing the experiences 
documented through the whole COPD pathway. 
2.7.2. History and COPD 
 
Several studies have recorded specifically the COPD experience and history  
of obtaining a diagnosis of COPD, and it is widely reported (Arne, Emtner, Janson, 
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& Wilde-Larsson, 2007; Pinnock et al., 2011). Common themes suggest prior to  
a diagnosis symptoms were a part of everyday life, or attributed to aging or 
smoking (Giacomini et al., 2012). The descriptive data published by Disler et al., 
(2014) highlight a number of key points in examining what has previously been 
published (between 1990 and 2012) on understanding the experience of COPD. 
These themes are resonant with much of what the literature from the Giacomini 
review also expressed, especially surrounding the understanding of the disease 
and its diagnosis. Many people did not know that COPD is a long term condition, 
or understand alien terms and language used, for instance, in terms of there being 
no cure and the experience of how the doctor or nurse would talk about the 
disease. Common descriptors highlighting experience included ‘conflict’, ‘fear’ 
‘regretted’ and related to people’s own lived experience through the context of  
an event or expressed through everyday life. 
 A further study, specifically on the negotiation of the diagnostic process  
by Lindgren et al., (2014, pp.441-445) used a phenomenological-hermeneutic 
analysis, which enables the research to approach the interviews with no prior-
judgement or understanding of the phenomena and the interview description  
of (n=8) mild to moderate COPD would argue that this was the case. Patients were 
interviewed about their experiences of being in the diagnostic process of COPD, 
although a small study. Lindgren et al.,  (2014, p.441) affirmed that the diagnosis 
of the disease in this study for participants that was 'prolonged' and 'unclear' with 
three themes being identified: ‘living with a body out of step with the diagnosis’; 
‘dealing with the past’; and ‘being challenged by the future' with descriptors used 
by participants such as ‘scared’, and ‘unaware’. Though descriptors used in these 
studies were similar in Study One (Andrew  2012), there were a number who used 
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additional terms such as 'shocked', 'surprised' and 'annoyed' as descriptors  
of getting a diagnosis which were not highlighted in previous studies (Disler et al., 
2014).    
Making sense of the diagnosis and the way this is communicated is a fundamental 
part of the journey of living with COPD. However, the Lindgren et al. (2014) study 
only explores experience of patients with mild to moderate COPD ranging from  
4 months to 8 years from diagnosis to interview. There is also no distinction 
between the time of diagnosis and experiences being recorded. It was also evident 
in the Disler, (2014) and Giacomini, (2012) systematic reviews that no real 
distinction between the categories of severity of the disease were made, thereby 
at times giving a broad overview of experience in the diagnostic phase which 
potentially, should not be generalised to the whole COPD population. What is clear 
from the literature is the need to have an understanding of negotiation during the 
diagnosis phase, where people shift to an acceptance and accepting phase. 
Information and experience are key in the delivery of the critical messages of 
diagnosis. This was supported by the Giacomini et al., (2012, p.11) review and 
synthesis of the qualitative empirical literature that highlighted a number of 
different experience themes which will continue to be discussed throughout this 
chapter.  ‘Receiving a diagnosis’ was also a key theme, highlighting 
miscommunication with diagnosis often ‘given in stages as medical events arose’. 
A recent large retrospective study (n=38,859) published in the Lancet by Jones et 
al., (2014, p.267) stressed the missed potential in COPD diagnosis as reported by 
patients’ negative experiences. The data presented suggested that opportunities 
for diagnosis were missed in 85% of patients’ clinical notes reviewed within the 
five years immediately preceding a final diagnosis of COPD. This data was 
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undertaken using primary care records. This supports the qualitative literature of 
the poor experiences of people getting a diagnosis right in the first instance. 
2.7.3. Usual care in COPD 
 
Information needs are an essential component to any long term condition. This is 
not just essential at diagnosis, but must be ongoing to ensure that patients, once 
diagnosed, understand their condition and how to manage it. Disler et al., (2014, 
p.17) emphasis that 'loss of hope and meaningless in life' are important concepts 
for healthcare professionals to maintain engagement in self-management 
techniques. The relationships that patients build with healthcare professionals are 
fundamental to the experiences of patients with COPD adhere to usual care.  
A quantitative study of 15 COPD patients by Corcoran et al., (2013, p.19) 
maintains throughout their paper on the experiences of patients with long term 
conditions, that understanding experiences associated with COPD will enable 
healthcare to tailor specific services. The study also highlighted that interaction 
with general practice is time limited and this interaction also emerged as a theme 
in the Giacomini et al., (2012, p.18) paper too. In essence, communication with 
healthcare professionals is key but Andrew, (2012, p.6) study highlights that 
patients are sometimes the ‘poor relation’. And a poor relationship with healthcare 
professionals has led to descriptors such as ‘frustration’ ‘confusion’ and ‘control 
(lack of)’ when discussing areas such as medication or conflicting information 
about the disease itself. These however are the same descriptors used in the 
diagnosis phase as previously described. Powell et al., (2013, p.353) claims that  
a flip side of communication is expressed in a positive experience when staff are 
knowledgeable and sufficient, descriptors used to describe the effect of this were 
‘it reduces anxiety’ and ‘alleviates fear’ There are additional responses by Andrew 
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et al., (2012, p.14) who advocates a positive experience from various healthcare 
professionals (physiotherapist/GP/nurse). Reporting that there is mutual respect 
when you are listened too but a sense of ‘frustration’ when you are not. Frustration 
was a common descriptor used in describing many aspects of COPD experience 
either by symptoms or the impact of living with the symptoms associated with the 
disease. Andrew, (2012, p.16) also stresses that in 'usual care' the descriptors 
‘enjoyment’ and ‘self-gratitude’ are also key in the management of care and 
relationships with healthcare professionals. It is must be noted that these positive 
descriptive terms are not reported in either the Disler or Giacomini papers, 
potentially introducing a bias in only reporting the negative experiences of patients 
with COPD. 
2.7.4. Everyday life with COPD 
 
The experiences of patients everyday life with COPD were captured in both 
systematic reviews as well as the other main papers (Doos et al., 2014; Lowey, 
Norton, Quinn, & Quill., 2013; Powell et al., 2013).  Disler et al., (2014, pp10-11) 
describes that everyday life is focused on the burden of symptoms such as 
‘breathlessness, fatigue resulting on reduced physical activity’ which impacts on 
daily life. Giacomini et al., (2012, p.11), draws from the literature that everyday life 
is fundamental to the 'whole ethos of understanding the patient journey'.  
Once a COPD diagnosis had been made, life changes and many people reported 
that the experience of living with the troublesome burden of symptoms,  
as previously described as ‘frightening’, ‘exhausting’ and filled with ‘fear’. Three 
common descriptors are used to describe daily life experience in patients in both 
reviews.  
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A later paper, as part of a larger study, by Corcoran et al., (2013) exploring 
experiences of several long-term conditions, examined 15 participants’ experience 
of living with COPD using semi-structured interviews. The results suggested that 
those interviewed were 'angry about the limitations' it forced on their life. With one 
third of participants signifying they pushed themselves to the limits. The feelings  
of 'being angry and frustrated' were also commonly reported. However, once again 
the authors do not indicate the severity of lung disease, either by measurement 
through spirometry or on a scale rating. Therefore it continues to be difficult to 
know whether these results can be extrapolated to the whole COPD population. 
But words such as ‘frustration’ and ‘exhaustion’ were similar descriptors to those 
described by participants in Study One (COPD PREM development).  
A further paper by Powell et al., (2013) showing a European perspective  of COPD 
participants (n=75) with an average length of time living with COPD of 15 yrs, used 
table discussion and a series of questions to inform discussion around the 
experience of living with COPD and its effects on daily life. The group provided  
a number of insightful experiences which covered the four main key themes 
previously identified. Key recommendations of the study were ‘different methods of 
assessment’ needed, and ‘treatments’ and future care needs to be ‘individualised’. 
The limitations on daily life were also a key theme identified across the whole 
group and are this was also explored further by Lowey et al., (2013) who explored 
the experiences of people (n=10) living with advanced COPD, using a qualitative 
descriptive research design. However, the severity of the participants were not 
disclosed, within the inclusion criteria participants had to be a current ‘home care 
patient’ and ‘oxygen dependent’, mean age 73. This suggesting that the 
description of severity in this study was based on activity and oxygen rather than 
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FEV1%. Lowey et al., (2013, p.353) propose descriptors of experience to included 
difficult symptoms, such as 'shortness of breath' as 'frightening' and 'acceptance'.  
It is apparent from the studies mentioned that the experience of participants 
describe and articulate powerful words which are used to describe living with the 
disease, based on a ‘lived experience’ of the disease. Their experiences of the 
severity of symptoms: ‘what was yesterday like?’ or from their last exacerbation 
(worsening of symptoms) echo and impact greatly on personal experiences 
connected by the disease itself. These further studies (Lowey et al., 2013; Powell 
et al., 2013) have supported the previous work on the experiences and descriptors 
of living with COPD and its impact on everyday life. 
2.7.5. COPD exacerbations 
 
It is evident that COPD exacerbations or flare-ups, a worsening of respiratory 
symptoms which can be infective or non-infective in presentation (Trappenburg et 
al., 2011, p.43) are a common occurrence for some patients, causing a sudden 
worsening of a person's reported normal day-to-day symptoms such as an acute 
worsening of breathlessness and increase in cough and sputum and in many 
cases the need for intervention (antibiotics and steroid tablets) and or 
hospitalisation (Arostegui et al., 2014; Osthoff & Leuppi., 2010; Pauwels & Rabe, 
2004). Alongside the reported increase in acute breathlessness and reduced 
activity, impacting greatly on quality of life, exacerbations are one of the most 
reported experiences documented (Disler et al., 2012; Mikelsons & Wedzicha, 
2009). Both Andrew, (2012) and Giacomini et al., (2012) report on the experiences 
of patients in acute exacerbation as 'advancing disease'. The recognition of an 
exacerbation and the severity of its symptoms is, in some patients, difficult to 
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predict and the introduction of phenotypes could predict patterns in COPD 
exacerbations (Han et al., 2010). 
Recognising the symptoms and access to quick treatment or primary healthcare 
are potential barriers to poor experience in exacerbations. The descriptive terms 
included with the literature summarised as ‘frustration’ ‘annoyance’ or ‘confusion’ 
over when to start medications or conflict of whether this was 'just another bad 
day'. The descriptors, however, were similar throughout the literature, except 
Disler et al., (2014) does not discuss exacerbations as a major or sub theme of 
experience in the study, but make reference only by suggesting an increase  
in exacerbations which is a non prognostic indicator of advancing COPD.  
The relationships and communication with healthcare professionals continues to 
be a major factor in the experience of an exacerbation. The expert advice or the 
need for ‘reassurance’ can be a key factor in both a positive and negative aspect 
of an experience. It is interesting that reassurance was not commented on as  
a descriptor in either of the two systematic reviews but was a key term used  
by Andrew et al., (2012). Patients seek reassurance especially in times of 
increased vulnerability such as an exacerbation. This is supported by the work by 
Lowey et al., (2013, p.355) which is suggesting that ‘COPD patients live in a cycle 
of intermittent exacerbations’. This recent qualitative descriptive research design 
also explored the current experiences of advanced COPD patients. Exacerbations 
were again predominant in the findings, with people describing them as ‘bouncing 
back (from an exacerbation)’ and using descriptors such as ‘declining health’ 
though professional relationships were less intrusively discussed but 
communication was key using descriptors such as ‘inaccuracies (of the diagnosis)’ 
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were used. The experience of exacerbations can clearly be varied but are 
described by similar experience descriptors as previously mentioned. 
2.7.6. COPD and the hospital 
 
The severity of acute exacerbations of COPD were also entwined within a much 
wider picture for some patients presenting to hospital either as an acute admission 
to the emergency department for assessment, and in the majority, a subsequent 
admission and period in hospital. Kessler et al., (2006, p.133-136) used a cross-
sectional study (n=125; mean FEV1% 40.9% predicted) and advocates that the 
frequency of exacerbations in patients living with COPD 'have an average of four 
to five exacerbations per year requiring some form of treatment or hospitalization'. 
This time many patients felt or expressed fears of an increase in dyspnoea 
associated leading to 'worry' and 'embarrassment' highlighted in Andrew et al., 
(2012, p.17). Due to the increase in symptoms and the need for additional 
treatments, 'uncertainty' was a common descriptor used not only to describe 
current health but also the 'future' or limitations another exacerbation may have on 
their future health. The Giacomini et al., (2012, pp.22-29) review gave a clearer 
emphasis on 'what the future held' and used descriptors such as 'prognosis' 
whereas Andrew et al., (2012, p.23) would argue that patients needed a very clear 
exacerbation pathway from pre-hospital decisions to discharge planning which 
wasn't dissimilar to previous, but less emphasis on the future as outlined in Table 
2.2. Both papers, however, make reference to the 'hospital discharge' following an 
exacerbation where the levels of 'uncertainly' grew in 'new aspects' such the 
prognosis and recovery time and others regarding everyday aspects such as 
'frustration' of waiting for medications.  
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A mixed methods approach to collecting data through interviews and a survey  
by Doos et al., (2014) with a small COPD sample (n=5) on the experience of 
patients on hospital discharge transition from hospital with COPD and Heart 
Failure (HF) also conclude that 'medication and clarity of information on diagnosis' 
was limited and the ongoing need of care descriptors of their experience 
‘confusing’ and ‘vague’, as previously similarly recorded. However, a limitation of 
this particular study is the number of participants (n=5), which is a small 
population. This is acknowledged by the author who suggests that they reached 
'no new theoretical insights' and therefore may not be an illustration of the total 
COPD and HF population. It is evident, however, that the Doos et al., (2014) study 
does add to the additional body of knowledge and that COPD as a disease  
is made more complex by the impact of significantly co-morbidities (Areias, 
Carreira, Anciães, Pinto, & Bárbara, 2014; Burgel et al., 2013; van der Molen, 
2010), impacting and adding to the negative experience of patients leaving 
hospital after an exacerbation of COPD with or without HF. 
2.7.7. Symptom Burden 
 
The burden of different symptoms associated with COPD is complex and varied 
(Tödt et al., 2014, p.1) even between the assessment of patient and healthcare 
professional. An interesting observational, cross-sectional, descriptive study 
completed by Miravitlles et al., (2013) with a total of 450 COPD patients 
investigated ten symptom items based on ranking by patient and healthcare 
professionals (Figure 2.5). The three most common perceived symptoms were 
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breathlessness, cough and fatigue which were matched by the patient and 
physician and the remaining seven items coincided by 52% (Figure 2.5). 
 
Figure 2.5 Ranking of COPD symptoms, Miravittles et al., (2013, p.1980). 
 
It is evident from this study that, like experience, the perception of symptoms can 
also be portrayed differently. Therefore access to professional healthcare can also 
support variation in people’s experience from the patient’s perspective and that of 
the healthcare professional if we can match symptoms effectively. However, there 
are a number of limitations to this study. Therefore results need to be observed 
with caution: within the patient characteristics, such as a gender imbalance with 
91% being male and the questionnaire used to range the symptoms was not 
formally validated and not tested for validity or reliability in such a research setting. 
Miravitlles et al., (2013, p.1981) argue not only the complex issues of symptoms 
but also three main symptoms which were also very apparent in the systematic 
reviews as key symptom experiences in the burden of COPD these being 
breathlessness/dyspnoea, fatigue/tidiness and cough. 
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2.7.8. Breathlessness/dyspnoea 
 
The most-reported theme expressed throughout the different themes and aspects 
of COPD care and experiences is the reported heavy burden that the symptoms  
of COPD place upon those diagnosed with the disease. Disler et al. (2014) and 
Giacomini et al. (2012) make significant reference to the burden of symptoms and 
living with these. Breathlessness and its major impact in quality of life has been 
reported extensively (DiBonaventura et al., 2012; Pauwels & Rabe, 2004).  
It was also a descriptor used in all the themes identified in both the systematic 
reviews, with associated descriptors such as ‘worsening’, ‘acute’ or 
‘breathlessness’ and the feeling of ‘suffocation’ . This was also highlighted 
significantly in the exacerbation theme and as the most commonly reported 
experience symptom in obtaining a diagnosis or seeking help in an acute episode 
pre-diagnosis. The association of breathlessness and reduced physical activity  
is also another common thread in COPD reporting, breathlessness being a major 
concern for a ‘reduction (in), or worsening (of) activity’. This can be in both the 
acute, chronic and progressive stage of the disease. The association of 
breathlessness and end of Life care is also widely reported in the literature with 
descriptors such as ‘social isolation’ and ‘imminent death’ associated with a poor 
experience (Disler et al., 2014;  Hodson   et al., 2013). 
2.7.9. Fatigue 
 
Fatigue was a sub-theme of the sustained symptom burdens highlighted by Disler 
et al., (2014, p 2) who recommends that fatigue is an altered behaviour and 
causes frustration which leads to changes in routine and changes in everyday life. 
Certainly, the descriptor of 'frustration' was a common theme identified in the 
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systematic reviews, along with synonyms of this such as ‘annoyance’ and 
‘irritation’. A Stage One instrument development on the measurement of fatigue in 
COPD  by Trendall & Esmond (2007, p.116) reports on the measurement  
of fatigue to be used by nurses to measure a level of fatigue. Trendall and Esmond 
(2007, p.118) identified a number of aspects in the measurement of this and the 
impact this has on daily life. One key finding of this development was the 
associated between fatigue and its relationship to breathlessness.  
2.7.10. Cough  
 
The management of cough in COPD over the last 40 years has received very little 
attention (Calverley, 2013, p.245), despite it being one of the most reported 
symptoms in COPD and playing an important role in the quality of life that patients 
reported as being a key burden of living with the disease. Cough, for many, has 
not been explored or assessed fully but the implementation of new measurements 
such as the COPD Assessment Test focuses on the question of cough (Figure 
2.6) 
 
Figure 2.6 COPD Assessment Test (CAT) 
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The need to refocus and discuss cough has become more apparent in clinical 
consultation. 
2.7.11. Smoking 
 
Smoking is a further theme that is intertwined through the different aspects  
of experience from experiences of stopping smoking, impact on smoking, not 
wanting to stop smoking, and information needs on smoking. Descriptors which 
described smoking in the context of experience included ‘self-blame’, ‘annoyance’ 
and ‘scared’. Smoking was identified within all of the systematic reviews, but with  
a greater emphasis on the review by Giacomini et al., (2012) who suggest that 
smoking and advice to quit respond in different ways was similar to the findings 
Andrew, (2012). One comment from a patient suggested the 'lack of understanding 
of the acceleration of smoking and its impact on COPD, knew it was 'bad' to 
smoke, but continued to do so. Descriptors included 'complicated' but others 
suggested it brought ‘pleasure’ and ‘comfort’.  A longitudinal study of smokers by 
Fidler & West, (2011) (n=2257), not COPD specific, looked at smokers and quit 
attempts support this reasoning behind not stopping. The results suggested such 
enjoyment of smoking is an opposing argument in people who decide to carry on 
smoking despite awareness of the dangers (Disler et al., 2014). 
2.7.12. Healthcare 
 
The experience of healthcare has been written about extensively and much of the 
change currently happening within the NHS for example is a direct response to the 
collection and greater understanding of the experience of patients’ use of 
healthcare. Experience of healthcare can generally be categorised into two fields: 
First, the experience of patients and the 'health service' and their use of services 
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within the NHS and that of ‘healthcare professionals’, and, second, patients’ 
experience of meeting healthcare professionals from a general practitioner to the 
COPD clinical nurse specialist. Giacomini et al., (2012, p.20) suggests that 
patients with COPD have a varied and often poor connection with healthcare and 
those that provide healthcare, with patients using words such as 'poor listening'  
or 'lack of compassion', describing themselves as seeming 'invisible to clinicians'. 
The review clearly highlights that patients with COPD are cut off from healthcare 
due to many reasons such as social isolation, continuity of care and logistical 
issues to do with visiting healthcare services due to lack of mobility, 
breathlessness and oxygen therapy. This is supported further by Corcoran et al., 
(2013, p.19) signifying that previous literature (Belfer & Reardon, 2009) highlight 
that basic activities can be strenuous and daunting, but this is changing. Corcoran 
et al. identified that one-third of patients in their study (n=5) reported engaging  
in physical activity. However, these results need to be taken with caution as due to 
the small sample group results cannot be generalised to all COPD patients. Disler 
et al., (2014) continue to focus on the healthcare professional and patient 
experience and was more on the downbeat aspects of information giving in areas 
such as smoking cessation and end of life care. One participant was quoted  
as saying (Disler et at 2014, p.11)  
The doctors, the nurses, especially Dr [name], he’d have an idea how long 
I’m going to last, but I don’t want to know, not bothered. 
 
Important aspects of information giving are fundamental to supporting patients with 
COPD. Disler et al., (2014, pp.10-12), makes it clear that the lack of discussion in 
many aspects of the patients’ journey impacts directly on patients experience of 
healthcare. The descriptors used for this impact included ‘decline’, ‘we don't 
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discuss’ with key healthcare professionals and a focus on the general practitioner. 
This was evident in both systematic views that the GP’s or physicians were 
important key providers of care, and thus a positive experience of their interaction 
was critical.  
A discussion paper by Powell et al., (2013) set in Europe suggests that the focus 
groups and discussion on information provision should be through the 'doctor', but 
recognised the fact that time and contradictory advice were often some of the 
pitfalls to providing information about COPD. Therefore these two issues provide 
patients with a poorer experience of healthcare and those providing it. A further 
study by McDonald et al,. (2013, pp.497-498) specifically explored the insight into 
older people (mean age 68, but range from 59-82, it has to be questionable if 59  
is old) but the healthcare experiences with managing COPD, using qualitative 
interviews (n=21) also identified the themes of ‘not being heard or recognised’ 
which impacts on experience not being involved in care as a collaboration.  
The paper fails to identify if it was specific healthcare identifying it as the 
‘healthcare team’, but throughout the paper the GP is identified as a key 
healthcare provider. But negative experiences were highlighted which include  
‘did not get heard by her GP’ with several participants identifying a lack  
of confidence in their GP. Information was a key factor in the delivery and 
understanding of the future outlook and understanding of COPD with confusion on 
diagnosis but always delivered by a healthcare professional. The Lindgren et al., 
(2014, p.441) paper on the patients’ experience of the diagnostic process  
of COPD claims that a diagnosis should be made with empathy, time and to allow 
patients to share stories, with good communication which is fundamental  
for understanding. However, it is evident that there is a wash of negative 
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experience impacting on people's experience of healthcare and that of healthcare 
professionals with many participants involved in these studies citing experience, 
time, lack of understanding and compassion for this long-term condition called 
COPD, the C being 'chronic' and not cancer as cited by one participant in the 
Disler et al., (2014) review. 
2.7.13. Interventions and Experience 
 
A 'potential' third arm of healthcare experience is that of interventions usually 
provided or recommended by healthcare professionals. This systematic review 
discussed throughout these sections included other studies (Corcoran et al., 2013; 
Rocker et al., 2013) that have also all focussed on particular aspects of the 
journey of COPD from pre-diagnosis through to and touching on end of life care  
in COPD along with the different recorded descriptors of patients experience 
through this journey. Many articles were not included as they focussed on specific 
detailed areas such as end of life care or advanced disease and other invasive 
interventions such as valve insertion or transplant. There are however, a number 
of specific interventions that are discussed over the next few pages as experience 
is highly reported in the literature with regards to two specific interventions and are 
not included in the selected two systematic reviews (Disler et al., 2014; Giacomini 
et al., 2012). These are the use of opioids and pulmonary rehabilitation, two issues 
which were highlighted in the Andrew, (2012) Study One (COPD PREM 
development). 
2.7.14. Opioid Use 
 
The use of opioids in COPD is increasing to support patients in breathlessness 
management (NICE 2010). However, there are limitations to this as we have for 
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more than twenty years known that in COPD morphine has supported a reduction 
in dyspnoea with little attention been given to this (Rocker et al., 2013, p.27).  
A qualitative study was undertaken by  Rocker et al., (2013) of 44 patients (mean 
age 74) participating in a 6-month trial of opioid therapy for refractory 
breathlessness. This trial was to understand patients’ experiences of opioids and 
used semi-structured interviews and other health-related QoL measures to 
document these experiences. Rocker et al., (2013, p.27) as ’I'm feeling 100% 
better than I did before’, and negative experiences such as I’m couldn't feel a feel 
anything at all in the line of difference’. Lowey et al., (2013, p.356) describe the 
experience of the trade-offs with living with advanced COPD suggesting that 
patients would accept interventions such as non-invasive ventilation, in order to 
reduce hospital utilisation common with COPD patients and exacerbations. Rocker 
et al., (2013 pp.34-35) claim that using opioids for refractory dyspnoea  
in participants suggest this is an ‘acceptable intervention for advanced 
breathlessness and patients experienced improved symptoms’.  
2.7.15. Pulmonary Rehabilitation (PR) 
 
Pulmonary Rehabilitation has long been seen as the gold standard for patients 
which consists of between 6-8 weeks of supervised exercise and an education 
programme aimed at improving quality of life by the better management  
of symptoms and an understanding of the lung condition (Lacasse, Martin, 
Lasserson, & Goldstein, 2007). This is normally delivered by specialist nurses and 
physiotherapists who are trained and have the expert  knowledge of respiratory 
disease (Nici, Lareau, & ZuWallack, 2010, p.655). There has been much written 
about PR which was excluded from this systematic review. However people’s 
experience of PR has been summarised by a systematic review of qualitative 
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research by de Sousa Pinto et al, (2013, p.141) who argue that there was a sense 
of increased well-being and health promotion summarised by an increased ‘way  
of life’. The Disler et al. (2014) review, however, made very little reference to PR 
except that one participant suggested that for the first time, we [participants of PR] 
were not going to cure or reverse COPD, again reflecting on the information needs 
previously mentioned. The advert that PR groups are delivered by specialist 
respiratory teams highlight the important impact on greater specialist knowledge.  
2.7.16. Long Term Oxygen Therapy 
 
Previous work by Clancy et al. (2009) was not part of the systematic search,  
but was already identified in the Giacomini et al. (2012) review, specifically  
in relation to COPD patients (n=10) and the use of long-term oxygen therapy. This 
longitudinal ‘Heiddeggerian’ study explored the experiences over time of which  
the conclusion demonstrated that oxygen had a negative effect on quality of life 
and lifestyle with descriptors used such as ‘blame’ and ‘fear’ saturating many of 
the descriptors previously presented in other aspects of COPD care. This is one 
example which suggests descriptors of experience can be interchanged and used 
as a negative or positive affirmative to experience (Roberts et al., 2012). 
2.8. Conclusion 
 
This chapter has given a comprehensive overview of the diverse aspects  
of experience in both health and business touching on the concepts of experience 
and satisfaction and the blurred understanding of these in practice. The systematic 
review concluded that there was currently no published instrument available  
to clinicians to measure experience in COPD. However, there is a plethora of clear 
literature that describes the experience of living with the disease and descriptors 
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that have been highlighted to describe many different aspects and interventions  
of the disease pathway from pre-diagnosis to end of life care. The literature also 
informed that the measurement of and collection of experience is fundamental to 
the quality (NICE, 2012) of healthcare but should not be measured in isolation 
(Robert & Cornwell, 2013). The introduction of the patient experience framework 
(NHS Institute for Innovation and Improvement [NHSIQ], 2003) gives an 
overarching contextual understanding of the principles needed to ensure quality 
patient experience by having these principles guide services to develop and 
ensure high quality patient-centred care. This is critical when ensuring the 
development of a new instrument. However this literature review has only touched 
on some of the key important messages in COPD and experience; intervention 
and other specific aspects of COPD care have not been discussed.  
The understanding of PROMs which have become routine clinical practice,  
and the use of PREMs is relatively new (Hodson et al., 2013). Therefore, Chapter 
Three will give the reader an appreciation of why and what we are measuring  
in healthcare and its important aspect and place in healthcare to ensure that 
quality care is being commissioned, measured and delivered to all. Collecting 
patient data in healthcare is evident in many forms such as patient reported 
outcome measures, Quality of Life and Assessment all of which will be 
summarised in Chapter Three. 
The experiences expressed by this rigorous literature review were similar to the 
thematic analysis that took place in Study One (COPD PREM development)  
as outlined in the themes and descriptors in Tables 2.3 and 2.4 suggesting the 
widespread qualitative literature available supports the descriptors and items 
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generated within each of the 4 themes for the preliminary COPD PREM-38 
instrument. 
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CHAPTER THREE 
 
3. Measuring Healthcare through Instruments 
 
3.1. Introduction 
 
The introduction to the literature review in Chapter Two gave a concise overview 
of what it meant by experience, how it is defined and also how experience is 
intertwined with many of the fundamental business values that we ourselves 
experience as customers and as users of the health service as patients. The 
literature review then focussed on a systematic search of the literature in relation 
to experience and COPD, firstly exploring if experience in COPD was being 
measured and then delving deeper into the understanding of the qualitative 
literature that surrounds the lived experience of people with COPD, and described 
in detail the impact it had on daily life from diagnosis to end of life care. This next 
chapter will explore further areas that have been touched on in previous chapters 
but now with a clearer focus on the meaning of healthcare measurement through 
instruments leading to the aim and objectives of this study. 
3.2. Patient Satisfaction 
 
Patient satisfaction was discussed in the opening section of the literature review in 
terms of the misconceptions that surround the terminology of patient satisfaction 
and that of the measurement of healthcare and the measurement of quality care 
which is now the focus of healthcare delivery. Much like the descriptors highlighted 
in Chapter Two Table 2.4 the experience and terminology is varied across the 
health service, from a series of smiling and angry faces, or tick boxes to describe 
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your personal satisfaction of a clinic appointment, to the annual NHS patient 
satisfaction surveys. Patient satisfaction surveys are now routinely used in 
hospitals in many European countries  as a benchmark of how well services are 
performing from the ‘patient perspective’ (Säilä, Mattila, Kaila, Aalto, & Kaunonen, 
2008). In a range of NHS hospitals and general practices in the UK, it is possible 
to complete satisfaction surveys at electronic booths in hospital foyers or as you 
leave the building at GP practices, moving towards real-time patient satisfaction 
feedback (Southampton University Hospital; Clapham Family Practice). This data 
is then often used to describe the ‘patient experience’ in quality accounts or trust 
reports. 
3.2.1. Patient Experience  ̶  Measuring what is important 
 
As Chapter One suggested there is a national drive to collect patient experience 
across NHS services and report for NHS organisations. The Health Foundation 
(2013) undertook a comprehensive evidence scan which explored further the 
concept of patient experience in the health service. The Health Foundation report 
(2013, p.20) like others (Black, 2013; Cornwell, 2012) advocate that the 
measurement of experience could potentially enhance patients’ expectations, 
experience and satisfaction of healthcare. The evidence scan explored 328 
empirical studies and gives a comprehensive overview of the current literature 
published, but, most importantly, understands and highlights that there are  
a number of different options for the ways in which healthcare can be measured as 
shown in Figure 3.1.  
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Figure 3.1 shows the number of examples of methods used to measure patient 
and carer experience of health services. Reproduced from Health Foundation 
Report (2013, p.7). 
 
Figure 3.1 Methods of Patient Feedback  
 
Figure 3.1 demonstrates that qualitative methods such as one to one interviews  
focus groups, which give more descriptive data as evidenced in Lindgren et al., 
(2014); Powell et al., (2013); and Lowey et al., (2013) previous papers in the 
studies of experience and living with COPD. There are also less descriptive 
methods of collecting data, such as using surveys and comments cards as used 
within. An example of this is the NHS England’s Family and Friends test as 
previously introduced in Chapter One (Dixon-Woods, Minion, McKee, Willars,  
& Martin, 2014). There remains confusion among health professionals between 
the definitions of experience and the terminology and the collection of ‘patient 
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experience’. The difference between healthcare professionals' definition  
of experience vs. satisfaction  in these new  methods of measurement such as the 
family and friends test (Hodson & Andrew, 2014) .  
 It has become clear that the different measurements and the collection  
of healthcare experience cannot be undertaken simply by one specific measure or 
measurement, because healthcare remains complex and varied, and there are  
a number of different elements that potentially impact on the measurement of 
experience in multifaceted health systems such as the NHS (Beattie, Lauder, 
Atherton, & Murphy, 2014, pp.1-4). However, it is critical to understand which 
methods to use to measure so that the right evaluation of the phenomena 
is made, enabling meaningful data to be collected which support service 
development or improve quality care (LaVela & Gallan, 2014). Traditionally, 
however, patient experience measures seek to measure the topics of the most 
significance to the majority of patients  (Graham & Woods, 2013). And an 
important aspect to note in the development of any new instrument is that they 
should be based partly upon evidence of what matters to patients, which is clear 
within the qualitative descriptors of experience and as identified by Disler et al. 
(2014). 
3.2.2. Patient Reported Experience Measures (PREMs) 
 
PREM is a measurement of a patient’s perception of their personal experience of 
the healthcare they have received. PREM instruments should focus on the aspects 
of the care that matter to the patient (Coulter et al 2009). PREM results can be 
used to improve services and provide a patient view on these improvements that 
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moves away from the technological or economic model that is often employed  
in service design.  
In contrast to PROMs, which have been utilised widely for elective surgical 
procedures, there has been very little research or practical application of PREMs. 
The Picker Institute UK have come closest with a number of questions within the 
UK based national NHS patient survey that explores generic patient experiences 
(Jenkinson, Coulter, & Bruster, 2002) using survey methods. As the previous 
literature suggests much of what has been collected in COPD has been 
descriptive data or feedback on symptoms, or experience of intervention used to 
improve service re-design.  
The previous rigorous literature review (Chapter Two) identified that there is,  
to date, no condition-specific PREM for COPD. While generic PREMs are 
important, they risk losing elements of a patient’s experience that are specific  
or weighted towards a particular disease or illness that is the dominant reason for 
a patient seeking healthcare assistance. These issues are even more complex in 
that a disease-specific healthcare experience for a patient may involve different 
facets of care that reflect different aspects of a patient pathway or journey,  
for example, a hospitalisation for a severe exacerbation compared with a routine 
annual review in primary care.  This may be similar in other complex long term 
conditions. The previous empirical scan (Health Foundation 2013), already 
highlights further a number of different surveys and questionnaires for 
measurement of experience in primary and hospital care, as well as the 
measurement for carers. One example is the Annual General Practice Patient 
Survey in England (GP-patient, 2014) designed to assess and review patients’ 
experience of general practice. However, a qualitative study of GPs and practice 
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staff suggest that there is a mismatch between the design of the survey and the 
actual patient ‘satisfaction’ reported (Asprey et al., 2013). This highlights and 
supports the earlier discrepancies around terminology of experience and 
satisfaction used within this type of service provision reporting on patient 
experience. Williams, (1994, p.509) agrees, suggesting that many satisfaction 
surveys only provide a false impression of consumerism, producing results which 
tend only to ‘endorse the status quo’. 
Both European international audits in COPD (Roberts, Luis Lopez-Campos,  
& Hartl, 2012) and UK National audits (Stone et al., 2009) and have shown 
significant deficiencies in acute hospital care for COPD when benchmarked 
against the guideline audits,  reporting wide variation between acute hospitals.  
In response these audits the Department of Health have produced a national 
service strategy document, underpinned by the National Institute of Health and 
Care Excellence quality standards. This document suggests that the measurement 
of patient outcome metrics. The suggested metrics measurement of both PROMs 
and PREMs for COPD gaining new insight with patients with COPD (Hodson et al., 
2013, p362). PREMs also have the potential to noticeably change the consultation 
with patients by re-focusing from what the clinician wishes to discuss to a patient-
centred approach with interaction based upon what is important to the patient.   
In the context of this thesis a disease specific PREM in COPD is essential. The 
need to focus on patients’ experience and capture important episodes in the 
patients journey such as ‘exacerbations’ are essential to the positive experience of 
a patient’s understanding of the healthcare system.  
At the time of writing, there are no COPD-specific PREMs that can be employed to 
measure the quality of a patient's interaction with healthcare, and reliance  
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is currently being placed on generic measures such as the national NHS Survey 
and GP survey to capture experiences of living with COPD. However, there are 
steps to explore further the concept of a PREM in COPD as the previous 
systematic literature showed (Hodson et al. 2014). A 5-year national audit for 
COPD (Royal College of Physicians 2013) for the first time has explored the 
feasibility of measuring a PREM in the COPD population by initially exploring  
a number of different patient collection sources (British Lung Foundation, 2014  
in press). 
3.2.3. Patient Reported Outcome Measures (PROMs) 
 
PROMs are self-report questionnaires or scales, and seek to measure patients 
perceptions of their health status or health-related quality of life, normally 
completed by patients  (Hodson et al., 2013).  PROMs are familiar research tools 
and are widely accepted, but are now ever more used to direct individual patients 
as a measure of an intervention and to provide patient related comparative data 
across health care providers. And are potentially  a useful measure of quality from 
the healthcare provider or clinician (Black, 2013).  
PROMs can be variable in their application to a population or even to a specific 
condition. The content tends to focus on one or more of physical functioning, 
symptoms, social wellbeing, psychological wellbeing, cognitive function and role 
activities such as the St Georges Respiratory Questionnaire (SGRQ) does (Jones, 
2011). Patients score their perceived status against a statement with a scale.  
The European  Quality of Life Instrument (EQ-5D) (EuroQol, 1990) is an example 
of a generic  PROM and the Oxford Knee Score (Dawson, Fitzpatrick, Murray,  
& Carr, 1998) is another example of where a condition specific tool has been 
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developed. For a PROM to be used in routine clinical practice it must be simple to 
complete and contain few items concentrating on those relevant to the patient.  
The EQ-5D has 5 domains with 3 questions in each while the Oxford Knee Score 
uses 12 questions covering mobility, pain, and activities. 
Since 2009, following reports recommending the introduction of PROMs use in the 
NHS (Darzi, 2008; Darzi., 2007) all NHS hospitals have been required to ask 
patients to complete a PROM questionnaire before and after four specific elective 
surgical procedures with results being published nationally. Black, (2013, p.346) 
stresses that the measurements and benefits of PROMs are still not fully known in 
the healthcare service. This is because of a combination of reasons partly as 
PROMs are embedded in research but also that they are commonly not used as in 
other countries.  
While PROMs for long-term medical conditions, such as COPD, as yet, do not 
appear in this formalised NHS data collection, they may in the future of care. 
Traditionally, PROMs for elective procedures are usually administered before and 
after the surgery itself to measure effect. Such an approach may be more difficult 
for some medical conditions, for example, an exacerbation of COPD, when 
patients are unwell. However the addition of such measures provides a new 
knowledge with which we can assess the effectiveness of an intervention.  There 
are a number of COPD specific PROM instruments which are broadly 
acknowledged forms of measurements in trials, for example the COPD 
Assessment Tool (Jones et al. 2009), and Chronic Respiratory Disease 
Questionnaire (CRDQ) (Jones, 2011) both of which are  
self-reported questionnaires and used widely within current COPD research 
(Kaplan, 2010). The CAT is a COPD specific PROM designed to focus on the 
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impact of symptoms on everyday life but is a much easier self-administered 
questionnaire consisting of 8 Items (Jones et al. 2009) compared to the CRDQ  
of 20 questions. 
An example of where PROMs are used widely in COPD care as an outcome  
of intervention is in the area of pulmonary rehabilitation and research. These 
programmes consists of an education and exercise and is the commonest 
intervention to effectively measure PROMs as a measure of patient reported 
outcome and measure for use pre- and post-intervention, in this case education 
and physical activity. The Quality standards produced by the BTS (2014) make 
recommendation that the measurements of simple PROMs are an effective 
measurement of outcome. Measurement of PROMs in PR has been standard  
in many clinical trials results in grade A evidence in PR (Mikelsons & Wedzicha, 
2009; Murphy et al., 2011; Seymour et al., 2010). An example of this  is a multi-
centred, prospective study (n=261) using the CAT within a pulmonary rehabilitation 
setting which demonstrated that the CAT could be used as a simple outcome 
measure as it improves in response to PR and allows for different categories  
of response (Dodd et al., 2011).   
It is clear that PROMs have become a common outcome measure used in  
a number of different clinical areas within healthcare. PROMs add a different 
aspect: they are more patient-centred than the measurement of satisfaction alone. 
If used correctly they are simple and effective ‘measures’ of clinical intervention, 
becoming routine in clinical practice. However, how can the ‘experience’ of this 
intervention be captured? Further work needs to be done with the use of disease-
specific PREMs and PROMs to determine their possible relationship to further 
improve the quality of life for patients living with COPD. 
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3.2.4. Quality of Life 
 
Shortness of breath, dyspnoea, breathlessness are all common descriptors  
of experience used to describe the most documented symptom experienced by 
people living with COPD. It is  recorded by COPD patients as having major  impact 
and an increased burden on health related quality of life (QoL) (Disler et al., 2014; 
Giacomini et al., 2012; Lowey et al., 2013). The measurement of quality of life has 
been reported on for many years. Mandzuk & McMillan, (2005, pp.12-14) claim 
that the use of the terminology of the concept health-related quality of life (QoL)  
is however, very often misunderstood or ill defined. This is emphasised more 
clearly by Allison et al., (1997, pp.221-222) who suggest the underlying construct 
of QoL instruments are often not valid, concentrating much more on the content 
rather than the relevance of the measurement and the complex aspect of 
constructs such as QoL.  
Quality of life is also being measured by the vast number of PROMs which were 
identified earlier as ways in which to interpret the views of patients in everyday 
activity or through the impact of intervention. This leads to a broader 
understanding of terminology used to describe quality of life measurement.  
The themes and descriptors used in the literature review of experience of patients 
with COPD also has a clear association with quality of life, from impact on 
symptoms, such as breathlessness and cough, to the effects of COPD has from 
diagnosis through to end of life care. A number of generic outcome measures 
explore specific aspects of care. An example of this is the use of the Dyspneoa-12 
(Yorke et al, 2010) which was developed to give a global score of breathlessness 
and encompasses both ‘physical’ and ‘affective’ aspect  but critically over a 
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number of different lung diseases such as COPD, Interstitial Lung Disease (ILD) 
and Heart Failure (HF) (Yorke, Moosavi, Shuldham, & Jones., 2010, p.21). 
3.3. Why COPD-Specific measures? 
 
3.3.1. COPD and PROMs 
 
As previously suggested it is evident that measurements that have been 
developed and validated for use with a specific condition such as COPD for 
identifying the evidence of views, opinions or experience being sought are far 
better than the use of more generic non-specialist measures at reflecting the 
emphasis on the holistic specialist needs of the patients (Hodson & Andrew, 2014; 
Weldam, Schuurmans, Liu, & Lammers, 2013). It is now common practice that 
COPD health measurement or quality of life measurement are central to research 
and  that reported changes in these have become a major driver for presentation 
and quantifying research affect (Jones, 2001).  
PROMs are now a regular aspect of measurement of outcome not just in 
pharmacological research, but also in interventional studies in COPD. One such 
example, is Davey et al., (2014) who used a number of PROMs as 'outcomes'  
in the use of lung volume reduction  surgery with endobronchial valves, in patients 
with heterogeneous emphysema.  Davey et al., (2014, p.2)  identified a number of 
PROMs such as  the 6 minute walking test (6MWT) and other outcome measures 
such as the CAT and quality of life measurement questionnaires (EQ-5D). These 
together were used to monitor secondary endpoints to the study, using changes  
in FEV1 as the primary outcome. 
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3.3.2. Assessment of COPD 
 
Terminology used in the assessment and measurement in COPD is confusing  
as to what is an ‘outcome measure’ of patient experience, satisfaction or of 
outcome intervention. There are an excessive number of patient reported 
instruments either disease specific or generic. Current instruments used widely in 
COPD constitute testing or assessing COPD through symptoms or endurance. 
The assessment in COPD merely becomes tailored on ‘descriptions’ of ‘symptoms’ 
and impact as outcomes for the overarching aim of improving COPD care for 
patients. Pulmonary Rehabilitation is a good example of where assessment  
of patient reported outcome, satisfaction and the experience of patients can be 
combined. This develops an ‘overarching holistic assessment’ of patients and 
‘outcome’ based upon their  experience, that is individualised and maximising 
patient-centred care and improving the quality of care measured by effectiveness 
of the service (PROM indicators) plus the patient experience. Further evidence  
is needed to understand fully the holistic understand of PREMs and PROMs 
together in providing and measuring holistic care for COPD patients. 
Like patient reported outcomes or (PROMs), terminology remains fragmented. 
Partly this has come from the vast number of instruments that have been 
developed which are either condition specific (CAT or SGRQ) or more generic but 
mapped within the respiratory umbrella. Validation and reliability in instrument 
development should remain at the heart of this alongside the patients and should 
remain the key factors in choosing an instrument to use with patients. But what is 
most important in all of this, and the key question, is what is being measured, and 
why? The early concepts of quality and patient experience are a third component 
of this suggestion that alongside the measurement of a patient reported outcome 
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you need further engagement with PROMs, PREMs and a measure of health 
status measures to compliment the vast number of measurements of instruments 
on patients. This is supported by previous work by Cornwell (2012, p.1) who 
recommends that patient experience should be aligned with other measures such 
as PROMs and health-related QoL measures such as the EQ-5D (Dolan 1997). 
There is currently a National Royal College of Physicians COPD audit reviewing 
three aspects of COPD care: primary care, pulmonary rehabilitation and 
secondary care. Alongside this there is a national recognition that the patient 
experience should also be captured alongside the medical, operational and clinical 
aspects of the COPD audit. A recent feasibility study by the British Lung 
Foundation (2014) explored a number of different options for the collection of 
patient experience data through on-line, postal and ‘live’ patient data collection. 
Preliminary results are indicating that postal questionnaires give a much greater 
return rate than relying on healthcare professionals or patients completing 
questionnaires on line (Picker Institute 2014). These different perspectives in 
patient data collection need to be considered to ensure that the data collected is 
meaningful, patient centred and that healthcare can develop and learn from this 
data to ensure quality care both now and into the future. 
3.4. Questionnaire Design & Validation 
 
The need to ensure that questionnaires or surveys have a robust methodology and 
appropriate methods used including sample size and population to reduce bias 
and appropriate rigor with a structured validation process through the testing of the 
proposed questionnaire through reliability and validity is important. The benefits of 
questionnaires include quick and reliable data to enable the appropriate analysis 
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and data collection (Rattray & Jones, 2007). The use of questionnaire design will 
be discussed further in Chapter Four. 
3.5. COPD PREM Development 
 
This following section will outline the overarching aims and objectives of the 
development of the patient experience measure in COPD as introduced within the 
introduction chapter of this thesis know as Study Two. 
3.5.1. Aim of Study Two 
 
The overall aim of this thesis (Study Two) was to continue the previous work of 
Study One (COPD PREM development) by developing a reliable and validated 
disease-specific patient reported experience measure (PREM) in COPD.  
The concept of the development was for the COPD-PREM to be used in everyday 
clinical practice by a variety of healthcare professionals from the multidisciplinary 
team. The COPD-PREM would also be used in a number of clinical settings such 
as pulmonary rehabilitation, nurse-led clinics or GP COPD annual reviews to 
support healthcare professionals understand the positive and negative 
experiences of people living with COPD.  
3.5.2. Research Objectives 
 
The following five research objectives were identified as part of this study: 
• Objective 1: To develop a COPD PREM item list that is relevant across all 
severities of COPD (Study One); 
• Objective 2: To refine and reduce the preliminary list of items to fit  
a psychometric model through Rasch analysis; 
• Objective 3: To assess the reliability of the final COPD PREM items; 
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• Objective 4: To assess the validity of the final COPD PREM items;  
• Objective 5: To assess whether the construct validity of items varies  
by patients clinical and/or demographic characteristics. 
The development of the COPD-PREM overarching aim is to improve the quality of 
life and care provided to people living with COPD. Though clinical audit, 
benchmarking and improving services for COPD patients. Whilst, engaging in 
conversation with patients using the PREM instrument to guide and improve the 
current experience of COPD patients. Overall thereby improving the accountability, 
transparency and quality of care provided to patients living with COPD. 
3.6. Conclusion 
 
There is a vast sum of literature summarised within these three main papers and 
reports: The Health Foundation (2013); LaVela & Gallan., (2014); Beattie et al., 
(2014) relating to the complexities and different constructs of healthcare 
measurement. Healthcare professionals' views on the understanding of 
measurement and definitions of patient satisfaction, experience and outcomes for 
patients is varied. However, what is evident is that conflicting terminology, not only 
just in what is written in the literature but also on the focus on the national 
definitions is also misunderstood.  
The current challenge needs to focus on the robust holistic assessment  
of patients, using the most appropriate tools in patient' measurement. The need to 
support healthcare professional assess and meet these needs of patients while 
designing quality services to ensure patient-centred care to measure quality and 
patient experience needs to be undertaken through  a wider concept of both the 
collection of qualitative and quantitative data.  
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The development of a disease specific patient reported experience measure 
(PREM) instrument in COPD, will add to this diverse number of measures, but 
through its robust design methodology and development. There is a need to 
measure the vast descriptors identified in Chapter Two which will help support the 
measurement of experience rather than the continued reporting of living with 
experience, to make a difference or change in health care. 
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CHAPTER FOUR 
 
4. Development of a Patient Reported Experience Measure in 
COPD 
 
4.1. Introduction 
 
Previous chapters have highlighted the complexities of the measurement of patient 
experience. And as the Literature Review highlights there is currently no 
measurement of experience of living with COPD or with the utilisation  
of healthcare. The results of Study One (COPD PREM development) of the PREM 
development process supports the current study’s aim that descriptions of 
experience of living with COPD can be quantified using a questionnaire format. 
The Literature Review did not highlight a measurement of patient experience  
in COPD; it did, however, support the item descriptors and themes of experience 
in COPD identified within Study One (COPD PREM development).  
This chapter presents the theory underpinning instrument development including 
measurement theory and key psychometric principles. The application of these 
principles in this thesis are described in Chapter Five which illustrate the methods 
used in Study Two. 
4.2. Methodology 
 
4.2.1. Latent Constructs and Measurement Theory 
 
Over recent years the development and construction of new instruments by nurses 
have evolved (Cappelleri et al., 2000; Green & Frantom., 2002; Yorke et al., 2014). 
The use of these instruments to measure different aspects of health care such as 
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patient satisfaction, quality of life, and disability/activity, continue to be used in 
both clinical and research settings. As such, it is imperative that such instruments 
are developed using rigorous and well-established methods and demonstrate 
appropriate reliability and validity. Instruments often measure subjective 
phenomena relating to something we observe in the real world such as a person’s 
perception of their quality of life, symptom experience or satisfaction with health 
care provision. They also measure phenomena that only exists as part of a theory, 
often called latent traits, such as an attitude or an ability, which can be measured 
directly or through observation (Hoijtink, 1991). Therefore, experience is a latent 
trait construct. Garger, (‘latent construct’ 2014), suggests to measure a latent 
construct, researchers should capture indicators that represent the underlying 
construct. In this study, experience, due to the complexities and its varied 
meaning, is difficult to measure directly through observation.  
Previous measurement models of experience have focused on the development 
indicators and/or measures that are directly reported through self-reported 
measures such as PREM questionnaires (Jenkinson et al., 2002). A number  of 
generic experience instruments have been developed to capture the experience  
of patients in relation to different aspects of healthcare and disease specific 
experience (Health Foundation 2013). 
An approach on the design and validation on PROMs by Atkinson & Lennox, 
(2006, p.65) the claim that the concept of ‘self-reporting’, suggests that such 
measurements who use this approach are ‘one step’ removed from the underlying 
construct of the PROM, to that of the actual phenomena. Therefore, it is feasible 
that you may only record what the outcome is measuring and not the observed 
construct. Because of the inferred nature of self-reported measures,  
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the development of any new experience instrument needs to ensure that it is 
credible through appropriate reliability and validity that must be demonstrated by 
testing the instrument’s theoretical relationships to other established criteria 
(McIntosh-Scott, Mason, Mason-Whitehead, & Coyle, 2014). There are several 
methodological approaches to consider in the measurement of experience. 
4.2.2. Levels of Measurement 
 
A level of measurement refers to that of a relationship between the numerical 
values assigned to the attributes that underpin a variable. In other terms, there can 
be many ways to measure a certain aspect of the underlying construct. For 
example, height can be measured in feet or inches, but it can also be classified as 
short, tall or very tall. The results are critical to understanding the statistical tests 
that can be undertaken on the results that follow. There are four main levels  
of measurement, these being nominal, ordinal, interval and ratio.  
Nominal is typically used for classification for example male or female, a.m. or 
p.m., and a number is then assigned to the word: male=1 and female=2,  
for instance. Nominal data can be used to categorise the data collected. This type 
of measurement will be used when results of some of the demographic data will be 
entered into the statistics package for analysing results.  
Ordinal measurement enables the researcher to collect data that provides  
a direction, for example low medium high or hot or cold. There are a number of 
additional outcome measures for breathlessness, for example, that provide a level 
of ordinal data. For example, participants could be ranked by the intensity  
of breathlessness, frequency of occurrence or its effect on activity or quality of life. 
For daily activity limitation, the scale could be 0=no limitation; 1=some limitation; 
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2=moderate limitation; and 3=severely limited (Yorke et al., 2010). The Medical 
Research Council scale (Appendix Seven) is also a good example of the collection 
of ordinal data and is a tool used in Study Two. 
The final two levels of measurement are interval scales, which take the idea of 
ranking items in order one step further, since the distance between adjacent points 
on the scale are equal. A good example of this is the measurement of time on  
a 24-hour clock. For example, it is the same difference in time if measured 
between 12:00 and 13:00 compared to 12:00 and 01:00. Other example of 
measurements in intervals is the measure of temperature. Temperature can also 
be used in the final scale of measurement 'ratio'. Ratio data is a special kind of 
interval data.  Like interval data, ratio data is measured on a scale that has equal 
gaps or intervals between the points on the scale.  However, with interval data the 
zero-value on the scale has no numerical significance attached to it.  It is merely  
a convenient but not an essential point on the scale.  Using temperature as an 
example, 0 0C conveniently describes the point at which water freezes.  However 
there is no reason why this point could not be assigned another numerical value 
(as it is using the Fahrenheit scale).  On an interval scale, the zero-value does not 
signify a necessary end-point to the scale.  It is possible to measure temperatures 
of -100C, -200C and below. 
Another example of a ratio scale often used in research is time.  In this sense  
it would be impossible for a participant in a reaction time experiment to obtain  
a score of less than 0 seconds. The participant would only obtain a score of  
0 seconds if his or her response were instantaneous. 
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4.2.3. Constructing Measures 
 
The development of new instruments can be intricate and requires a number of 
different steps to ensure that the instrument developed is reliable and valid for use. 
The diversity in the types of measurement models exist in the psychometric testing 
of instruments to ensure the quality of the instrument and to develop and 
demonstrate its reliability and validity (Polit & Beck, 2012). For the purposes of this 
chapter the underlying construct of measurement will focus on two main 
psychometric theories: Classical Test Theory (CTT) and Item Response Theory 
(IRT). Much of the earlier work surrounding psychometric testing and the reduction 
of items within an instrument was guided through the CTT (Nunnally & Bernstein, 
1994, p.65). Contemporary psychometric approaches one being Rasch, apply IRT 
for the development and refinement of instruments (Pallant & Tennant, 2007, p.7). 
Rasch analysis is the most commonly applied approach in health care and is 
recommended by the US Food and Drug Administration (FDA) (Appendix Twelve) 
for the development of patient reported outcome measures (U.S. Department of 
Health and Human Services FDA Center for Drug Evaluation and Research, U.S. 
Department of Health and Human Services FDA Center for Biologics Evaluation 
and Research, & U.S. Department of Health and Human Services FDA Center for 
Devices and Radiological Health, 2006). Through the development and methods 
of item reduction, contemporary models have become more accepted, in particular 
Rasch analysis, which has grown momentum not just in developing new 
instruments (Green & Frantom., 2002; Tor., 2011; Yorke, Horton, & Jones, 2012A) 
but also in the assessment of well-established instruments (for example the 
Hospital Anxiety and Depression scale) (Zigmond and Snaith, 1983) in order to 
gain a greater understanding of their measurement properties (Pallant and 
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Tennant, 2007). These two psychometric approaches are concerned primarily with 
the same challenge, measuring a subjective phenomenon (a single point of view), 
but constructed upon altered levels of mathematical theory and different methods. 
The next few paragraphs will review these two approaches, CTT and IRT, with the 
focus being on the theory and application of Rasch analysis. 
4.2.4. Classical Test Theory (CTT) 
 
Classical Test Theory (CTT) includes a set of concepts and methods that give a 
basis for a number of the measurement instruments currently used in health today. 
These concepts of CTT date back to work by Francis Edgeworth (late 19th 
century) and Spearman (early 20th century). Central to the theory are three areas, 
that of the observed score variable is based upon two other components: the true 
score variable and the error score variable. The principle is that an observed total 
score on an instrument, X, consists of the sum of a ‘true score’, T, and an ‘error 
component’, E as shown in Figure 4.1: 
(X) Observed = True + Error 
Figure 4.1 Classical Test Theory Equation (Millsap & Alberto 2009) 
 
This equation therefore suggests that the CTT for answers to an instrument will 
only expose a participant’s observed score, but this may not always be reflective 
of their ‘true’ score. Therefore this equation is highlighting that there is always 
something in the 'environment' that impacts an individual’s performance shown in 
the equation as a ‘error’. It has therefore been suggested that a limitation of the 
CTT is that any instrument that is designed to ‘measure a construct’ true score  
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is limited or flawed due to the possible underlying nature of ‘error’ in an instrument 
(Graduates-First, 2014).  
One of the founding principles of CTT within psychometric testing is the concept to 
recognise and develop reliability of psychological tests and assessments. Normally 
this is measured by the performance of a participant undertaking the test and the 
difficulty of the questions within a test. Reliability, therefore, is calculated by the 
participant’s individual score on the instrument or test (observed score) and the 
number of errors in the test itself (error). These two areas give a suggestion of a 
participant’s ‘true score’, without errors in the measurement. However,  
as mentioned, random errors can happen due to a number of different reasons 
such as being tired or hungry as well as errors with the process of testing itself. If a 
'common error' however is found this can potentially be removed thereby reducing 
the 'common error'. A higher test error would generate more positive and reliable 
scores.  
Though a popular theory and widely used for measurement of instruments, to date 
there have been a number of limitations that have been identified. These include 
the need for a precisely ordered continuum of items with the purpose  
of representing a unidimensional construct, and secondly the under representation 
of additive of rating scale data (Prieto, Alonso, & Lamarca, 2003). 
4.2.5. Rasch Model 
 
In contrast to the CTT, the Rasch model is an item response theory which 
explores how well each item fits to the overall instrument – that is, that all items fit 
the Rasch unidimensional model and measure the same underlying construct. 
George Rasch (1960), a Danish mathematician, initially developed a dichotomous 
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logistic response model that was further developed to include polytomous 
response options. The Rasch model takes responses for each item entered on a 
'linear probabilistic interaction' in terms of a participant’s ‘ability’ and on items of 
'difficulty' (Rasch 1993). The Rasch model creates a line of measurement with the 
items located hierarchically and presents a group of fit statistics. Fit statistics in 
Rasch show just how well the different items entered in the instrument describe 
the group of participants and how well individual participants fit to the total group 
(Prieto et al., 2003). Wilson, (2005, p.123) clarifies that 'fit statistics pinpoint 
problem items and can be helpful in diagnosing the causes of problems'. 
Essentially, the model examines the relationship between the latent traits and their 
response to the items tested in a proposed instrument. Therefore in the 
measurement of experience in COPD, patients’ responses in the Rasch model will 
make an association between the level of item experience (0=good and 5=bad) 
experience compared to the underlying latent variable being measured by the 
instrument (individual item patient experience).  
The Rasch model deals with scales that have a multiple response, allowing for the 
results of these to be summed together and then tested against what is expected 
by the model. This turns out to be a probabilistic form of Guttman scaling (Tennant 
& Conaghan, 2007). Thus, if an item associated with a good experience is 
confirmed by a participant, there is a high probability that other items with a lower 
score will also be confirmed by the same participant (in this thesis participants who 
have good experience are more likely to score lower on all items). The probability 
of a participant choosing a definite response to an item is called the log-odds (i.e. 
a logistic function) of the difference between the level of experience represented 
by the item and that possessed by the participant. The experience estimates are 
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probabilistic and reported in ‘logits’ – the log-odds of affirming an item (Tennant 
and Conaghan, 2007).  
Therefore the Rasch model is designed to be a template in what the model 
expects and the actual data being read. There are also a number of other 
concepts which are taken into account such as category ordering (do the 
categories of an item work as you would expect them to?). It also explores item 
bias.  
Using the Rasch model and entering the raw data into this model enables a well-
designed approach to undertaking a number of key methodological approaches 
associated with scale instrument development and construct validation needed for 
the PREM-COPD development. The Rasch model has already been used to 
develop a number of patient reported outcomes commonly used in COPD care 
(Yorke et al., 2010; Jones et al., 2009), thereby already measuring different 
constructs of COPD care such as symptoms and health status. Rasch has also 
been used to test a number of different instrument developments in long term 
conditions and experience measurement such as Parkinson’s, Multiple Sclerosis 
and Stroke care (Franchignoni, Giordano, & Ferriero, 2008; Mills et al., 2012; Mills, 
Young, Pallant, & Tennant, 2010).  
The Rasch model is being used as the underlying theory base for the development 
of the preliminary COPD PREM.  This model allows instruments to be designed 
with a set of items which are intended to be summed together to provide a total 
score. This model has been designed to meet expectations and demonstrate 
unidimensionality. This approach enables the model to measure one attribute at  
a time, allowing for items to function in unison to form a single underlying pattern 
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in a data matrix (McNamara, 1996). In Rasch terms, this means that all of the non-
random variance created within the data can be accounted for by a distinct single 
dimension of difficulty and ability (Sick, 2010). 
CTT and IRT are, in general, consistent and balanced; however, the Rasch model 
makes more rigorous assumptions and has several advantages over the CTT. For 
example, the Rasch model broadens the conception of reliability. With CTT, the 
accuracy of an instrument (i.e. the degree to which measurement is free of error) 
is marked on just a single estimate of reliability – which is the ratio of true score 
and observed score variance (Borsboom, 2005, pp.6-8). This is restricted to 
providing a test’s average reliability. Therefore, the measurement accuracy  
at particular score levels is unknown, whereas in the Rasch model the analysis 
measures scale accuracy across the instrument’s entire scaling range, even 
though it may not be consistent across the whole range. Rasch analysis tests the 
functioning of each item at different groups of severity levels (referred to as class 
intervals) (Tennant and Conaghan, 2007). Rasch analysis enables the severity 
score for both the participants and the severity of the questionnaire items’ 
responses to be located on the identical metric scale (Tennant and Conaghan, 
2007). This means the participant and severity of an item can be evaluated 
significantly. 
4.3. Key Concepts in Measurement 
 
4.3.1. Instrument Characteristics 
 
The development of an instrument is a complex science and instruments can 
possess many different characteristics, each requiring assessment to ensure that 
it captures and measures what it purports to be in a reliable and valid manner. 
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Chapter Three gave a broad overview in the different types of current 
measurements used within healthcare including the use of PROMs, patient 
satisfaction and experience measures.  
4.3.2. Instrument Response Options 
 
There are a number of diverse instrument designs and response or item scaling 
options that can be used to measure the phenomenon of interest. The response 
options used will be different depending on the theoretical underpinnings and aims 
of the instrument being constructed. This also clearly impacts on future analysis 
decisions.  
The Likert-type scale, sometimes known as a frequency scale, is the most 
common scale used within outcome measures for COPD care (Jones et al. 2009). 
This type of scale is fixed choice so aims to discover a participant’s particular 
opinion or attitude. It collects ordinal data on, for example, how strongly a person 
agrees or disagrees with a statement or the severity of a symptom, for example. 
The advantage of this type of scale allows for a degree of opinion and enables for 
a wider breadth of understanding for further research and comparison. However, 
one of the major disadvantages of this type of scale is that it allows the participant 
to have some variance in their response and they may therefore rate a symptom 
more positively than a true reflection would see (McLeod, 2008). This type of 
scale, along with dichotomous scales, can be divided into categories. Normally a 
yes/no questions are used, but it can also include other types of categories such 
as true/false or agree/disagree. Each dichotomous scale must have only have one 
answer and cannot be both. An advantage of this type of scaling is that it gives  
a clear and concise answer, therefore reducing bias. However, disadvantages of 
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this type of scaling are that it limits the responses to a question, and, therefore, the 
data is not as rich given the simple data to be analysed. Many phenomena 
measured in health are not as simple as being present or not; rather, they exist 
along a continuum of frequency of occurrence or severity. This is familiar in the 
instrument design for patient satisfaction surveys. The GP Patient Survey (Picker 
2013b) was a clear example of a design using of both types of scales in one 
instrument.  
A further example of instrument response items at interval level is a semantic 
differential scale. This is normally a seven-point bipolar rating scale using 
adjectival opposites, and it was developed by Osgood, Suci and Tannenbaum in 
the 1950s. An example of this could be the rating of happiness on a scale of 1 to 
7, with 1 being happy, and 7 being unhappy. The participant chooses a number 
from 1 to 7 to answer that particular question. An advantage of this type of scaling 
is that it is easy to implement, but also gives the participant a range to choose 
from. A disadvantage, however, like the Likert scale, is that these types of options 
leave open the door to wide variance.  
4.4. Instrument reliability and validity 
 
4.4.1. Internal Reliability 
 
The reliability of an instrument is important in demonstrating that the values 
assigned are consistent and that it can be used repeatedly, (Rattray & Jones, 
2007).This section will highlight a number of the statistical measures that test 
these qualities and form part of the overall Rasch model analysis too. In any 
instrument development, one of the first phases is to undertake an hierarchical 
item reduction, which enables items that have been tested in a population to 
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assess for any correlations with a number of different population characteristics 
such as age or gender to be removed, thereby ensuring the development of the 
reliability of the instrument to ensure satisfactory properties (discussed further in 
the methods in Chapter Five). 
A common practice in developing new instruments is to demonstrate the reliability 
of the instrument by displaying the use of the Cronbach's alpha (α) statistic. This 
statistic uses inter-item correlations to decide whether constituent items are 
measuring the same construct (Jack & Clarke, 1998; Rattray & Jones, 2007). 
There are a number of different levels of alpha measurement depending on what 
is being measured, but for comparing groups, α values of 0.7 to 0.8 are regarded 
as satisfactory. For clinical purposes, reliability of α values should be higher with 
the minimum being 0.9 (Bland & Altman, 1997,  p.572). Specifically to the Rasch 
analysis the analogous measure is the Person Separation Index (PSI). The PSI is 
equivalent to the α statistics, and Tennant & Conaghan, (2007, p.1361) 
recommend that the minimum value of 0.85 is appropriate for individual use.  
The PSI is the estimate of logit scale for each person and formulates part of the 
overall fit statistics shown in the Rasch model.  
To ensure stability of an instrument over time, it is key that the instrument being 
tested is reviewed and is able to track and is sensitive to change over time. A test-
retest method of reliability can be an effective measure of stability over time and 
can be used to review its consistency over time (Frank-Stromborg, 1988). Any new 
instrument development needs to ensure that for its reliability the results of two 
measurement points offer no significant changes in the two points measured.  
This is an important factor if  instruments are  to be used in clinical audit or for use 
123 
in patient assessment  as an instrument to detect patient change (Rattray & Jones, 
2007). 
4.4.2. Internal Validity 
 
An essential element to instrument development is its validity. Validity  
is fundamental to ensuring that the instrument measures what it is supposed to 
(Rattray & Jones, 2007, p.236). Validity can be complicated to establish. A simple 
initial approach is whether on face value the questionnaire appears to be 
measuring what it was set out to do. Face validity is a simple way to either get 
expert opinion or patient involvement in the questionnaire construct and whether at 
face value the questionnaire covers the construct that is potentially being 
measured  (Nevo, 1985). This however, is not adequate enough to ensure  
a robust validity to any instrument development and a process called ‘construct 
validity’ is another key element to the Rasch process. This process involves 
correlating the new instruments with existing validated instruments that relate or 
are used widely within the measured areas. Thus it is important that data is also 
collated as part of any instrument development and study design. Correlations 
against these different measures can then be made and subsequent validity 
sought or acknowledged. 
4.5. Summary 
 
This chapter has explored the underlying methodological approaches to 
instrument development focusing on key aspects and starting to introduce some of 
the main psychometric principles such as the classical test theory and item 
response theories. It is acknowledged that there are a number of other item 
response theory's that could have potentially been used within this study. 
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However, the Rasch model was a familiar model used within COPD and 
healthcare, there was also additional support and expertise in the Rasch model 
and not others. In summary, Study Two will adopt a test-retest questionnaire 
development design. The analytical approaches using the Rasch model are 
designed to identify the appropriate items to develop a preliminary COPD-PREM 
with items that have the most reliable measurement properties, and are free from 
bias in relation to age and gender, and fit a unidimensional model in Rasch.  
The reliability and validity of the proposed new instrument will be tested using the 
PSI and fit statistics as demonstrated in the Rasch model. 
Further detail on the specific methods used in Rasch and how this will be applied 
to the development of Study Two will be shown further in Chapter Five. 
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CHAPTER FIVE 
 
5. Outline of Study Plan 
 
5.1. Introduction 
 
The research plan outlines the development of a new instrument to measure the 
experience of patients living with COPD. The two studies as previously mentioned 
will be explained further and divided into four phases. The two studies are known 
as Study One (Andrew et al., 2012) which is applied to the instrument’s 
development, and Study Two, the testing, refinement and subsequent reliability 
and validity testing. Both studies involved a number of different steps and different 
patient populations. My role part of the leadership team for Study One. This role 
included research design, ethics, recruitment of participants, undertaking 
interviews and analysis of results. In Study Two (this thesis), the author undertook 
and led the development, conduct and analysis of the study. Study Two is the 
main focus of this thesis and sets out to reduce the item set further through a 
hierarchical item reduction and Rasch analysis, generating a newly developed 
instrument, while testing its reliability and validity. 
5.1.1. Overarching Study Plan 
 
STUDY ONE (completed) 
1. Identification of items for initial inclusion using discovery interviews with 
patients with COPD; 
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2. Development of the initial selection of a 38 item pool through thematic 
analysis of interviews. 
STUDY TWO 
Phase I: Item reduction  
1. Hierarchical item reduction  
2. Further item reduction using Rasch analysis 
Phase II: Preliminary reliability testing and structure of the final item set 
1. Fit to the Rasch model  
2. Demonstrate reliability using the Person Specification Index (PSI) 
3. Test and re-test reliability  
Phase III: Preliminary validity testing of the final item set 
1. Face validity with expert and patient opinion 
2. Concurrent validity with clinical variables  
3. Correlations with the following PROMs: COPD Assessment Tool (CAT) and 
Hospital Anxiety and Depression Scale (HAD). 
5.2.  Background Overview of Study One 
 
5.2.1. Study One – Development of the initial selection of 38 item pool 
 
The initial instrument development (Study One) and funding of the initial phase 
was commissioned as part of the North East London, North Central London and 
Essex, Health Innovation and Education Cluster (NECLES HIEC), in partnership 
with Anglia Ruskin University. The research team for Study One and Two was 
multi-disciplinary, including nurses, academics and professors of nursing and 
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professors of respiratory medicine. The author, a COPD nurse consultant, was 
project team lead throughout Study Two and was responsible for the development, 
conduct, analysis and reporting of the work.  
The Study One research was not conducted as part of this doctorate submission 
but the author led on its development and was also involved in the recruitment, 
interviews and wider development of the item pool. For clarity and context 
however, for this chapter an overview of the findings are highlighted and the full 
report found (Andrews, et al., 2012) in Appendix One, as it formulated the basis for 
Study Two as the findings from Study One (COPD PREM development) led to the 
items generated for the next phase of the instrument generation and creation  
of the final instrument.  
A small team from the HIEC set out to develop a COPD-PREM in partnership with 
the British Lung Foundation and Royal College of Physicians. Following the 
development of a protocol and ethical approval the experiences of living with 
COPD for 64 patients with COPD across the community of North East London, 
North Central London and Essex (NECLES) region, with a range of COPD severity 
and presentation. A further 19 patients with recent (within the last 3 months) 
hospitalisation due to COPD-related conditions, were captured using a discovery 
interview technique. The experiences for both groups (n=83) were then grouped 
and coded separately leading to the development of experience items pertaining to 
both primary (community) care and acute patient groups. This led to the 
development of a 55-itemed preliminary experience instrument which was scaled 
from 0-5 with a good experience item scaled to a poor experience item. 
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The preliminary instrument Table 5.1 went through an initial face-to-face validity 
phase with an expert group consisting of a respiratory professor, professor of 
nursing and the research group (Appendix Three). From this expert panel, each 
item was examined and discussed and the group reduced the number of items 
from 55 to 52. Three items were removed as it was professionally felt that they 
were duplicate items as they asked the same question but in a different sentence 
construct. Finally, a cognitive debriefing on the remaining 52 items took place 
through a face-to-face discussion with COPD patients (n=25) (varying severities 
from mild to very severe) in a number of different places in both primary and 
secondary care. This included pulmonary rehabilitation groups and one local 
Breathe Easy group, in East London. It also included COPD patients (n=5) who 
were under the care of the local COPD 'hospital at home service', and who were 
all receiving treatments for exacerbations of COPD, and  patients who were on the 
local respiratory ward for exacerbations of COPD requiring hospital admission. 
This ensured that the instrument items had a degree of patient involvement prior to 
the large-scale testing. Anecdotal comments included that they could ‘relate to the 
instrument’ as it used ‘words’ that described their COPD such as ‘scared’ and 
‘frustrated’. No changes were made to the instrument post the face-to-face 
discussions with patients. Therefore the 53-item PREM (Table 5.1) was submitted 
as part of the Study Two PREM COPD in two phases: one, concentrating on 38 
items in four domains of long-term primary (community) COPD care: 
1. My history with COPD; 
2. Usual care in COPD; 
3. My everyday life with COPD; 
4. COPD exacerbations. 
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And a further 14 items concentrating on hospital experience were split into  
4 domains as follows: 
1. On arrival at hospital;  
2. On the ward; 
3. Discharge from hospital;  
4. Follow-up care.  
The Hospital preliminary COPD PREM instrument development is being 
undertaken in a separate study and does not formulate part of this doctorate. 
Table 5.1 
Phase one: Preliminary COPD PREM-38 Item instrument. 
MY HISTORY WITH COPD 
These questions are about your health history with COPD 
No. Low Score 0 1 2 3 4 5 High score 
1 
 
I am not shocked by my 
COPD diagnosis 
 
      
I am shocked by my COPD 
diagnosis 
2 
 
I have come to terms 
with my diagnosis of 
COPD 
 
      
I have not come to terms 
with my diagnosis of COPD 
3 
I have given up smoking 
and I am confident that I 
will not start again 
      
I have given up smoking 
but worry that I might start 
again 
4 I want to stop smoking 
and I believe I can       
I want to stop smoking but I 
believe I just can’t 
5 
It was a relief to have a 
diagnosis for my 
symptoms 
      
Not having a diagnosis for 
my symptoms was 
frightening 
USUAL CARE IN COPD  
These questions relate to the everyday usual care given for your COPD 
 Low Score 0 1 2 3 4 5 High score 
6 
 
I understand my 
diagnosis 
 
      
I am confused about my 
diagnosis 
7 
I am confident that my 
GP will listen to my point 
of view 
      
I am concerned that my GP 
won’t listen to my point of 
view 
8 
I am very pleased with 
health care workers who 
look after my COPD that 
I see on a regular basis 
      
I am not at all pleased with 
health care workers who 
look after my COPD that I 
see on a regular basis 
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9 
I am happy with the 
length of time that it 
takes to get an 
appointment with my GP 
when I need to 
      
I am angry about the length 
of time that it takes to get 
an appointment with my 
GP when I need to 
10 I really enjoyed pulmonary rehabilitation       
I didn’t enjoy pulmonary 
rehabilitation 
11 
 
 
I found pulmonary 
rehabilitation useful 
 
      
I didn’t find pulmonary 
rehabilitation useful 
12 
I understand my 
condition and this helps 
me to manage my fear 
      
My lack of understanding 
about my condition makes 
me frightened 
13 
The information I have 
been given from the 
health care workers 
about my COPD is 
consistent 
      
I have been given 
conflicting information from 
health care workers about 
my COPD 
14 
I have enough 
information about my 
condition 
      
I am frustrated by my lack 
of information about my 
condition 
15 
 
I understand about my 
COPD tablets 
 
      
I am confused about my 
COPD tablets  
16 I am confused about how to use my COPD inhalers       
I understand how to use 
my COPD inhalers 
17 I understand how my COPD treatments work       
I am confused about how 
my COPD treatments work 
18 
I don’t find going to a 
hospital outpatient clinic 
frustrating 
      
Going to a hospital 
outpatient clinic is 
frustrating 
19 I know how to use my inhaler properly       
I am confused about how 
to use my inhaler properly 
MY EVERYDAY LIFE WITH COPD 
These questions relate to your everyday life with COPD 
 Low Score 0 1 2 3 4 5 High score 
20 
 
I have accepted the 
limitations to my lifestyle 
caused by COPD 
 
      
I am frustrated and 
unhappy by the limitations 
to my lifestyle caused by 
COPD 
21 
I feel that I have good 
support from others like 
my family, friends, 
neighbours or carers 
      
I feel that I don’t have any 
support from others like 
friends, family, neighbours 
or carers 
22 
 
Overall I am satisfied with 
my life 
 
      
Overall I am very 
dissatisfied with my life 
23 
 
I am not depressed 
 
      I am feeling depressed 
24 
 
Overall I am satisfied with       Overall I am very 
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the care given to me 
 
dissatisfied with the care 
given to me 
25 
 
I am not embarrassed to 
tell others about my 
condition 
 
      
I am embarrassed to tell 
others about my condition 
26 
 
I feel that I am in control 
of my condition 
 
      
I feel that I don’t have any 
control over my condition 
27 
 
I am motivated to keep 
going and to not give up 
 
      
I am not motivated and I 
feel like giving up 
28 I am happy to talk about the future       
Talking about the future 
makes me feel depressed 
29 
 
I am not concerned about 
the future 
 
      
I am concerned about the 
future 
30 
 
I am not worried about 
the season 
 
      
I worry about the season 
and my COPD 
31 
 
I keep going and try to 
enjoy my life 
 
      
I feel like giving up and I 
don’t enjoy my life 
COPD EXACERBATION (Flare up) 
These questions relate to a flare-up of your COPD 
 Low Score 0 1 2 3 4 5 High score 
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I am confident in a ‘flare 
up’ I have quick access to 
treatment e.g. a rescue 
pack or access to my GP 
      
I am worried that in a ‘flare 
up’ I don’t have quick 
access to treatment e.g. a 
rescue pack or access to 
my GP 
33 
 
I do not feel anxious 
about my current health 
 
      
I feel anxious about my 
current health 
34 
I am not worried about 
the care I will get from 
health professionals when 
I get a ‘flare-up’ 
      
I worry about the care I will 
get from health 
professionals when I get a 
‘flare-up’ 
35 
 
I am not scared of getting 
a cold or an infection 
 
      
I am scared of getting a 
cold or infection 
36 
 
I am not frightened of 
being breathless when I 
have a ‘flare-up’ 
 
      
I am frightened of being 
breathless when I have a 
‘flare-up’ 
37 
I am not frightened to go 
to sleep when I am 
having a ‘flare up’ of my 
COPD 
      
I am frightened to go to 
sleep when I am having a 
‘flare up’ of my COPD 
38 
I try not to panic when I 
have a ‘flare up’ as it will 
make my breathlessness 
worse 
      
I panic when I am having a 
‘flare up’ and this makes 
my breathlessness worse 
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5.3. Study Two:  Method and Design 
 
5.3.1. Introduction 
 
The method section on measurement theory (Section 4.2) highlighted the different 
aspects of instrument development. These tests identify the items with optimal 
measurement properties. This includes testing items for potential bias (such as 
gender and age), reliability and validity. Item reduction also decreases patient 
burden by removing redundant items. This following section relates to the methods 
used and describes how objectives one and two (p.103) were achieved.  However, 
achieving Study Two involved administering the 38-item instrument to patients with 
COPD, along with collecting patient demographics and spirometry (FEV1% 
recorded). Initially, the criteria for the selection of participants and the data 
collection methods are described in this chapter, along with the methods and 
process for item reduction to formulate a shorter COPD PREM instrument.   
This study adopts a test-retest questionnaire development design. In summary, 
data was collected by asking participants to complete questionnaires at two time 
points: time of recruitment (baseline) and one week later (follow-up). This time 
period is thought to be long enough for participants to recall their experience and 
for their clinical condition to remain fairly constant. A self-report global health score 
was also obtained to determine if a patient’s perceived general health condition 
had changed between the two time points. Demographic data was also collected 
at the time of recruitment using specific data sheets (Appendix Four). 
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5.3.2. Population and participant recruitment 
 
Participants with COPD were recruited from a number of NHS secondary and 
integrated care organisations which included pulmonary rehabilitation, respiratory 
clinics and wards. Also British Lung Foundation Breathe Easy groups (self-
supported groups for people affected by lung disease) from various locations 
across England and the Channel Islands. A detailed process of the recruitment 
sites and venues is detailed in Figure 5.1.  
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Figure 5.1 Overarching research process map for study two 
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5.3.3. Inclusion and exclusion criteria 
 
Inclusion and exclusion criteria were developed to ensure that participants 
recruited from within each recruitment area were consistent. Criteria for inclusion:  
• A confirmed diagnosis of COPD (mild to very severe COPD (FEV1 <100% 
with symptoms); 
• Able to consent and sign a consent form; 
• Able to follow written and verbal instructions in English (Due to the 
availability of advocacy services, those whose first language is not English 
and who are unable to read or understand verbal English will not be able to 
participate in the study, unless a family member is available to support and 
translate during the study period); 
• Agreed to take part in the study. 
Exclusion criteria:  
• Other respiratory conditions such as Asthma/pulmonary fibrosis; 
• Who are nearing end of life; 
• Had significant other co-morbidities such as severe heart failure.  
 It was important to ensure that a range of patients was recruited for this study to 
guarantee a fair representation of patients living with COPD across the country 
with ranging severities. No potential patient was excluded because of age, ethnic 
origin, disability or gender, however, all patients needed to fulfil the inclusion 
criteria set and complete the relevant paperwork and understand the consent 
process. 
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5.3.4. Recruitment of Participants 
 
A predicted sample size of over 150 was needed to fulfil the aim of the study and 
the requirements of the Rasch Model. This is based upon a sample size ensuring 
accuracy for a test-re-test reliability, thereby ensuring that there are at least three 
class intervals of approximately 50 participants in each class (Pallant & Tennant, 
2007). Potential participants were approached by the ‘research team’ who 
consisted of nurses and physiotherapists working in respiratory teams. It was also 
important to ensure that participants were recruited from across different 
healthcare settings such as pulmonary rehabilitation, outpatient clinics and 
hospitals.   
Potential participants who engaged in discussion on the study were given a patient 
information sheet (Appendix Five), if the participant showed interest or wished to 
think about the study further. The research team were available to answer any 
questions at the time and afterwards. All participants, of course, had the right to 
decline to take part in the study, from the initial discussion and  at any time and 
were informed that participation was completely voluntary and would not affect any 
care if potential participants declined to take part or withdraw at any stage.   
Participants who agreed to take part in the study were encouraged to keep the 
patient information leaflet as a source of reference and contact details of the 
research team if questions arose post completion. Each participant had the time  
to ask questions about the patient information sheet and the researcher 
highlighted the key aspects of the patient information sheet and the reason for the 
research. Once participants had informed a member of the research team that 
they agreed to take part in the study, a member of the research team asked the 
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participant to complete a written consent form (Appendix Six) outlining the different 
aspects of consent and data protection. The consent form was also signed by the 
member of the research team. Participants were also informed that the study was 
completely confidential, and each participant was issued with a unique ID number 
which was added to the consent form and all subsequent instruments and 
paperwork. The data collected was to be stored for a minimum of seven years and 
held within the research team’s locked office. 
Once consent was given and signed by both the researcher and participant, the 
participant was then asked to complete a demographics sheet (Appendix Four) 
which asked a number of standard questions on age, date of birth and smoking 
history. Participants were then asked to undertake a spirometry test. If participants 
declined at this point or recently had a spirometry test at their General Practitioner 
(GP) or hospital, a letter was sent to the GP/Hospital requesting a copy of this 
spirometry if undertaken within 1 year.  
Once demographic details and spirometry were obtained by participants, they then 
were asked to complete questionnaire 'Pack A' which consisted of the preliminary 
38 itemed COPD PREM questionnaire plus a number of other outcome measures 
(Table 5.2). Once completed participants were then asked to complete 'Pack B' 
consisting of the preliminary 38 itemed COPD PREM and a global rating of change 
questionnaire. Participants were then asked to complete the two questionnaires 
one week later and return to them to the researchers’ office. A stamped addressed 
envelope was included for this purpose. The aim was to achieve a 20% return 
(Jones et al., 2012). 
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Table 5.2 
List of other outcome measures identified 
 
Outcome Measures  
Demographics*  
Smoking Status  
Spirometry  
Pack A **  
  COPD PREM-38 Questionnaire  
  COPD Assessment Test (CAT) 
  Hospital & Anxiety Questionnaire  
  MRC Dyspnoea Scale Questionnaire 
Pack B 
  COPD PREM-38 Questionnaire 
  Global Rate of Change Questionnaire**  
  Stamped Address Envelope  
* Age / Gender  
** Appendix Seven 
 
5.3.5. Ethics  
 
NHS ethical approval was obtained from Bloomsbury Research and Ethics 
Committee (Appendix Eight). As a number of different institutions and 
organisations were also involved, ethical approval or consideration was also 
received from the following (Appendix Nine): 
• University of Portsmouth;  
• Local Research Ethics Committee of the Region;   
• Research & Development approval at participating NHS sites;  
• British Lung Foundation approval letter.   
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Ethical approval was obtained from the acute trusts that covered the specific 
hospital from which participants were recruited. Ethical approval and permission 
from the British Lung Foundation to approach Breathe Easy groups was also 
sought  
There are a number of the items on the PREM instrument which are potentially 
ethically sensitive statements regarding the 'future', and therefore the research 
team were made specifically aware that participants were to be informed of these 
and an opportunity to discuss them further was provided at the time or within the 
patient information sheet. The research team advised participants to speak to their 
local respiratory nurse or to contact the Chief Investigator if they should wished to 
discuss any aspect further. 
5.4. Methods of Data Collection 
 
All participants that consented were issued with a unique ID number this was 
added to all self-reported instruments and on any correspondents about the 
participant.  
5.4.1. Instrument data 
 
The 38-itemed COPD-PREM along with three commonly used outcome measures 
in COPD care were used for data collection. This formulated part of the reliability 
and validity process of the item generation, along with a correlation across these 
outcome measures, this being a secondary objective (numbers four and five on 
page 107) of the study. All outcome measures used within this study have 
research reliability and validity and are widely used within current respiratory 
research including COPD (Puhan,et al., 2010). The outcomes allow for meaningful 
data  
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of participants with COPD and their response rate to completing instruments. 
Outcome measures included are highlighted in Table 5.2 and points  
of measurement are highlighted Figure 5.2 (Recruitment process map). 
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Figure 5.2 Recruitment process map
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Participant recruitment and study flow is outlined in the recruitment process map 
Figure 5.2. For NHS recruitment the following protocol was conducted: 
1. A nominated healthcare professional conducted daily screening (Monday 
through to Friday) of patients admitted to the hospital with an acute 
exacerbation of COPD. They conducted screening of outpatients attending 
pulmonary rehabilitation clinics (time and days varied dependent on activity) 
and community COPD patients; 
2. A nominated healthcare professional approached eligible patients and their 
families prior to discharge, or earlier dependent on how unwell the patient 
was. They described the study and invited the potential participant to take 
part in the study. If, during screening, the patient did not fit the inclusion 
criteria the patient was not  entered on to the study; 
3. The nominated healthcare professional administered and signed a consent 
form along with the participant. Pack A (Table 5.2) was given to the 
consenting patient; 
4. Participants then had three options to do the following:  
a. take Pack A home with them and return the questionnaires in  
a stamped address envelope to the participating NHS organisation, 
or, where it was a Breathe Easy Group, send all instruments back to 
the CI organisation as the chief investigator of the study; 
b. take Pack A home and return the completed pack to the pulmonary 
rehabilitation or COPD clinic from where the participant was 
recruited; 
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c. complete Pack A ‘there and then’ (preferred option) and complete 
Pack B (COPD-PREM and global rate of change instrument) sent 
back to the Chief Investigator one week later in the provided SAE. 
5. Throughout the process, regardless of which option of completing the 
instrument packs, the consent, spirometry and demographic data had to be 
completed at the time of recruitment. All instruments were labelled with the 
participants’ unique letter and number code.  
Participants recruited from within the Breathe Easy Groups were self-selected and 
follow the same steps from 3 to 5. 
5.4.2. Research Instruments for Data Collection 
 
COPD Patient Reported Experience Measure (PREM) Instrument  
The 38-itemed COPD-PREM instrument developed as part of a stage one was 
included as the instrument in development. Each participant was asked to 
complete this and choose a score from zero to five. A low score suggested more 
positive experience the higher the score suggestive of a higher negative 
experience. 
Medical Research Council Dyspnoea Scale (MRC) 
The Medical Research Council scale (Appendix Seven) is a self-reported measure 
of dyspnoea intensity. It is a simple five point scale which has been validated and 
is a widely accepted tool to use within COPD (NICE 2004). The scale is used to 
assess severity of disease or monitor symptom severity by an assessment of tasks 
that incite dyspnoea or functional disability that results from dyspnoea (Fletcher, 
1960). The scale allows the patient to point out the degree of dyspnoea that 
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affects their mobility. Participants were then asked where they thought they were 
on the MRC scale on the day of the assessment and this response was then 
recorded. 
Hospital Anxiety and Depression Questionnaire (HAD) 
The Hospital Anxiety and Depression Scale (HADS) (Appendix Seven) was 
designed to detect symptoms of anxiety and depression through a scoring system 
and a series of questions relating to usual activities which may reflect a higher 
degree of anxiety or depression, or both. It is a well-validated tool for measuring 
an increasing issue within COPD care and is designed to measure changes in 
symptoms over time (Garrod, Marshall, Barley, & Jones, 2006).  
COPD Assessment Test (CAT) 
The COPD Assessment Test (Appendix Seven) is designed to offer  
a measurement of the impact of COPD on a person’s health. It is a short, validated 
questionnaire comprising of 8 questions that relate to a variety of different aspects 
of COPD and its effects on health status. The main aim of the questionnaire is to 
support and guide healthcare professionals gauge a better understanding of how 
COPD is currently impacting the patient in order to help tackle these issues and 
progress the management of COPD and improve the quality of care (Jones et al. 
2009).  
Global Rate of Change (GRC) 
The Global Rate of Change questionnaire (Appendix Seven) is a simple 
questionnaire that is designed to detect changes in patients’ health status over  
a period of time. Patients were asked to consider if there had been an 
improvement or a deterioration in health status since completing the first set of 
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questionnaires. This type of questionnaire is usually used in clinical practice to 
assess ‘intervention’ and quantify to healthcare professionals any changes in 
medical or therapy management for the patient (Rabe et al., 2007). 
5.5. Data Analysis – Phase I 
 
This study adopts a test-retest questionnaire development design aimed to 
develop a new COPD PREM instrument. The aim of data analysis is to assess  
the instruments reliability and validity, ensuring constancy of data and identify the 
most reliable and valid items to be included in the final PREM-COPD (Rattray  
& Jones, 2007). 
5.5.1. Summary of demographics  
 
Firstly a summary of the baseline demographic characteristics of participants was 
undertaken using descriptive statistics including the mean and standard deviation 
values for age, gender and FEV1 % predicted. This data was then taken from the 
demographic sheets and entered onto the SPSS Statistics v.20 (Statistical 
Package for the Social Sciences). This is a formal statistical package for the 
analysis of results and is widely used by researchers (Polit, 2010, p.374). The 
demographics, including age, gender, FEV1%, MRC and the results of the 
questionnaires and preliminary COPD-PREM were also recorded and entered into 
SPSS. This section supports objective two of the overarching research objectives 
set (p.103) and is phase one of study two.  
5.5.2. Hierarchical Item Reduction   
 
A formal approach to the first stage of item reduction was used following a series 
of different statistical approaches and following a traditional psychometric theory 
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(Hand., 2011). The items for potential reduction were focussed on generating  
a reliable and meaningful measurement that reduced bias and therefore generate 
more concise and appropriate instrument. Using the SPSS computer software,  
a number of statistical tests were undertaken to formulate a structured plan of item 
reduction. Below is the protocol overview of each item reduction method:   
1. Firstly, age bias was explored against the total items. This is a statistical 
test that assesses the correlations between age and the each item in an 
instrument. It can be measured using a Spearman’s rho or Pearson’s 
Correlation coefficient, dependent on whether data entered is parametric or 
non-parametric. The reason this test is carried out is in order to find out 
whether there are any items that have a specific correlation against age. 
For example, does a certain item appear more often with a certain age 
group? The reason this is important is to ensure that all items answered 
across the age spread are not biased by a certain age group. For the 
purpose of this study Spearman’s rho was used and Items identified with a 
p value (p< 0.05) were excluded as part of the item reduction phase of this 
study; 
2. Items were also tested for gender bias against the total items. This is a 
statistical test which assesses the differences in response between male 
and female answers and within each item in an instrument. It can be 
measured with a t-test or a Mann-Whitney U (p< 0.05) test dependent on 
whether the data is parametric or non-parametric, but essentially two 
unpaired groups are being compared and measured. The reason this test is 
carried out is to find out whether there are any items that show a more 
favourable answer to males over females or vice versa. This test is 
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important is to ensure that both genders and all items have been answered 
equally across both groups, therefore reducing a gender bias. A Mann-
Whitney U test was completed and Items identified with a p value (p <0.05) 
were excluded at this item reduction phase of the study; 
3. It is normal with instrument development that participants do not complete 
every item in the questions asked (Jenkinson et al., 2002). Removal of 
missing data is undertaken. This test ensures that items where there are 
large amounts of missing data are removed from the item list as part of the 
item reduction process. For this study this was set at 15%;  
4. The incidence of maximum (ceiling) and minimum (floor) scores for each 
items were recorded. A significant concern in healthcare measurement is 
the extent to which an instrument displays a lack of sensitivity to change the 
extremes of the distribution, known as floor and ceiling effects. Ceiling 
effects are reported when there is variance in measuring an independent 
variable. And where a ceiling effect occurs, when you have answered the 
highest discriminatory value possible within the scale of an instrument.   
For example, in the preliminary COPD PREM using a scale of 0-5, and 
select the percentage of the participants reported a five score.  However, 
you cannot be clear whether the participants response was five or 
potentially could have been higher but as a ceiling affect was reached 
therefore the exact level of their answer cannot be determined (Wang et al., 
2009). 
When gathering data from the instrument this means that you potentially 
may have a group of participants who are answering at the upper end of the 
scale, thereby a ceiling affect is reported. Therefore, an item could be 
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introducing bias as it may not represent the true population sample. A floor 
effect is the opposite to this, when the lower scale number is reported. In 
this study such items may detract from the instrument’s psychometric 
properties, because they were not selected by the majority of the 
participants. These items therefore fail to discriminate between patients with 
different experiences in COPD. Because such items make the instrument 
longer to complete, these items were deleted (Jones, et al. 2009) A floor to 
ceiling effect > 40% was set and any items above this were deleted.  
5. The item to item correlation is a statistical test to demonstrate where certain 
items are correlated to each other and therefore the results potentially may 
be similar. Results are expressed as an r value. Items with a value greater 
or equal r=0.80 were removed from the main item list.  
After the final items were identified these then were entered into the Rasch 
Model following a expert group discussion. 
5.5.3. Face Validity 
 
Following the hierarchical item reduction a pool of items remained. These 
remaining items went through a face validity process with an expert panel and 
feedback from participants. A number of potential items were then also deleted 
further and a set number of items remained. After this process the remaining items 
were further scrutinised in the Rasch phase.  
5.6. Rasch Phase 
 
Following the hierarchical item reduction and face validity, the pool of items that 
survived this process was entered into the RUMM2030 (Rasch Model 2030) 
package where a further set of statistical tests scrutinised these items further using 
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the Rasch analysis. The process of item removal in Rasch is an iterative process 
however there is no clear set of processes and parts of the process do not happen 
in a uniform way. The data entered into RUMM2030 were polytomous data, this 
means that the model sees the thresholds between categories as the same across 
all items entered (Tennant & Conaghan., 2007, p.5). The main objective of the 
Rasch model is to test how well the observed data fit the expectations of the 
measurement model.  
Once the data were entered into RUMM2030, failure of items to fit the model led to 
a precise number of actions using a range of techniques (Mills et al., 2010) as 
there is no one single test that can be used to examine the data and the model 
relationship in Rasch (Hagquist, Bruce, & Gustavsson, 2009). Therefore a number 
of tests were undertaken to explore the data and to understand the current fit to 
the model. These will be explained further over the next few pages.  
5.6.1. Ordering of response categories – Thresholds 
 
The threshold ordering of polytomous items examines the category structure. This, 
in short, examines whether the responses to the items are consistent with the 
metric estimate of the underlying construct and is ordered in a number of category 
responses. If disordered data appears, as in this case, then items were needed to 
be rescored and categories collapsed.  
For a polytomous scale, the ordering and distance of response categories for each 
item is measured by exploring the threshold between each of its response 
categories. If the response options are correctly ordered, the probability  
of endorsing mild options should increase in a logical manner according to the 
level of experience of each participant. 
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Threshold ordering (i.e. the transition between two points) was compared in 
RUMM2030 by checking the class interval distributions. This allowed each item 
and their responses to cross a threshold and whether there was a natural 
continuum of responses for an ordered threshold. The thresholds correspond with 
the threshold points between two different scores, at this point it is likely to obtain 
either score (i.e. for a specific item, the point which the probability is a one on the 
item or a two on the item is 50/50).  
A disordered threshold meant that the item is not working properly, that is,  
the current scoring categories are not progressing in a logical order. Therefore, 
some items had to be collapsed and rescored (Pallant and Tennant, 2007). 
5.6.2. Class Intervals (CIs) 
 
Participants were automatically be placed into groups once the data had been 
entered into the Rasch Model. These groups are called class intervals and are 
defined by the experience within each item. This is highlighted further in the results 
section.  
In RUMM2030, participants are ranked automatically and placed in groups and 
divided into CIs of approximately equal numbers. This ensures that the mean 
observed scores for each class interval are then compared to a number expected 
by the Rasch model. This then divides all patients into groups dependent on the 
severity of COPD. 
5.6.3. Tests for individual item fit  
 
In Rasch there are several different ways to explore item fit. Individual item fit 
refers to the ability of each item to discriminate between patients with different 
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levels of experience. Tests of item fit to the model reflect the differences between 
the observed responses and that expected by the Rasch model. These are 
presented as residuals and as a Chi-Square probability statistic within chapter six 
of the results. 
Fit investigations begin by examining the residuals – the difference between the 
observed score and the expected score – for a particular person and item. A fit 
residual is a summation of individual person and item deviations from model 
expectations. Item residuals between ±2.5 are considered to show a sufficient fit to 
the model. Negative residuals indicate over-discriminating items and are usually 
linked with a high Item-Total correlation in CTT. This indicated the redundancy of  
a particular item. 
Positive residuals indicate under-discriminating items. Individual item fit was also 
viewed graphically, using the Item Characteristic Curve (ICC). The ICC plots the 
model fit for each class interval (black dots) against the expected model curve and 
examples of the ICC are highlighted in the results chapter. 
 A Chi-Square statistic was used within RUMM2030 which compared the 
difference between the observed experience values with expected values across 
the class intervals for each item. A non-significant Chi-Square statistic greater than 
p=0.05, or Bonferroni adjusted value suggests a good fit to the Rasch model.  
The Bonferroni adjustment in this methodology involves dividing the original  
α-level (0.05) by the number of times a statistical test is repeated. Within the 
RUMM2030 model this is done automatically for every statistical test individual.  
If an item demonstrated a significant Chi-Square statistic then it is considered to 
misfit the Rasch model expectations and it was removed from the overall model 
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and item list. This process was repeated several times and items deleted to get  
a final negative Chi-square statistics as part of the overall fit statistics.  
5.6.4. Summary of Item Removal using Rasch modelling 
 
Throughout this methodology chapter it has made reference to a number of 
potential ways in which a number of item are removed either through the 
Hierarchical methods of item reduction or deleted through the Rasch analysis as 
ill-fitting items do not fit the overall unidimensional model of Rasch. This becomes 
clearer in chapter six of the results. 
5.7. Reliability & Validity of the final item Phase – Phase II & III  
 
In chapter four the concept of instrument reliability and validity was indicated in the 
development of any new instrument and fulfils the primary objectives three-five of 
the researchers study (p.103). Therefore the final aspect of the data analysis, post 
the Rasch model, was the final steps undertake to test the preliminary reliability 
and validity of the final items generated from the Rasch model. The steps involved 
in this testing are described below. 
5.7.1. Reliability 
 
Person Separation Index (PSI) 
In RUMM2030 the Person Separation Index (PSI) is used for statistical purposes 
which is an estimate of the internal consistency of the scale known as the PSI. It is 
an equivalent measure and has similar traits to Cronbach’s alpha. A PSI of  
a minimum value of 0.85 is needed for individual use (Tennant & Conaghan, 2007, 
p1361 ). This is shown and reported on within the results section.  
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Test-retest  
As previously mentioned a test-retest of the items was undertaken. This takes the 
measurement of the same instrument but compares the results of the two 
instruments at two different time points, in this case one week apart. For the 
purpose of this study participants were encouraged to complete a second COPD-
PREM one week after completing the first instrument. Participants were also 
encouraged to complete the Global Rate of Change questionnaire as previously 
mentioned. The results of the test-retest are presented in the results chapter.  
5.7.2. Validity 
 
Face Validity 
Face Validity took place as part of the validity stage with participants from  
a number of different locations and included participants from pulmonary 
rehabilitation groups and Breathe Easy Groups. This ensured that patients with 
COPD were able to review the proposed final item and ensured that at 'face-value' 
it measured what the aim of the study proposed. 
Content Validity  
To examine content validity the preliminary COPD PREM (after Rasch analysis) 
was  taken and reviewed by an expert research panel consisting of respiratory 
professors, respiratory academics and clinicians familiar with instrument 
development and Rasch analysis.  
Concurrent Validity  
To examine concurrent validity of the reduced preliminary COPD PREM 
instrument was tested using the Pearson’s coefficient and applied to test 
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differences between the new preliminary COPD PREM and the COPD 
Assessment tool and Hospital Anxiety and Depression Scale. These are accepted 
and widely used PROMs used in COPD care (Jones et al. 2009) These results are 
reported along with the other aspects of validity in Chapter Six.  
5.8. Chapter Summary 
 
This chapter has given a detailed overview of the Study Two research study plan 
including the key stages to the design, recruitment of participants and the item 
reduction protocol using a hierarchical item reduction and item securitisation within 
the Rasch analysis. The final phase introduces the reader to the reliability and 
validity of the final preliminary item set and subsequent testing of this COPD 
PREM instrument against other patient reported outcomes frequently used within 
COPD care and research. It also highlights how the research objectives outlined  
in Chapter Three are being undertaken in the three phases of this thesis.  
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CHAPTER SIX 
 
6. Results 
 
6.1. Introduction 
 
The previous chapter on methodology and methods gave a concise overview of 
the process of developing a new instrument and the number of steps taken  
to generate results, and the further development and refinement of the COPD-
PREM. This chapter will present the results of the both the hierarchical item 
reduction and of the Rasch analysis. These methods are designed to reduce 
patient burden by removing redundant items and developing a more concise 
instrument. This section relates to the results of Study Two and the primary 
objectives of two to five (p.103). Initially, the participants’ characteristics will be 
described, followed by the method results outlined in Chapter Five on the process 
of reducing the pool of 38 items, to a core set of items using the hierarchical 
methods and Rasch modelling (Rasch, 1960). A final core group of items will then 
be presented known as the COPD PREM-9. 
6.2. Participant Characteristics 
 
A total of 228 patients were approached to take part in the study. 40 declined to 
take part for a number of different reasons which included initial interest, but then 
refusal to take part. The other reasons being are too many questions, time, 
language and unwell. A further 14 participants agreed to take part, consented and 
took the questionnaire packs, but failed to return them. For that reason they had to 
be removed from the study. Therefore, a total of 174 patients was recruited into 
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the study; their baseline characteristics are shown in three groups highlighted in 
Table 6.1:  
1. total number of recruited participants (All); 
2. recruited from secondary care, PR and home (Hospital); 
3. recruited from Breath Easy Groups.  
Table 6.1 
Baseline characteristics of all COPD patients included in the study 
 
  
1 
All 
2 
Hospital 
3 
Breathe Easy 
 N = 174 N = 86 N = 88 
Age, years (Mean ±SD) 71± 9.1 71± 9.8 71± 8.4 
Gender    
Male (%) 83 (48%) 45 (52%) 38 (43%) 
Female (%) 91 (52%) 41 (48%) 50 (57%) 
Smoking status, number    
Active smokers 20 (12%) 16 (19%) 4 (4%) 
Ex-smokers 125 (72%) 51 (59%) 74 (84) 
Not disclosed 29 (16%) 19 (22%) 10 (12%) 
Spirometry   
FEV1 (% predicted) 
(Mean ±SD) 59±21.9 53±22.3 48±21.3 
FEV1 % /FVC (Ratio)  
(Mean ±SD) 50±20.4 53±17.2 67±21.4 
NICE classification*† % (n)   
Mild 23 (13) 12 (13) 11(13) 
Moderate 46 (26) 27 (31) 19 (21) 
Severe 50 (29) 32 (37) 19 (21) 
Very Severe 26 (17) 11 (13) 15 (18) 
Outcome measures    
Medical Research Council (MRC)  
(Mean ±SD) 3.4±1.0 3.5±1.1 3.3±1.0 
COPD Assessment Tool (CAT) 
(Mean ±SD) 20±8.5 23±9 21±7.8 
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Anxiety Score  
(Mean ±SD) 7.6±4.1 7.8±4.1 7.3±4.2 
Depression Score  
(Mean ±SD) 6.1±3.9 6.3±3.8 5.8±3.9 
Data shown represented mean ± SD unless 
otherwise indicated 
FEV1: Forced expired volume in one second; 
FVC: Forced vital capacity 
*NICE (2010) Classification  
† Only 145 people with spirometry information 
   
 
There was an even distribution between the two groups in which the Packs were 
completed. English was the first language for most people completing the pack but 
this was not recorded. All patients had a confirmed diagnosis of COPD. 
Participants were recruited from a number of different locations across England 
and the Channel Islands (Table 6.2). 
Table 6.2 
Recruitment sites of participants 
Recruitment Site N 
London 120 
Manchester  15 
Guernsey  8 
Essex 5 
Norwich 7 
Portsmouth  19 
 
6.2.1. Missing Data  
 
Overall, there was less than 10% missing data, except spirometry, which was 
recorded at 25%. There were a number of questions in the item-list that 
demonstrated a high level of missing data including item 4 relating to smoking  
(76%) and item 15 on COPD Tablets (28%). These two items were removed  
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as part of the item reduction protocol. Less than 2% of participants failed to 
complete the additional questionnaires (CAT, HAD and MRC). To account for 
missing data ‘exclude cases pair wise’ was selected in SPSS. This is an 
acceptable exclusion criteria for excluding the participant only if they were missing 
the data required for a specific analysis (Pallant., 2010). 
6.3. Hierarchical Item Reduction – Summary of results 
 
The hierarchical item reduction process will now be shown for each step and the 
items that were removed. A final table showing all items deleted and the reasons 
for his will be shown at the end of this section in Table 6.3. 
Table 6.3 
Overview of item reduction results 
Q 
No Question (Low Score Answer) 
Missing 
>15% 
Floor  
> 40% 
Age 
Correlation R Value 
1 I am not shocked by my COPD diagnosis 
   
 
2 I have come to terms with my diagnosis of 
COPD 
    
3 I have given up smoking and I am confident 
that I will not start X 
   
4 I want to stop smoking and I believe I can X 
   
5 It was a relief to have a diagnosis for my 
symptoms X 
   
6 I understand my diagnosis 
 
X 
  
7 I am confident that my GP will listen to my 
point of view 
   
Q13 
8 I am very pleased with health care workers 
 
X 
 
Q13 
9 I am happy with the length of time to see GP 
    
10 I really enjoyed pulmonary rehabilitation X 
  
Q11 
11 I found pulmonary rehabilitation useful X X 
 
Q11 
12 I understand my condition and this helps me to 
manage my fear 
  
X 
 
13 The information I have been given is 
consistent 
 
X 
 
Q8 
14 I have enough information about my condition 
 
X 
  
15 I understand about my COPD tablets X 
   
16 I am confused about how to use my COPD 
inhalers 
    
17 I understand how my COPD treatments work 
 
X 
  
18 I don’t find going to a hospital outpatient clinic 
frustrating 
    
19 I know how to use my inhaler properly 
 
X 
  
20 I have accepted the limitations to my lifestyle 
caused by COPD 
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6.3.1. Age Bias 
 
Items which had an age bias towards items from the initial 38-item pool were 
removed using a p value < 0.05. This process resulted in six items being removed. 
Table 6.4 summarises the lower scored answer items. These six items were 
removed. 
Table 6.4 
Items removed due to age bias 
Q Question (Low Score Answer)  Spearman rho* Remove 
12 I understand my condition and this helps me to manage my fear 0.007 X 
29 I am not concerned about the future 0.012 X 
30 I am not worried about the season 0.017 X 
33 I do not feel anxious about my current health 0.002 X 
35 I am not scared of getting a cold or an infection 0.037 X 
36 I am not frightened of being breathless when I have a ‘flare-up’ 0.002 X 
* p value < 0.05 
 
 
21 I feel that I have good support from others 
    
22 Overall I am satisfied with my life 
    
23 I am not depressed 
    
24 Overall I am satisfied with the care given to me 
 
X 
  
25 I am not embarrassed to tell others about my 
condition 
 
X 
  
26 I feel that I am in control of my condition 
    
27 I am motivated to keep going and to not give 
up 
 
X 
  
28 I am happy to talk about the future 
 
X 
  
29 I am not concerned about the future 
  
X 
 
30 I am not worried about the season 
  
X 
 
31 I keep going and try to enjoy my life 
 
X X 
 
32 I am confident in a ‘flare up’ I have quick 
access to treatment 
    
33 I do not feel anxious about my current health 
  
X 
 
34 I am not worried about the care I will get with 
'flare-up' 
    
35 I am not scared of getting a cold or an infection 
  
X 
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6.3.2. Gender Bias 
 
Items demonstrating gender bias towards items from the initial 38-item pool were 
removed at this initial point. This process resulted in one item being removed 
(Table 6.5). 
Table 6.5 
Items removed due to gender bias 
Q Question (Low Score Answer)  Mann Whitney 
– U (p value)* Remove 
35 I am not scared of getting a cold or an infection 0.010 X 
* p value < 0.05 
 
6.3.3. Removal of items with >15% missing data 
 
Items which had missing data for more than 15% were removed from the item list. 
This process resulted in six items being removed (Table 6.6). 
Table 6.6 
Items removed due to missing data 
Q Question (Low Score Answer)  Missing (%)* Remove 
3 I have given up smoking and I am confident that  I will not start 19% X 
4 I want to stop smoking and I believe I can 76% X 
5 It was a relief to have a diagnosis for my 
symptoms 17% X 
10 I really enjoyed pulmonary rehabilitation 18% X 
11 I found pulmonary rehabilitation useful 17% X 
15 I understand about my COPD tablets 28% X 
* missing data >15% 
 
6.3.4. Floor and ceiling effects > 40% 
 
No items were eligible for removal for ceiling effects (i.e. more than 40% of 
participants) scoring the item. Twelve items were removed for floor effects  
(i.e. more than 40% of participants) scoring the item a zero (Table 6.7). 
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Table 6.7 
Items removed due to floor effect 
Q Question (Low Score Answer) Missing (%)* Remove 
6 I understand my diagnosis 47% X 
8 I am very pleased with health care workers  46% X 
11 I found pulmonary rehabilitation useful 44% X 
13 The information I have been given is consistent 44% X 
14 I have enough information about my condition 43% X 
17 
 
I understand how my COPD treatments work 40% X 
19 I know how to use my inhaler properly 55% X 
24 Overall I am satisfied with the care given to me 46% X 
25 I am not embarrassed to tell others about my 
condition 53% X 
27 I am motivated to keep going and to not give up 49% X 
28 I am happy to talk about the future 44% X 
31 I keep going and try to enjoy my life 49% X 
* floor effect >40% 
 
6.3.5. Item to item correlation 
 
The final process before Rasch analysis was to remove items that correlated with 
another item within the instrument. This was undertaken using a spearman’s rho 
measure to identify the relationship is between two variables.  Four of the 38 items 
had a positive r value (r>0.80) and therefore were removed (Table 6.8). Table 6.8 
summarises the lower answered experience item. These four items were also 
highlighted for removal in earlier tests.  
Table 6.8 
Items removed due to item to item correlation 
Q Question (Low Score Answer) Spearman’s rho* Remove 
8 I am very pleased with health care workers  0.83 Q13 
10 I really enjoyed pulmonary rehabilitation 0.83 Q11 
11 I found pulmonary rehabilitation useful 0.83 Q11 
13 The information I have been given is 
consistent 0.83 Q8 
* r value > 0.80 
 
164 
There was one additional item, item no. 7 (‘I am confident that my GP will listen to 
my point of view’) with a high Spearman's value (0.83), which suggested  
it correlated with item 13 (‘the information I have been given is consistent’). This 
item remained as the research team felt that the two items did not necessarily 
match or measure the same area and therefore item 7 was retained as this was 
relevant to patient experience. 
6.3.6. Overview of Questions Removed 
 
From the original 38 items listed, 22 items were removed (Table 6.9) following the 
hierarchical item reduction, which meant 16 items remained for further analysis in 
the Rasch model. 
Table 6.9 
List of items removed and retained 
Q Question (Low Score Answer) 
Removed Item 
Yes No 
1 I am not shocked by my COPD diagnosis   X 
2 I have come to terms with my diagnosis of COPD   X 
3 I have given up smoking and I am confident that I will 
not start  X   
4 I want to stop smoking and I believe I can X   
5 It was a relief to have a diagnosis for my symptoms X   
6 I understand my diagnosis X   
7 I am confident that my GP will listen to my point of view   X 
8 I am very pleased with health care workers  X   
9 I am happy with the length of time to see my GP   X 
10 I really enjoyed pulmonary rehabilitation X   
11 I found pulmonary rehabilitation useful X   
12 I understand my condition and this helps me to 
manage my fear X   
13 The information I have been given is consistent X   
14 I have enough information about my condition   X 
15 I understand about my COPD tablets X   
16 I am confused about how to use my COPD inhalers   X 
17 I understand how my COPD treatments work   X 
18 I don’t find going to a hospital outpatient clinic frustrating X   
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19 I know how to use my inhaler properly X   
20 I have accepted the limitations to my lifestyle caused by COPD   X 
21 I feel that I have good support from others    X 
22 Overall I am satisfied with my life   X 
23 I am not depressed X   
24 Overall I am satisfied with the care given to me X   
25 I am not embarrassed to tell others about my condition X   
26 I feel that I am in control of my condition   X 
27 I am motivated to keep going and to not give up X   
28 I am happy to talk about the future   X 
29 I am not concerned about the future X   
30 I am not worried about the season X   
31 I keep going and try to enjoy my life X   
32 I am confident in a ‘flare up’ I have quick access to treatment   X 
33 I do not feel anxious about my current health X   
34 I am not worried about the care I will get with 'flare-up'   X 
35 I am not scared of getting a cold or an infection X   
36 I am not frightened of being breathless when I have a 
‘flare-up’ X   
37 I am not frightened to go to sleep 'flare-up'   X 
38 I try not to panic when I have a ‘flare up’    X 
 
 
6.4. Face validity 
 
Prior to the Rasch analysis and following the hierarchical item reduction a total of 
16 items (Table 6.10) were retained. Face validity with these items by the research 
team along with the qualitative exploration of themed items was undertaken. 
6.4.1. Face validity testing 
 
Each item was then scrutinised for its use within an experience measure and for 
professional respiratory opinion, as well as feedback from participants who 
completed the questionnaire, regarding the question structure and the meaning of 
what it was perceived to measure was discussed and debated, the predominate 
feature was 'confusion' on how it could measure experience in COPD. This was 
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done in two rounds and a further three questions were deleted as a result in as 
outlined in Table 6.10. 
Table 6.10 
Items removed following face validity  
Question 
No 
Question  
(Low Score Answer) Theme 
1st 
Validity 
Screen* 
2nd 
Validity 
Screen** 
1 I am not shocked by my COPD diagnosis Diagnosis X   
2 I have come to terms with my diagnosis of COPD Diagnosis     
7 I am confident that my GP will listen to my point of view Primary Care     
9 I am happy with the length of time to see my GP Primary Care     
14 I have enough information 
about my condition Education     
16 I am confused about how to 
use my COPD inhalers Education     
17 I understand how my COPD treatments work General     
20 
I have accepted the limitations 
to my lifestyle caused by 
COPD 
General     
21 I feel that I have good support from others  General     
22 Overall I am satisfied with my life General     
26 I feel that I am in control of my 
condition Control     
28 I am happy to talk about the future Future     
32 I am confident in a ‘flare up’ I have quick access to treatment Exacerbation      
34 I am not worried about the care I will get with a 'flare-up' Exacerbation      
37 I am not frightened to go to 
sleep 'flare-up' Exacerbation    X 
38 I try not to panic when I have a 
‘flare up’  Exacerbation    X 
* 1st Validity Screen – items removed 
** 2nd Validity Screen – items removed 
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In the first round, item 1 the ‘diagnosis theme’ was deleted as after reviewing 
comments from participants, several felt that because they had been diagnosed 
with COPD for many years now they were no longer shocked about their COPD 
diagnosis, and therefore chose to give item 1 a ‘0’, ‘I am not shocked by COPD 
diagnosis’ or left it blank. 
The two further items (37 & 38) were removed after exploring the item spread 
(Figure 6.1 & 6.2) across the COPD disease severity. Both items 37 and 38 did not 
correlate well across a wide distribution of COPD patients in severity and age. 
 
Figure 6.1 Poor distribution across severity of COPD for item 37 
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Figure 6.2 Histogram showing poor distribution across age for item 38 
 
After the face validity outlined in section 6.4.1 a further three items were deleted 
from the remaining 16-item list. This therefore 13 items to be entered and 
reviewed further in the Rasch Model.  
6.5. Rasch Analysis 
 
6.5.1. Introduction 
 
After the hierarchical reduction process, Rasch analysis was performed on the 
remaining 13 items (Table 6.11). 
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Table 6.11 
Remaining 13 items entered into the Rasch Model 
 
 
Q Low Scoring Question (0)*  High scoring Question (5)** 
2 I have come to terms with my diagnosis of COPD  
I have not come to terms with my 
diagnosis of COPD 
7 I am confident that my GP will listen to 
my point of view  
I am concerned that my GP won’t 
listen to my point of view 
9 
I am happy with the length of time that 
it takes to get an appointment with my 
GP when I need to 
 
I am angry about the length of time 
that it takes to get an appointment with 
my GP when I need to 
14 I have enough information about my 
condition  
I am frustrated by my lack of 
information about my condition 
16 I am confused about how to use my COPD inhalers  
I understand how to use my COPD 
inhalers 
17 I understand how my COPD treatments 
work  
I am confused about how my COPD 
treatments work 
20 I have accepted the limitations to my lifestyle caused by COPD  
I am frustrated and unhappy by the 
limitations to my lifestyle caused by 
COPD 
21 
I feel that I have good support from 
others like my family, friends, 
neighbours or carers 
 
I feel that I don’t have any support 
from others like friends, family, 
neighbours or carers 
22 Overall I am satisfied with my life  Overall I am very dissatisfied with my life 
26 I feel that I am in control of my 
condition  
I feel that I don’t have any control over 
my condition 
28 I am happy to talk about the future  Talking about the future makes me feel depressed 
32 
I am confident in a ‘flare up’ I have 
quick access to treatment e.g. a rescue 
pack or access to my GP 
 
I am worried that in a ‘flare up’ I don’t 
have quick access to treatment e.g. a 
rescue pack or access to my GP 
34 
I am not worried about the care I will 
get from health professionals when I 
get a ‘flare-up’ 
 
I worry about the care I will get from 
health professionals when I get a 
‘flare-up’ 
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6.5.2. Threshold Plot Map 
 
There were a number of items that had a disordered threshold. Figure 6.3 clearly 
shows this by denoting items seven and nine with the ** symbols. In Rasch these 
items are not being scored in a logical order. Therefore, the disordered thresholds 
were collapsed appropriately to get a more appropriate fit as shown in Figures 6.4 
and 6.5 which uses item 26 as an example to give a diagrammatic representation. 
 
Figure 6.3 Threshold Plot Map showing a normal threshold (2) 
 
The disordered and ordered thresholds are shown more clearly in 6.4 and Figure 
6.5 as the results are plotted for each score in an item. 
 
Figure 6.4 Example of a Disordered Threshold 
 
Figure 6.4 is an example of a disordered threshold for item 2 ‘0 = I have come  
to terms with my diagnosis of COPD’ and ‘5= I have not come to terms with my 
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diagnosis of COPD’. Figure 6.4 demonstrates that even when the likelihood  
of scoring a 1 is at its peak the probability is that a 0 will be scored instead. 
Figure 6.5 is an example of an ordered threshold for item 26 ‘0= I feel I am  
in control of my condition’ and ‘5=I feel I am not in control of my condition’ 
 
Figure 6.5 Example of an Ordered Threshold 
 
The y-axis looks at the probability of a given response to an item and the x-axis 
represents the participants’ experience expressed as a logit. The category 
response therefore is ordered in the appropriate threshold. 
6.5.3. Class intervals (CIs) 
 
In RUMM2030, patients are automatically placed into groups called class intervals 
(CIs). CIs are defined by ordering all patients in terms of experience and then 
splitting them into groups of approximately equivalent size of 50 persons in each 
group across the sample, in order to approximate groups. A number of fit statistics 
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are applied at the CI level (Hendriks, Fyfe, Styles, Skinner, & Merriman, 2012).  
In this study the number of class intervals was 3 as shown in Table 6.12. 
Table 6.12 
Class intervals (CIs) 
 
Item CI*1 CI*2 CI*3 
2 54 55 57 
7 54 54 54 
9 57 57 51 
14 51 53 52 
16 53 54 55 
17 50 51 52 
20 55 52 52 
21 53 52 52 
22 53 51 50 
26 52 52 52 
28 54 51 52 
32 52 50 52 
34 52 51 48 
* 3 groups of Class Intervals 
 
This represents a good equal sample size in each of the Class intervals 
 
6.5.4. Tests of individual item fit 
 
Once all items have been re-scored the data can then be explored further looking 
at the item characteristic curve (ICC), which is a graphical representation of the 
data and this also gives further detail on why an item maybe not be fitting a model. 
The ICC plots the model fit for each class interval (black dots) alongside the 
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accepted model curve as outlined in Figures 6.6, 6.7 and 6.8. There were a total  
of 3 items (2, 9 and 16). Also as mentioned in the Chapter Five a non-significant 
Chi-Square statistic less p>0.05 would also suggest a good fit to the Rasch model. 
Items 2, 9 and 16 will be highlighted as poor-fitting items to the Rasch Model with 
results shown. Figure 6.6 gives an example initially of an item fitting along the ICC. 
6.5.5. Item 14 Example of well-fitting item characteristic curve  
 
Figure 6.6 shows an ICC for a well-fitting item 14 ‘I have enough information about 
my condition’ (low score question). 
 
Figure 6.6 ICC for item14, a well-fitting item 
 
The y-axis represents the item severity and the x-axis represents patient severity 
in logits. The curved line represents the expected scores for the item, and the dots 
represent the observed scores for the class intervals at the different severity 
levels. The fit residual (along the top) is +0.978 and the Chi-Square probability  
is 0.394, indicating no significant deviation between the expected and observed 
scores for this item. 
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6.5.6. Item 16 removal  
 
Figure 6.7 is an ICC for item 16, a non-fitting item: ‘I am confused about how to 
use my COPD inhalers (high score)’. This item is over-discriminating. 
 
 
Figure 6.7 ICC for item 16, a non-fitting item 
 
The observed scores (black dots) form a flatter curve than the expected scores 
(the curve). The fit residual for this item was 6.29 and a significant chi-square 
(p=0.00). This item was also disordered and had to be collapsed to 3 scores.  
This item was consequently removed. 
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6.5.7. Item 9 removal 
 
Figure 6.8 shows an ICC for item 9, a non-fitting item: ‘I am happy with the length 
of time that it takes to get an appointment with my GP when I need to’ (low score). 
 
Figure 6.8 ICC for item 9, a non-fitting item 
 
This item is over-discriminating – the observed scores (black dots) form a steeper 
curve than the expected scores (the curve). The fit residual for this item was 4.14 
and it has a significant chi-square (p=0.013). This item was also disordered and 
had to be collapsed to 3 scores. This item was consequently removed. 
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6.5.8. Item 2 Removal 
 
Figure 6.9 shows an ICC for item 2, a non-fitting item: ‘I have come to terms with 
my diagnosis of COPD’ (low score). 
 
 
Figure 6.9 ICC for item 2, a non-fitting item 
 
This item is over-discriminating – the observed scores (black dots) form a steeper 
curve than the expected scores (the curve). The fit residual for this item was 2.56 
and it had a significant chi-square (p=0.010). This item was also disordered and 
had to be collapsed to 3 scores. This item was consequently removed. 
Therefore there was a total of 10 items that had a fit to the overall Rasch model 
shown in Table 6.13. 
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Table 6.13 
10 items with Rasch Fit 
 
 
 
 
 
 
 
 
 
 
 
Q Low Scoring Question (0)*  High scoring Question (5)** 
7 I am confident that my GP will listen to 
my point of view  
I am concerned that my GP won’t 
listen to my point of view 
14 I have enough information about my 
condition  
I am frustrated by my lack of 
information about my condition 
17 I understand how my COPD treatments 
work  
I am confused about how my COPD 
treatments work 
20 I have accepted the limitations to my lifestyle caused by COPD  
I am frustrated and unhappy by the 
limitations to my lifestyle caused by 
COPD 
21 
I feel that I have good support from 
others like my family, friends, 
neighbours or carers 
 
I feel that I don’t have any support 
from others like friends, family, 
neighbours or carers 
22 Overall I am satisfied with my life  Overall I am very dissatisfied with my life 
26 I feel that I am in control of my 
condition  
I feel that I don’t have any control over 
my condition 
28 I am happy to talk about the future  Talking about the future makes me feel depressed 
32 
I am confident in a ‘flare up’ I have 
quick access to treatment e.g. a rescue 
pack or access to my GP 
 
I am worried that in a ‘flare up’ I don’t 
have quick access to treatment e.g. a 
rescue pack or access to my GP 
34 
I am not worried about the care I will 
get from health professionals when I 
get a ‘flare-up’ 
 
I worry about the care I will get from 
health professionals when I get a 
‘flare-up’ 
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6.5.9. Overall fit to the Rasch model 
 
Table 6.14 
Overall Fit residual and Chi-square figures for remaining 10 items 
Item Fit Residual Non-significant Chi-Square* 
7 0.1 2.95 
14 -0.98 1.86 
17 -0.45 2.07 
20 1.04 1.03 
21 0.55 0.20 
22 0.92 0.24 
26 -0.39 4.9 
28 -1.10 3.2 
32 1.23 5.3 
34 0.24 0.42 
* (p value <0.01) 
 
6.5.10. Overall fit statistics in the Rasch model. 
 
Following removal of the three items which were then deleted, a summary of fit 
statistics are shown in Table 6.14. At this 10-item stage the p value was non-
significant, and therefore a Rasch model was achieved with 10 items. However, 
the aim was to develop an instrument with the minimal amount of patient burden, 
therefore using the Rasch model to develop the least amount of items possible. 
Despite, the overall fit of the 10 item solution the targeting of the item set was wide 
spread and therefore appeared suboptimal. 
Therefore, further analysis was conducted to remove items in an attempt to 
improve the targeting (distribution). This then led to demonstrate and review the fit 
statistics for results of a ten, nine and eight itemed solution, which is presented 
further. 
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6.5.11. Ten item fit statistics 
 
Table 6.15 give the over 10-item fit statistics followed by the person-item threshold 
distribution in figure 6.10.  
Table 6.15 
10-item fit statistics 
 
 
 
Figure 6.10 Person Item threshold distribution for 10 item fit 
 
6.5.12. Nine item fit statistics 
 
Table 6.16 give the over 9-item fit statistics followed by the person-item 
threshold distribution in figure 6.11.  
 
 
Item 
Location 
Person 
Location 
Item Fit 
Residual 
Person Fit 
Residual 
Chi Square 
Interactions 
PSI* PSI** 
M SD M SD M SD M SD Value df p 
0 0.2 -0.99 1.40 0.20 0.87 -0.52 2.38 22.2 20 0.33 0.77 0.77 
M – Mean 
SD – Standard deviation 
PSI* -  With extremes 
PSI** - No extremes 
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Table 6.16 
9-item fit statistics 
 
 
Figure 6.11 Person Item threshold distribution for 9-item fit 
 
6.5.13. Eight item fit statistics 
 
Table 6.17 give the over 8-item fit statistics followed by the person-item threshold 
distribution in figure 6.12.  
Table 6.17 
8-item fit statistics 
Item 
Location 
Person 
Location 
Item Fit 
Residual 
Person Fit 
Residual 
Chi Square 
Interactions 
PSI* PSI 
** 
M SD M SD M SD M SD Value df p 
  
0 0.1 -1.01  1.49 0.36 0.95 -0.47 2.10 14.2 18 0.71 0.75 0.71 
M – Mean 
SD – Standard deviation 
PSI* -  With extremes 
PSI** - No extremes 
Item 
Location 
Person 
Location 
Item Fit 
Residual 
Person Fit 
Residual 
Chi Square 
Interactions 
PSI* PSI 
** 
M SD M SD M SD M SD Value df p 
0 0.11 -0.99  1.50 0.43 1.10 -0.51 2.38 17.3 16 0.36 0.75 0.73 
M – Mean 
SD – Standard deviation 
PSI* -  With extremes 
PSI** - No extremes 
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Figure 6.12 Person item threshold distribution for 8 item fit. 
 
At an expert panel meeting consisting of nursing and medical academic 
professionals and healthcare professionals with an interest in COPD, the 3 models 
were presented. After discussion the 9-item solution was deemed to be the optimal 
solution for the final instrument because: 
• It has a fit to the Rasch Model;  
• The logit range was adequate between -0.134 -- 0.142;  
• Better person item distribution (Figure 6.11); 
• Expert panel felt item 22 would not add any additional value to the overall 
aim of the instrument.  
Therefore item 22 (‘Overall I am satisfied with my life’; ‘Overall I am not satisfied 
with my life’) was removed. This left a final 9-item instrument (Table 6.18). 
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Table 6.18 
Final 9 items identified 
 
6.6. Reliability & Validity of the nine item instrument 
 
6.6.1. Person Separation Index (PSI) 
 
The Person Separation Index (PSI) for the 9 items was 0.71. This shows where 
the estimates are on the logit scale for each person. This result suggests that 
there is good person separation reliability. 
 
 
Q Low Scoring Question (0)*  High scoring Question (5)* 
1 I am confident that my GP will listen to 
my point of view  
I am concerned that my GP won’t 
listen to my point of view 
2 I have enough information about my 
condition  
I am frustrated by my lack of 
information about my condition 
3 I understand how my COPD treatments 
work  
I am confused about how my COPD 
treatments work 
4 I have accepted the limitations to my lifestyle caused by COPD  
I am frustrated and unhappy by the 
limitations to my lifestyle caused by 
COPD 
5 
I feel that I have good support from 
others like my family, friends, 
neighbours or carers 
 
I feel that I don’t have any support 
from others like friends, family, 
neighbours or carers 
6 I feel that I am in control of my 
condition  
I feel that I don’t have any control over 
my condition 
7 I am happy to talk about the future  Talking about the future makes me feel depressed 
8 
I am confident in a ‘flare up’ I have 
quick access to treatment e.g. a rescue 
pack or access to my GP 
 
I am worried that in a ‘flare up’ I don’t 
have quick access to treatment e.g.  
a rescue pack or access to my GP 
9 
I am not worried about the care I will 
get from health professionals when I 
get a ‘flare-up’ 
 
I worry about the care I will get from 
health professionals when I get a 
‘flare-up’ 
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6.6.2. Test-retest reliability 
 
Test-retest reliability was evaluated via Intraclass Correlation Coefficients (ICCs) 
and was 0.78 for the 9 item instrument. This suggests that there was a good test-
retest reliability. 
6.6.3. Validity testing – correlation with PROMs 
 
These were measured using an r value* and would only be significant, i.e. they are 
measuring the same construct as the COPD PREM, if they had a significant  
r  value which was set at less than 0.01. The results were also plotted to show any 
possible correlation on a scatter gram (Table 6.19 and Figures 6.13, 6.14 & 6.15). 
Table 6.19 
Correlations: COPD PREM-9, CAT, Anxiety & Depression scale 
  CAT Score* Anxiety* Depression* 
Total 9 0.42 0.30 0.41 
* r value = 0.01 
 
Scattergram Figure 6.13 (overleaf) shows there is a mild correlation with the total 
of the COPD PREM -9 and the total of the CAT score. 
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Figure 6.13 Scatter gram for total Scores of COPD PREM-9 & CAT 
 
Figure 6.13 suggests that people living with COPD can have good and bad 
experience regardless of severity of COPD (the higher the CAT score the 
perception that the worse COPD). This is similar to the results of the total Anxiety 
and Depression scores association with the total for COPD PREM-9, as shown  
in Figures 6.14 and 6.15.  
185 
 
Figure 6.14 Scatter gram total COPD PREM-9 and Anxiety Scores 
 
Figure 6.15 Scatter gram total COPD PREM-9 & Depression Score 
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6.7. Chapter Summary 
 
This chapter has presented the results of the testing of the preliminary instrument 
in a cohort of 174 participants with a range of people living with COPD from across 
the country. The precise process of item reduction through the various techniques 
as demonstrated has reduced a 38 itemed instrument to a succinct 9-item 
instrument of which further discussion will take place in the remaining chapters.  
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CHAPTER SEVEN 
 
7. Discussion 
 
7.1. Introduction 
 
The comprehensive overview of the results in Chapter Six detailed the overview 
population study and the subsequent scrutiny of the item reduction process.  
This thesis has produced a validated concise nine-itemed experience 
questionnaire using appropriate procedures to ensure that the items addressed 
issues of importance to people with COPD. The COPD PREM-9   covers a number  
of different aspects of COPD care divided into three main themes:  
1. Everyday life with COPD; 
2. COPD and usual care; 
3. Exacerbation management in COPD. 
These three themes identified are broad areas and have a variety of component 
items but address a number of specific topics in COPD, such as primary care 
relationships and self-management. The quality of fit of the COPD PREM-9 to the 
Rasch unidimensional model implies that the questionnaire has true interval 
scaling properties. This section will explore this thesis's findings and the COPD 
PREM-9 questionnaire in the context of contemporary research and national and 
international guidance and practice frameworks. The chapter will also demonstrate 
the associations between the items of the COPD PREM-9 against the Department 
of Health (2011) Patient Experience Framework. This framework introduced in the 
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literature review, gives eight overarching concepts recorded for a perceived 
positive patient experience. 
7.2. The journey from thirty-two to nine items 
 
7.2.1. Population & Demographics 
 
In this thesis, a number of clinical variables were obtained at the time of 
recruitment. These included spirometry, MRC scores and smoking status.  
All participants recruited had a confirmed diagnosis of COPD, previously 
measured by lung function. Participants were recruited from a number of different 
NHS settings which included pulmonary rehabilitation, community COPD teams 
and hospital wards. Another group were recruited from the BLF Breathe Easy 
groups from across the country. These groups tend to meet monthly in a variety of 
locations from church halls to community halls and hospitals. This wide 
recruitment of potential participants has ensured that there is some variation 
between the baseline characteristics of the participants and between groups.  
All results discussed are of total participants unless specifically mentioned in 
reference to those participants recruited from hospital/community and those from 
the Breathe Easy (BE) groups. The overall severity of participants in this study 
showed a good representation of the general COPD population. There was  
a wider variation of severity of disease across the four different NICE (2010) 
classifications of participants with representation from mild to very severe disease. 
However, the mean FEV1 for all participants was classified as moderate  
(FEV1 59%), with the mean (FEV1 48%) being severe in the Breathe Easy cohort. 
Due to the nature of data collection and the frailty of some of the participants 
recruited from the BE groups in particular, it is acknowledged that 17% (n=29)  
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of the spirometry data is missing from the overall baseline characteristics. But as 
there was already a good distribution of severities this is not detrimental to the 
study’s overall aim.  
The mean Medical Research Council (MRC) score was 3.4 (scale 1-5). This result 
also supports that a wide degree of distribution among the severity of COPD was 
recruited, with participants scoring 1 to 5 on the MRC scale, with 42% (n=73)  
of participants scoring an MRC of 4 or 5. This emphasises the fact that the 
population had a varied degree of breathlessness based upon the impact on an 
individual. There was no difference in MRC between those recruited from BE and 
hospital/community.  Participants were mainly recruited from a diverse population 
across London Boroughs ensuring a broad representation of COPD patients. 
However, the study was not restricted just to London. There were also another five 
recruitment sites in England and the Channel Islands. However, written 
information and instructions were only available in English and therefore it is 
recognised that the study did not specifically target a number of groups of people 
in terms of ethnicity, people with learning disabilities and where English was not 
the participants’ first language. Ethnicity was not recorded as part of this thesis but 
it must be acknowledged that due to the diversity of London there were a number 
of participants who represented the black and minority ethnic communities. Further 
testing is required within these groups including potential translation of the 
instrument.  
There was no upper age limit set within the inclusion or exclusion criteria for the 
study, however all participants had to be over the age of 18.  The mean age of the 
participants was 71 years which is not a dissimilar mean age to many of the 
previous studies identified in the literature review (Corcoran et al., 2013; Doos et 
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al., 2014; Rocker et al., 2013). The recent 2012/2013 National COPD Audit, also 
showed a mean age of 73 amongst the population who were included within the 
audit  (British Thoracic Society, 2013). However, the NICE (2010) COPD 
guidelines suggest that COPD is suspected in those aged 35 years and older and 
therefore it was important that the distribution of age range was varied.  
The systematic and meta-analysis of the Global burden of COPD by Halbert et al., 
(2006,  pp.526) emphasises  the importance of age as a contributing factor to the 
growing prevalence of COPD, investigating studies with populations from < 40 
years to > 65 years with a diagnosis of COPD.  
The participants, therefore, in this thesis, were aged from 42 to 91 years, 
demonstrating a extensive spread of age groups who completed the preliminary 
COPD-PREM. However, this variation in age may have been responsible for the 
identification of seven items associated with an age bias. The steady decline  
in lung function and its association with age is well documented (Gavin C 
Donaldson et al., 2005). It is also recognised by Ito & Barnes (2009 p.176)  that it 
is not clear how the aging process is involved in the decline of lung function and 
inflammation in COPD. Donaldson (2002 p.842) however, argues that the number 
and frequency of acute exacerbations of COPD can contribute to a long-term 
decline in lung function in people with moderate to severe COPD. Age, therefore, 
cannot be seen in isolation to understand whether people have a good or bad 
experience of living with COPD, as other contributing factors such as 
exacerbations and the rate of decline in lung function also contribute to the burden 
of symptoms. The Fletcher et al. (2011 p.2) international survey of the working 
population (age 45-67 years) argues that COPD also has a 'significant personal, 
economic and societal burden on the working age people'.  
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In this thesis the item reduction process for linking individual items and testing for 
associations with age was the Spearman’s Correlation, which resulted in six items 
being removed. These items which were deleted through this process were 
associated with different aspects of COPD care, from scared of getting a cold to 
the understanding of the condition and management of fear. There was a direction 
with these responses towards a positive experience (low score) in the older age 
groups, thus suggesting that within the six items deleted they were correlated 
towards the specific older age group and not the severity of COPD. On reviewing 
the six items, all apart from one item did not mention COPD or was linked to  
a symptom associated to the disease. Thus, the items were very generic in nature 
and could potentially be applied to any condition. It is important to note that 90% of 
the sample group were over the age of 60 years potentially contributing to the 
number of age bias results. Other respiratory instruments in their development 
designs (Yorke et al., 2012) have also deleted items due to age bias thus this 
thesis is not isolated in this area.  
The gender of participants may have also introduced bias to the PREM 
development. While no attempt was made throughout the recruitment process to 
collect equal numbers of male and female participants, an even distribution was 
achieved with 52% (n=91) of the sample being female. There was a slight 
mismatch in the two different groups with an increase in females, 57% (n=50) 
recruited from the BE groups. However, as previously mentioned, all results were 
investigated as a total population. This even distribution allowed for gender bias to 
be analysed using the hierarchical method and the use of the Mann-Whitney-U 
test. The even distribution may have contributed to the fact that only one item was 
deleted at this stage which was item 35 I am not scared of getting a cold or an 
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infection (low score item answer). This item had already been deleted in the age 
bias process. The descriptor ’scared’ used to describe the experience of getting  
a cold or infection was not a descriptor word used in the rigorous literature review 
in other studies on experience, but was a predominate description of colds and 
infections identified in the initial qualitative study. The concept of an infection was 
also used in other items in the instrument (items 32, 37, 38) to describe infection 
but terminology was changed and the instrument used 'flare-up' as another 
descriptor of infection. It may suggest that people relate infection to other ailments 
and not colds. COPD patients use terms such as flare up which are more 
commonly used to describe this in COPD (Osthoff & Leuppi, 2010).   
The two systematic reviews of patient experience by Disler et al., (2014);  
& Giacomini et al., (2012) did not attempt to highlight whether there was a real 
distinction in the experiences and descriptors used for age or gender to describe 
their experience. COPD however, has been traditionally been seen as an 'old 
man's disease', associated with higher incidences of smoking among men. This 
perception is changing with smoking rates for women increasing now overtaking 
men in some countries (Watson et al., 2004). In a large cross sectional study 
questionnaire based study of 65, 717 of cigarette smokers in Norway by 
Langhammer et al., (2000, p.917) stressed that women report much more 
respiratory symptoms than men. Cigarette smoking is the number one cause of 
COPD globally. Gender differences in COPD are  widely reported and the Aryal et 
al., (2013) review and update on smoking concludes that a number of differences 
exist between men and women living with COPD.  A number of studies reviewed 
by Aryal et al., (2013, p.212) relate to the clinical presentation of the disease.  
For example, women had higher levels of anxiety and depression and also self-
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reported dyspnoea was higher in females. His review also advocates a number  
of other gender differences in the diagnosis, treatment options and epidemiology 
in COPD care. There is no indication of the measurement of gender difference in 
the experience of living with COPD. But a great understanding of the effects of 
COPD on both age and gender in the physical, functional, social and psychological 
affects have been well reported by a number of qualitative and mixed method 
approaches (Skumlien, Haave, Morland, Bjørtuft, & Ryg, 2006; Tsiligianni, Kocks, 
Tzanakis, Siafakas, & van der Molen, 2011). 
7.2.2. Hierarchical methods of item reduction 
 
As previously stated the process of item reduction through hierarchal methods 
ensures internal validity (rigor and the removal of bias) and external validity  
(the ability to generalise) among the initial proposed items. To ensure consistency 
across all items, six were deleted as part of the hierarchical methods where more 
than 15% of participants had failed to complete them. Two of the items (10 and 11) 
were concerned with the experience of undertaking pulmonary rehabilitation.   
PR is a significant non-pharmacological approach to the management and care of 
COPD (Ries et al., 2007), and experience in this is critical to capture. But as part 
of the wider programme of COPD work a PREM in PR was also being considered 
and this thesis will also inform the direction of this future work. Additionally, PR is 
not undertaken by every COPD patient who may complete the COPD-PREM. 
Therefore the deletion of these items reduced the confusion that may lie with 
completing the questionnaire and added value by making the instrument more 
generic in its field. This is possibly the reason why there was a high level of 
missing responses for these two specific items, if participants were unaware of 
what PR was. This is similar to two further items (3 and 4) which asked about the 
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experience of smoking history. Item 3, I have given up smoking and I am 
‘confident that I will not start’ and item 4, I want to stop smoking and I believe I can 
– lower score answers – had a large missing value at 76% (n=132).  
This is further supported in that 72% (n=125) of the participants completing the 
questionnaire were self-reported as being ex-smokers, and 12% (n=20) as non-
smokers. Smoking cessation, like PR, is a major part of COPD care, but it is clear 
that many people choose not to answer these items. Giacomini et al. (2012) 
identified two conflicting accounts to the recording of smoking. Firstly, the belief 
that smokers were diagnosed with COPD for other reasons than accepting 
smoking was the cause. And patients who expressed ‘blame’ and ‘regret’  
for knowing that smoking did cause COPD. A longitudinal and descriptive study 
investigating the experiences of self-blame and stigmatisation for self-infliction 
among individuals living with COPD by Halding et al., (2011, p.100) affirms these 
accounts clarifying that patients often felt ‘disgraced’ with a heavy burden of self-
stigmatisation. But it is also claimed that there is a lack of support from healthcare 
professionals which may not be localised to the COPD population (Jenerette  
& Brewer, 2010). In an editorial review on the patients validation of self-reported 
smoking by Rebagliato, (2002 , p.163) concludes it is also acknowledged that  
self-reporting can be unreliable if the participant is under pressure because of 
social or medical disapproval. However, Soulakova et al., (2012, p.952), reporting 
on a large cohort study on the reliability of adult self-reported smoking history, 
argues that their findings suggest that ‘self-reported smoking history 
characteristics can be reliable’. The high proportion of ex-smokers in this cohort is 
a positive finding but must be taken on the backdrop of differing option and 
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evidence. The high level of missing data for these two smoking items supports 
this. 
The overall aim of the questionnaire was to explore the experience of living with 
COPD, or of healthcare.  Having deleted these two smoking-related items similar 
to PR items the proposed questionnaire feels more patient-centred and COPD 
generic, but remaining disease specific in its measurement.  Another item that was 
deleted because it had missing data of 17% was item five: It was a relief to have  
a diagnosis for my symptoms. This item caused a great deal of discussion among 
the participants and was the item that most frequently needed explaining (which in 
itself suggests the item is not worded clearly enough to be worthy of inclusion). 
However, within the literature the notion of the ‘diagnosis’ of COPD was a key 
theme in Study One (COPD PREM development), and was supported by 
McDonald et al., (2013, p.28) who stipulate that many of the participants from their 
study were ‘frustrated’ or ‘disconcerted’ about not having a diagnosis for 
symptoms. But, a number of participants completing the preliminary COPD-PREM 
also made similar references to this, comments such as ‘it was such a long time 
ago I can’t recall if it was or not [a relief]’; ‘of course it wasn’t a relief, I had just 
been diagnosed with COPD, and I just thought it was down to my age’ and ‘who 
knows?’ The diagnosis of COPD is an important part of the patient’s journey.   
The experience however, of this ‘diagnostic phase’ shows wide variation from mis-
diagnosis to living years with symptoms before a diagnosis is finally made. Both 
examples impact greatly on the patient supported by the literature review (Disler  
et al., 2014).  
Therefore, to measure the experience of the diagnosis in a PREM questionnaire 
proved difficult. This may be due to the terminology used or the length of time  
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it takes from symptoms to diagnosis. The study by Lindgren et al., (2014, pp.441-
442) on the experience of the diagnostic phase of COPD highlights that diagnosis 
of COPD is a complex and a life-changing event where patients are dealing with 
many new terms such ‘chronic’ and ’self-inflicted’. COPD is not isolated in this.  
A phenomenological study to look at the lived experience of people with Multiple 
Sclerosis (MS) by Lowden et al., (2014, p.E14) stressed ‘acknowledging the illness 
as part of oneself’ was a key theme from the research and that was clearly denied 
in another long-term condition, advocating that the experiences of other long-term 
conditions follow similar avenues. 
Communication with healthcare professionals is an important aspect in the long 
term understanding of the relationships between the different groups of healthcare 
professionals (HCPs) and the patients, which this instrument does not address 
specifically. Lindgren et al., (2014, p 443) makes the suggestion that there are two 
main areas of communication at the diagnosis phase: that of ‘negotiation’ and that 
of ‘acceptance and new understanding. Reflecting on the comments made when 
participants were discussing the item, it is feared that many were still in the 
‘negotiation phase’, making it harder to answer the item.  
 The final item which was deleted due to missing responses was item 15,  
‘I understand about my COPD tablets’. This item also caused a lot of discussion 
with healthcare professionals and participants as a high number of participants 
involved in the study were not on oral medications for their COPD, but were on  
a number of other oral medications for other conditions. Some were unclear if they 
were on 'tablets' for their COPD or not. Therefore, it was not answered in 28% of 
participants, and a high number scored it a 0 (the lower score number, but good 
experience) I suspect as they were unclear. Unlike inhaled devices, people who 
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are taking oral medications for their COPD tend to be in the very severe 
classification. A number of patients with COPD also had experienced 
exacerbations of their COPD caused by infection, with a need to introduce rescue 
medication which is recommended by NICE (2010). Additional oral medication is 
taken in tablet form as well as continuing inhalers. The debate about whether this 
was included as ‘COPD tablets’ caused a lot of discussion, especially in the 
different Breathe Easy groups, and it was not isolated to one group. Therefore the 
deletion of the item enabled the final PREM-COPD items to focus on more concise 
items which were understood across a larger group of COPD patients.   
The hierarchical methods continued to test for the floor and ceiling effects of an 
item. This entailed setting a ‘cut-off’ level for item selection, in this case more than 
40% of patients, as a total group, responded a ‘zero’ (floor effect). Of the twelve 
items deleted due to the floor effect was an item had already been deleted (item 
11 on PR). All items which were deleted were items which were all devised from 
the themes identified in Study One (COPD PREM development) and based and 
supported within the literature review on the concerns with usual care in COPD 
and living with COPD. In particular, item 25 ‘I am not embarrassed to tell others 
about my condition’ (good experience answer), had a 59% ‘zero’ response rate. 
This suggests that over half of the total participants were not embarrassed by their 
condition. ‘Embarrassed’ is not a descriptive word used within the Giacomini et al., 
(2012) or Disler et al., (2014) reviews to describe similar experiences, other similar 
items seeking experience on daily life and COPD included items 27, 28, 29 and 31 
which explored areas such end of life (a similar question was retained) and ‘I enjoy 
my life’. The remaining items deleted all had connections to medication 
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management (items 17 & 19). A further two items had already been deleted in 
other areas of the item reduction process.  
There were a further two other items (8 and 13) which had a floor effect and were 
deleted. These were also included in the item-to-item correlations. The two items 
were exploring the experience of healthcare workers, item 8 being ‘I am very 
pleased with health care workers’ (low score answer) and item 13 ‘The information 
I have been given is consistent’ (low score answer). The hierarchical methods 
reduction showed a positive r value (>0.80) suggesting there was an internal 
correlation to each other and item 11 on PR which had now been deleted.  
The reasons for this are open for discussion, but there is a strong link between 
pulmonary rehabilitation and an increase in improved information need in condition 
specific learning for the disease, alongside an increased activity and improvement 
in quality of life (Ko et al., 2011). Together staff anecdotally also receive high 
praise and patients experiences are generally overall positive. However, the Royal 
College of Physicians (RCP), in partnership with the British Thoracic Society, is 
working to undertake PREM-specific research in pulmonary rehabilitation, as little 
is known nationally about the experiences of patients undertaking this exercise.  
It is hoped that this work will also influence some of the thinking related to 
partnership with them. However, a systematic review by de Sousa Pinto et al., 
(2013), specifically researching COPD patient experiences with pulmonary 
rehabilitation, only identified eight studies, but did support earlier thinking that PR 
empowers patients through health education, including specific aspects of the 
COPD journey. There were no items that achieved a ceiling affect. It is unclear 
why such a high number of items reached a ceiling affect. Some discussion on 
these items was apparent on the internal discussion that happened in the Breathe 
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Easy Groups and individually over the meaning of items. But to ensure 
consistency and increase the appropriateness of the PREM COPD instrument 
items, need to be deleted to ensure maximum reliability and validity. 
Therefore, in summary, there were a total of twenty-two items deleted (Table 6.9)  
as part of the hierarchical methods of item reduction taking into account the 
demographics including severity of lung disease, age and gender. Having 
discussed the items that were removed it is evident that appropriate items were 
deleted to develop a more patient-centred instrument to be used with the whole 
COPD population, reducing bias against age or discriminating against smokers or 
whether a person had undertaken pulmonary rehabilitation or not.  Focusing on 
reducing items also ensures consistency and increases relevance to the aim of the 
study (O’Leary & Jones, 1998). 
7.2.3. Face Validity  
 
The remaining sixteen items were then discussed within a respiratory expert panel 
to develop face-to-face validity. Each item was assessed individually. Initially, 
none of the data was shown and then subsequently each item was scrutinised 
including the data from the item reduction hierarchical process, as well as 
reviewing the aims and objectives of this study. Participants’ comments were also 
noted for each item and were shared among the group. In the first round of face-
to-face validity, item 1 was removed (‘I am not shocked by my COPD diagnosis’). 
This decision was made on the basis of comments similar to that of item 5 
regarding the relief for having a diagnosis. The descriptive word ‘shocked’ 
confused some participants, many suggesting it was such a long time ago they 
were now not sure how they felt at that time. Also this descriptor was not identified 
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in either of the systematic reviews by Giacomini et al., (2012) or Disler et al., 
(2014) or the quantitative paper specifically exploring the experiences of the 
diagnostic process of COPD. Descriptors such as ‘negotiation’,  ‘past’ and 
‘challenge’ were used (Lindgren et al., 2014).  
There were a further two items (37 and 38) that were also deleted following  
a second round of face-to-face validity. These two items were associated with 
exacerbations of COPD. Two of the respiratory experts suggested that they did not 
add ‘value’ to the additional items in the measurement of experience. It was 
agreed that both items were related to ‘symptoms’ associated with exacerbations 
of COPD rather than experience. Both items also had a poor severity distribution 
which could give a potential bias. Sleep is an important aspect of COPD care, 
however it is recognised by Eckerblad et al., (2014) as an associated high 
symptom burden when assessed using a multidimensional symptom profile,  
with patients with stable COPD. However, this is contrary to the Giacomini et al.,  
(2012) review which argued that patients were more frightened about not waking 
from sleep due to symptoms. After further discussion within the expert group and 
further review of the distribution of the severity of COPD, given these two different 
opinions it was agreed that both items 37 and 38 would be deleted leaving a total 
of 13 items to be included in the final Rasch analysis. 
7.2.4. Rasch Analysis 
 
The reduction process of the remaining 13 items followed a rigorous methodology 
when entered into the Rasch model. The items that were of poor fit or poor 
measurement properties were deleted following the intricate process outlined in 
Chapters Six and Seven. The three items deleted following the Rasch analysis 
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went through this process and supports the proposal by Jones et al. (2009, p.652) 
that  
when deciding whether to include or exclude an item during questionnaire 
development, it is necessary to balance its weaknesses and strengths 
against its overall contribution. 
 
Therefore not only were the three items (16, 9 and 2) deleted because they did not 
fit the unidimensional Rasch model. But also examined in there context and overall 
expert scrutiny of whether the items that remained were broad enough to cover the 
initial aim of the study. Item 16, ‘I am confused about how my inhalers work’ (high 
scoring answer) was deleted as it did not fit the Rasch Model and had a high fit 
residual and thus there was an overt discrimination between the interval class 
groups within this item (16). The Rasch model suggested that, overall, participants 
had a higher-than-expected ‘bad experience’ and a higher-than-expected ‘good 
experience’ than the model predicted using the three class interval groups along 
the continuum as diagrammatically shown in Table 6.12 (Chapter Six, p.169). 
The three items which were deleted in Rasch were also reviewed by the expert 
group. There was concern that item 16 which related to 'medicine management' 
and the use of inhalers would be a 'good' item to use because of wide-spread 
literature on inhalers (Molimard et al., 2003). It is common knowledge among the 
respiratory community that patients and healthcare professionals have poor 
inhaler technique. A cross-sectional study of GP practices in the Netherlands 
undertaken by Hesselink et al., (2001, pp.255-256) identified that over 24%  
of patients made one critical mistake in using their inhaler. This was similar to 
other studies, some with a much higher percentage making mistakes such as 
Hämmerlein et al., (2011, p.61) reporting 78.9% of patients with poor technique. 
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When considering the aim of the thesis and the evidence behind inhaler technique, 
the inclusion of this item could potentially have been useful. If a patient scored  
a zero (good experience) potential for modifications of inhaler technique could be 
missed. The checking of inhalers, however, should be a routine part of COPD care 
and is outlined both in the Quality Outcome Framework for general practice as well 
as a recognised part of the COPD assessment recommended by NICE (2010).   
The two further deleted items, item 2 'I have come to terms with my diagnosis of 
COPD’ (low score answer), and item 1, regarding 'being shocked' about the 
diagnosis of COPD were very similar. From participant feedback regarding this 
item a number of participants had expressed that they continued not come to 
terms with the diagnosis, but did not want to score a higher value (denoting  
a worse experience) as even though they hadn't accepted the diagnosis of COPD, 
it wasn’t affecting their everyday life or experience of living with the disease. 
However, coming to terms with a diagnosis is an important aspect of the patients 
pathway, as previously discussed in the literature (Disler et al., 2012; Giacomini et 
al., 2012). The Lindgren et al., (2014, p446-447) study also stressed earlier that 
descriptors such as ‘struggle’ and ‘honesty’ must also be considered at diagnosis. 
However, this item did not fit the Rasch model and to ensure an appropriate fit to 
Rasch and reflecting on the previous statement by Jones et al., (2009), on finding 
the ‘right balance’ in the instrument, this item was deleted. Though diagnosis 
remains a key feature of COPD care, there are conflicts over reported concerns in 
the literature and with the findings of the previous qualitative study (Study One) 
and how participants report their findings in completing an instrument. This is an 
important finding and will be reported back to the COPD group. As all items 
relating to the diagnosis of COPD were now deleted from the original COPD 
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PREM-38 through item reduction. The four themes previously identified in Study 
One (COPD PREM development p.126) would now be reduced to three themes, 
again allowing for a more concise instrument in its final stages.  
The final item to be deleted was item 9 (‘I am happy with the length of time to see 
GP’) (lower scored answer). The GP is a key orchestrator of care and the literature 
primarily focuses on the relationship and experiences with patients’ GP 
consultation rather than the time it takes to get an appointment (Powell et al. 2013; 
McDonald et al., 2013). The descriptors describe ‘communication’ and 
‘understanding’ as important words used to describe this experience. This item 
was also deemed more ‘patient satisfaction’, if we reflect on the definitions of this 
rather than capturing the experience of the relationship between the patient and 
the GP as discussed as an important concept in the literature review.  
As the results suggest, after these three items were deleted there was  
a subsequent fit to the Rasch model with a non-significant p value. The expert 
group, consisting of the initial reference group plus additional academic staff who 
were familiar with the Rasch process and familiar with scales and instrument 
development, as well as representation from the British Lung Foundation, 
reviewed the remaining items and, after discussion about the overall construct of 
the questionnaire and the data in relation to the overall distribution of the items 
and their logic value, there was an agreement to delete item 22 (‘Overall I am 
satisfied with my life’ (low score answer). It was agreed that the terminology used 
to describe the item was not in relationship with the experience of living with the 
disease. This is supported by the literature; neither Giacomini et al., (2012)  
or Disler et al., (2014) use the descriptor ‘satisfied’ to describe any aspect of care 
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documented in the systematic reviews. The deletion of this item now left this a final 
9 items, from now on called the COPD-PREM-9 (Figure 7.1).  
Internal consistency was used to estimate homogeneity of the items of the COPD 
PREM-9; that is the extent to which the nine items generally measure the same 
construct. This was assessed by analysis of the Person Separation Index (PSI). 
An acceptable PSI score of 0.71 was found. This is indicative of the new 
instrument’s internal consistency for the population studied. Though these results 
suggest that there is good person separation reliability, it was recommended in the 
methods that a PSI of 0.85 (Tennant & Conaghan, 2007) was needed for 
individual use. Expert advice on the Rasch analysis was therefore sought and  
a member of the expert respiratory panel was asked to provide this. Discussion 
suggested that the PSI for reliability for this cohort and development of the final 
PREM COPD-9 was of a good level and thus is reported as such.  
Stability of the COPD PREM-9 was then assessed over seven days. Extended 
delays for questionnaire returns were minimised as much as possible and those 
returned after the seven days from the initial return date were not included in this 
aspect. 50% (n=87) of participants returned Pack B of which just over half (56%) 
were from the Breath Easy groups so there was a good distribution of participants 
from all areas. This was a much higher return rate than was suggested of 20% 
(Jones et al., 1999). A systematic review of postal returns by Edwards, (2002, 
p.23) concludes that a lack of return of questionnaires can potentially add bias and 
reduce validity to a study. When testing the stability of a questionnaire,  
it is important to compare like with like. In relation to the underlying construct being 
measured by the questionnaire, participants’ health status needs to be relatively 
constant over the time period of assessment. To assess stability of participants’ 
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health status, participants completed a global health change score at follow-up. 
Correlations between the COPD PREM-9 and between baseline and follow-up 
were examined for those who reported that their global health was ‘the same’.  
The ICC for the COPD PREM-9 was high, indicating that the scale was stable at 
the time. Given that the time period between completing the questionnaires was 
seven days, the observed stability is more than likely a true reflection of stability 
rather than participants repeating and remembering responses to the initial COPD 
PREM questionnaire (Yorke et al., 2012a). 
7.3. The COPD PREM-9 
 
The final content of the COPD PREM-9 covers three main areas in COPD, using  
a wide-ranging scale from zero (good experience) to five (bad experience) making 
it concise to administer and easy to use as a patient. The first section is on 
'everyday life with COPD', concerned with four questions covering aspects that are 
specifically patient-centred, and drawing upon current patients' experience of living 
with the disease and including questions on support and guidance on living with 
the disease. The second three questions relate to the experience of 'everyday care 
in COPD and are constructed on primary care and information and understanding 
of the disease. And, finally, a third section has two further questions on self-
management of exacerbations of COPD.  
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Figure 7.1 Final COPD PREM-9 Instrument 
 
208 
Set within the national guidance of NICE (2010) and The Department of Health 
and NHS England context, and reported within this thesis the heightened 
importance of measuring experience is fast becoming a fundamental aspect  
of daily healthcare. Therefore, it was imperative that any generation of new 
experience instruments or measures must fulfil all or part of the Department of 
Health (2011) NHS Patient Experience Framework as used as the framework 
underpinning this study. The framework approved by the NHS National Quality 
Board (NQB) has a working definition of patient experience to enable and guide 
the clinicians and managers in the measurement of patient experience across the 
NHS. This framework, as previously mentioned within the literature review, 
outlines the eight key concepts which are critical to the patients’ experience or 
journey through NHS Services (Department of Health 2011). Thus, a correlation  
of the COPD PREM-9 and the framework was undertaken to establish whether 
any appropriate links and associations are made between the underpinning 
experience framework and the items generated for the new COPD PREM-9 
instrument.   
As previously mentioned the COPD PREM-9 was finalised into three groups: my 
everyday life with COPD; usual care in COPD, and; COPD exacerbations. It was 
clear there is a correlation or association across all of the eight concepts of the 
NHS patient experience highlighted within the framework and the 9 items 
generated in the final PREM questionnaire. This adds value and professional rigor 
to the newly created instrument demonstrating that the values of experience as 
shown in the framework such as person-centred, communication, involvement of 
family and friends and access to care are being addressed in the items generated 
within the new PREM-COPD-9. The robust process in the development of a new 
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instrument by patients for patients is a critical focus in this development, as the 
experience framework was developed by patients for patients. To illustrate these 
points further and demonstrate this association between the COPD PREM-9 and 
the Department of Health (2012) Patient Experience Framework the three themes 
will be discussed as well as further discussion on the current literature. 
7.3.1. My everyday life with COPD 
 
The four items that are included within this section are connected to the everyday 
life of living with COPD and include questions relating to the limitations (item 4)  
on lifestyle and whether participants had accepted them or were frustrated by 
them. Both the Disler et al., (2014) and Giacomini et al., (2012) systematic reviews 
identified ‘frustration’ as a common descriptor of lifestyle and the impact that 
COPD had on daily life was a theme throughout the literature. Talking about the 
future (item 7) and control (item 6) were also themes as previously identified in the 
literature review and reported by Lindgren et al. (2014). The association of 
'everyday life' with the 'NHS Patient Experience Framework' highlighted a number 
of concepts in this framework, firstly, the concept of ‘welcoming the involvement of 
family and friends’, though the literature review only touches on this area. The 
impact of carers and family is an important factor with many carers feeling 
‘helpless’ and ‘afraid’ as evidenced in the systematic reviews by Giacomini et al. 
2012. And this question is identified by item 5. Understanding whether support is 
provided by family and friends is an important aspect to managing long term care. 
If patients feel unsupported or have no support (bad experience), this would 
promote the healthcare professional to identify future help or guidance and ensure 
carers and family are involved and maintain support for all parties in future care.  
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A exploratory, descriptive design study by Caress, Luker, & Chalmers, (2010, 
pp.571-572) explored both the 'patients and carers' views on promoting the health 
of COPD. This example and their findings emphasise the point that healthcare 
professionals need to maximise the benefits of health promotion to patients and 
families, to maintain healthier lifestyles. This is one good approach in which 
patients and family can work together to improve health and the experience  
of living with the disease.  
The experience of emotional support and impact of disease items 4-7 address this 
issue exploring the earlier discussion on control and limitations in COPD. 
Addressing these issues of experience and enabling and opening up discussion 
between the healthcare professional and patient, on issues such as anxiety and 
depression, are critical to diagnose and treated to ensure the positive experience 
and improve quality of life of people living with the disease. Information, 
communication, and education are all critical to every patient, and are highlighted 
as one of the eight concepts in the framework.  One of the key aspects of this is 
the association with health promotion but also prognosis. The evidence in the 
Disler et al., (2014) and Giacomini et al., (2012) reviews make it clear that 
discussions on prognosis and end of life care is sparse. One of the reported 
challenges in this is that healthcare professionals feel unprepared or unable to 
approach end of life discussions. Crawford, (2010, p.1164) affirms that ‘there is 
little evidence that open discussions regarding end-of-life decision-making are 
taking place routinely’. Item 7 of the questionnaire identifies this issue using 'the 
future’, rather than end of life or medical terminology such as prognosis. Item 7  
'I am happy to talk about the future' (low scoring answer) gives potential in two 
ways, firstly it enables the patient to take control over the decision on their current 
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experience of ‘the future’ and secondly allowing the healthcare professional to feel 
empowered to explore this item further over time with patients, potentially opening 
up conversations about the future. From the discussions that were had in the 
Breathe Easy groups it was very much seen as a ‘positive’ question. This 
approach is maintained by MacPherson et al., (2011, p.1)  whose qualitative 
research on interviewing patients nearing end of life suggests 
improved information provision could improve relationships between 
patients and healthcare professionals, as well as enabling patients to be 
more involved in current  decisions about their care 
 
The underlying principles of patient experience are concerned with improving 
quality of care to patients.  If the development of this PREM can help start these 
important discussions then the quality and patient-centred aim of the COPD 
PREM-9 is achieved.  
Current clinical status such as symptoms are measured in other health related 
quality of life scores such as the CAT. Other areas such as fatigue, control and 
limitations are essential components to the COPD PREM-9. This approach 
deviates from the measuring the traditional experience of the impact of symptoms 
and on quality of life, shifting this approach towards the measurement of the 
experience of living with COPD and generating an holistic understanding of this 
experience, whether certain aspects are good or bad along a scale measure, 
translating to whether there is a move towards a good experience of shift towards 
a poor one.  
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7.3.2. Usual care in COPD 
 
The three items under this heading were related to usual care given to patients 
with COPD and are supported by the literature (Disler et al., 2014; Giacomini et 
al., 2012) in terms of the aspects of experience which they are measuring.  
This section of the questionnaire links a number of the concepts of the NHS 
Experience Framework together: 'access to care and the care setting' to a concept 
of 'information, communication and education' which fit well with item 2 & 3 on the 
information and understanding of COPD and its treatment.  
It was evident in the literature review that the GP was the key healthcare 
professional that patients wanted to be involved in their care and is usually the first 
'port of call' in times of exacerbation or 'need' (Powell et al., 2013). Item 1 clearly 
supports this experience of GP engagement looking at the positive and negative 
experience of whether the 'GP will listen or would not listen to the concerns'. Disler 
et al., (2014, p.5) reported that many patients had poor experience in terms of 
communication with their GP which included themes such as diagnosis, 
treatments and current symptoms. This item is critical item as Powell et al. also 
suggest through their focus groups with patients that the GP should be the 'gate 
keeper' of care in the community. So patients need to ensure a positive experience 
and feel listened to. This item, like all items, will also support the healthcare 
professional understand concerns and help open up discussion around them or  
if used in the GP practice help the GP understand the patients' experience further.   
The further two items concerned with information and understanding COPD use 
the descriptors that were most commonly reported in the literature and by COPD 
patients. The descriptors 'confused' and 'frustrated'  were key words which 
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participants related most whilst undertaking the study, with several comments 
reporting 'confused' 'yes that's exactly how I feel'. These two items allow for 
discussion with the patient on the level of understanding and information needs 
often not addressed together. There are potentially a number of strategies which 
could be used to improve experience in these two areas. This section and the 
items identified are strengthened by the support of the literature and the underlying 
concepts within the NHS experience framework. 
7.3.3. COPD Exacerbations 
 
The two last remaining items relate to exacerbations of COPD and access  
to healthcare professional support and treatments (item 8) as well as to the care 
related to this (item 9). The Literature Review supported the need for the inclusion 
of exacerbations in the PREM. This was an important aspect as the Literature 
Review and subsequent supporting literature (Arostegui et al., (2014) and 
supported by Steele et al., (2009) suggests exacerbations are a frequent 
occurrence in patients with COPD, of which the need for healthcare intervention is 
great (NICE 2010). However, the experience of exacerbations and their 
management is varied. The descriptor ‘worried’ was used in many different 
aspects of COPD experience including diagnosis and end of life care and it was  
a descriptive word used and supported by the Literature Review (Giacomini et al., 
2012) in exacerbations. Worried, was also well documented and one of the 
descriptive words used within Study One (COPD PREM development).  
The correlation of both items to the NHS experience framework are associated to 
the concepts of ‘emotional support’ and ‘access to care’.  
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Ensuring that COPD patients have quick access to appropriate support and  
to medical advice in time of an exacerbation is critical (Arostegui et al., 2014). The 
benefits of ‘rescue medications’ in an acute exacerbation continues to be 
highlighted. The impact of implementing self management plans and rescue 
medications across three hospitals by Khachi et al., (2012, p.2903) made 
recommendations that this access to rescue medication reduces re-admission into 
hospital (5.7%).  Therefore understanding the experience of the use of these in the 
COPD PREM-9 will give important information not only to the patient but also the 
healthcare professional.  
The COPD PREM-9 has the potential to be used in a number of clinical settings 
(discussed in Chapter Eight), but in summary, every patient completing the COPD 
PREM-9 will score each item and each section individually. After completing the 
questionnaire a total score out of 45 is indicated.  In essence the higher the total 
score the worse the COPD experience.  
It was evident that the COPD PREM-9 has good relationships to the concepts of 
the Department of Health (2011) NHS patient experience framework.  
This Framework was designed to ensure that the eight concepts of patient-centred 
care are fundamental to that of patient experience. The framework was not used in 
any part of the decision making process in the development of the questionnaire. 
The Framework has however, formulated a strong association across the eight 
concepts supporting the underlying principles of the experience captured using the 
COPD PREM-9. The instrument has demonstrated that experiences of COPD can 
be both positive and negative (good and bad) as set out in the underlying 
construct of the PREM regardless of severity of COPD. And it could be a useful 
tool in routine clinical practice. 
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7.3.4. Correlations with PROMs 
 
As this was the first ever patient experience measure designed specifically for 
patients with COPD, it is difficult to make correlations through validity with other 
measures, unlike PROMs where there are a number of different measurements 
such as the St George’s Respiratory Questionnaire or COPD Assessment Test. 
Currently the measurement of patient experience in COPD is yet unknown. It was 
evident in the measurement in healthcare that PROMs are used to help explore 
either an intervention or the management of symptoms and looks at health related 
quality of life or mood. The COPD-PREM 9 was used within the validation process. 
Therefore, it was assessed against other commonly used tools within COPD care, 
and although the results suggest that there is an association between the CAT and 
the PREM it is quite weak, with only 16% shared variance. This shows that the 
PREM is measuring something different from impaired health status and mood as 
measured by the HAD, which showed similar results – which is good evidence for 
divergent validity. Disler et al., (2014) concluded from their review that any further 
research should focus on the interventions that address patients’ ongoing needs, 
of which the generation of the COPD PREM-9 is an example, where the 
instrument can measure a number of points, therefore continuing to assess and 
re-assess the experience of patients living with COPD. 
7.4. Use with PREMs, PROMs and EDQ5 – A recipe for Quality 
 
A key finding of the literature regarding ‘experience’ is that the collection of patient 
experience cannot happen in isolation and that to make any difference in the 
quality of care we provide or commission for patients then patient experience has 
to be a component of this, alongside other measurements in health such as patient 
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reported outcomes or other measurements of health status. Reflecting on the work 
by Robert & Cornwell, (2013, p.20) regarding what is important to patients, it is 
possible to see that they identified that any future development or implications for 
the recording of PREMs in the NHS should be covered by  the following five 
fundamental principles:  
1. Simultaneously seek to improve accountability, transparency and quality; 
2. Align with clinical outcomes (e.g. Patient Reported Outcome Measures); 
3. Be evidence-based; 
4. Be simple; 
5. Be embedded in quality standards (e.g. the ongoing work of the National 
Institute for Clinical Excellence); 
It can be evidenced that the development of the COPD PREM-9 also correlates 
with these 5 fundamental principles. The tool could be used with other healthcare 
measures to reflect on the three main areas of quality, these being previously 
identified by the 2012 NHS Framework that quality is built on accountability, 
transparency and patient experience. 
7.5. Length of Questionnaire 
 
The length of the new COPD PREM-9 was an important aspect to the design of 
the questionnaire. Even though there were 38 items generated in the preliminary 
COPD PREM the process of reducing the burden of completing a lengthy 
questionnaire was evident in the recruitment phase, as potential participants were 
‘put off’ by the initial length of the instrument. This, I suspect, is due to the nature 
of the disease as breathlessness and high anxiety are part of the symptoms 
experienced by many with COPD (NICE 2010). To produce an instrument which 
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had the least number of items but ensures the appropriate level of measurement 
was an important factor in development, along with the questionnaire appearance 
and wording (Mccoll et al., 2001). This is supported by Prieto et al., (2003, p.27) 
who argue that the accessibility of shorter instruments would provide advantages 
in different settings both in research and clinical practice. They also report that 
efforts to develop shorter questionnaires or instruments have been generated from 
using existing questionnaires and reducing items. This supports the notion that the 
generation of a new, short instrument will add value to the quality of instruments 
currently used within the COPD population. 
7.6. Chapter summary 
 
This chapter presents a discussion of the results and underlying literature, 
including the Department of Health NHS theoretical framework that supports the 
evidence of patient experience identified within the rigorous literature review.  
All nine items developed used the descriptors of patient experience and that 
specific to COPD. The new instrument has good reliability and validity properties, 
resulting in a concise and scientifically robust PREM COPD-9, which can be used 
within everyday clinical practice. This chapter concludes the discussion of the 
development of a validated and reliable PREM instrument. 
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CHAPTER EIGHT 
 
8. Conclusions 
 
8.1. Introduction  
 
This final chapter provides a summary of the findings described in the thesis. 
Suggestions for future work in the field of experience, clinical and research 
applications of the COPD PREM-9 are presented.  
8.2. Summary of Work 
 
This thesis has covered a wide range of topics relating to COPD and the patient 
experience, and had set the context for the development of a new nine-itemed 
patient reported experience measure, the generation of a new instrument and 
understanding the complex language used within patient outcome reporting's.  
The development of a disease specific PREM hopes to add a new dimension into 
improving quality of care provided to patients. Proving a patient-centred view of 
healthcare and of living with the disease is fundamental to the Department of 
Health patient experience framework. The instrument also has the potential to add 
a richer dialogue to improve communication, adding value and time to the 
healthcare professionals consultation with patients, reviewing and reflecting on the 
answers given. 
The conceptual framework guiding this work was based upon a framework 
developed and agreed by NHS England Quality Board. The concept that 
experience is multidimensional requiring a number of different aspects but  
a disease specific instrument needing to reflect the language used by patients to 
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describe it (Janelle Yorke et al., 2014). This thesis has presented the development 
and validity testing of a new questionnaire, the COPD PREM-9, which reflects this 
experience framework as demonstrated in the discussion. This is a unique 
instrument, since it quantifies experience using the descriptions (words) and items 
generated by patients for patients. The final three key themes as identified in the 
COPD PREM development were supported by the relevant qualitative literature in 
the experience of living with the disease and the interaction with healthcare. 
Understanding the different aspects of a patients journey from diagnosis to end  
of life care. The subsequent development of the instrument reduced the themes to 
three after the diagnosis items were deleted. But it must be acknowledged that, 
although these items were deleted, subsequent discussion on diagnosis will 
formulate part of other items on the PREM. The literature also informs us that 
currently there is no published instrument in COPD of this kind. The COPD PREM-
9 is applicable to all severities of COPD patients, regardless of age. Though  
a larger validation study with a wider population is needed prior to using the 
instrument further into clinical practice, I am confident that the nine items are 
relevant, appropriate and capture a wide range of areas relevant to patient-centred 
care and not the clinician.  
It is perceived that the development of instruments are increasingly being created, 
adapted or translated with little scrutiny regarding their psychometric qualities, 
their structure, reliability and validity, and therefore, substantial doubts and 
concerns should emerge regarding their findings. This study has used a robust 
and commonly reported methodology, using the Rasch model to ensure that items 
included in the PREM COPD-9 were appropriately scrutinised ensuring 
appropriate reliability and validity of the instrument. For example, a positive return 
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rate of 50% of Pack B ensured the stability of the COPD PREM instrument and 
ensured consistency and appropriate reporting with a higher than expected return 
rate. The process of item reduction outlined also ensured that items put forward to 
Rasch were free from bias strengthening the argument that the development of the 
COPD PREM-9 has good psychometric qualities, structure and reliability and 
validity.  
The aim and objectives (p.103) of the thesis were achieved through the 
appropriate stages undertaken and set our within the chapters of the thesis. 
Resulting in a validated patient-centred COPD PREM-9 questionnaire. 
8.3. Clinical Implications and Applications 
 
The clinical implications for this COPD PREM-9 are varied and wide. Certainly 
there is a need to continue to validate its use within clinical practice. The COPD 
PREM-9 has been shown to a number of patients who participated in the study 
and completed the initial PREM-38. They were surprised about how concise and 
easy to understand it was. It was identified that the questions were helpful  
to express how they felt in a number of different subject areas.   There are a 
number of implications for clinical practice, firstly for the first time we have  
a questionnaire that is centred around the patient living with COPD and exploring 
the patient's own experience of living with the disease which is not focussed on the 
symptoms that are associated to it. There will be associations made about 
symptoms and the limitations this causes.  
The most critical implication for clinical use is the focus on an improvement in 
communication between patient and healthcare professional by measuring 
patients experience in a systematic way, the results of the questionnaire will give 
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the clinician an indication of a total score of experience. But this can then lead to 
discussion points of areas in which a high score has been given or potential further 
discussion on where a low score has been given. This improved dialogue between 
clinician and patient enables a more focussed patient centred approach to COPD 
care focussing on experience and what matters to patients debate. Improving 
focussed areas has the potential to increase quality of care delivered to patients 
living with COPD.  This could be done through an audit process using the tool to 
benchmark practice of experience with appropriate action and subsequent follow-
up.   
The COPD PREM-9 has the potential to provide a valuable measurement for 
clinicians to use alongside current PROMs for example the CAT and HAD 
questionnaires. This PREM has the potential to become the leading measurement 
of experience in COPD and enable healthcare professionals across the world to 
improve the experience of patients living with the disease, by understanding the 
impact experience has in three key aspects of COPD care. There is increasing 
demand, as the literature and introduction to this thesis suggests that to improve 
service delivery.  The quality and effectiveness of these services needs 
addressing. This instrument has the potential also to be the first disease-specific 
instrument to support quality improvement by benchmarking experience scores 
within improvement programmes to compare scores to facilitate and present 
findings.  
The COPD PREM-9 has already received international coverage at the European 
Respiratory Society Annual conference (Appendix Ten) and interest in its 
development and translation and inclusion in research studies and clinical use is 
growing. The COPD PREM-9 has also been included in the Royal College  
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of Physicians 5-year National COPD Audit programme, subject to final agreement. 
This highlights the need for such an experience instrument and helps support the 
robust methodological and scrutiny this study has undertaken. 
8.4. Limitations of the study 
 
There are a number of limitations of this study which will be reported however, 
limitations become opportunities for future development or review.  
A limitation to the study was that a background study identified no measure  
of COPD experience. There had, however, already been two comprehensive 
systematic reviews on the experience of people living with COPD up to a certain 
point; the undertaking of a full systematic review for this thesis was therefore not 
undertaken. However, a rigorous review of the literature, giving indications  
of quality review and an update of the literature exposed a number of current 
papers that helped to generate a greater understanding and influenced this 
previous understanding of the experience of people living with COPD.  
And, therefore, as there was no published data on an instrument to measure the 
experience of people living with COPD, the results from Study One (COPD PREM 
development) were derived from  this learning and cross matched against studies 
which have explored the severe to very severe groups, giving insight into the older 
person and the younger person living with COPD. 
A key limitation of the study was that the  COPD PREM-9 was only developed and 
currently tested for reliability and validity in England and was only available in 
certain areas, which is not dissimilar to other instrument development (Trendall  
& Esmond, 2007). Although there were a number of participants, English was not 
always their first language. However, this was not recorded so there are no 
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conclusions or analysis which can be made on this. The validation of any new 
instrument remains in constant development and further steps are needed in 
international studies of the PREM COPD-9 to test further its psychometric 
properties. Use of these standardised techniques will ensure linguistic and cultural 
validity in a variety of languages (Jones et al., 2009).   
Due to the frailty of some of the potential participants and those that agreed to 
take part in the study, it was identified that some participants were not able to or 
declined to undertake spirometry at the time of recruitment. This was for many 
reasons such as a recent exacerbation of COPD, or they had it recently for an 
annual review. Instead spirometry results were sought from their local general 
practitioner or hospital. However, this was not always possible for a number of 
reasons, such as no response from request or spirometry not undertaken recently 
(within the last year), this left a 16% of spirometry results no collected in the 
population. Though a broad range of severity was capture in the study. 
The rich discussion that was also undertaken in the Breathe Easy and pulmonary 
rehabilitations groups, as mentioned within the discussion, also helped support 
many of the items that were deleted. This discussion, however, was not recorded 
which is a limitation of the study as therefore no thematic analysis of these 
recordings can be made. However, to understand the lived experience and  
to understand the discussion that was provoked from all items gave an insight into 
how the COPD PREM-9 could be used in clinical practice. The 'conversation' that 
followed after patients answered a question also gave justification for their answer 
of a good or bad experience, sometimes reflecting on an event or an example of 
how the item made them feel was useful method of ‘'validating’ the questionnaire 
through a face-to-face conversation giving effective discussion for future usage.  
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A further potential limitation relates to the collection of 'rich data'. In the instrument 
itself there are no free text boxes to collect any qualitative comments from 
participants. But the concept of the questionnaire was to generate an overall 
experience score and then use the instrument as a discussion tool with patients to 
examine where the score is high (worse experience) and use as a prompt to 
support particular aspects of care.   
A key finding from the literature, though not reported is the specific role that carers 
and families have in the care of loved ones with COPD. The relationships that 
carers and family also is an accepted and acknowledged aspect of patients care. 
The literature review touched on this but it is acknowledged that there is a far 
greater pool of evidence supporting this aspect. The COPD PREM-9 does 
highlight one item on whether family and friends are involved in care. The concept 
is highlighted in the NHS patient experience framework and focus on the friends 
and family test, but further work on measuring the relationship between patients 
with COPD and families or carers needs, addressing alongside the qualitative 
work previously undertaken.   
A final limitation of the study and its use within clinical practice is the focus on the 
conflict of terminology and understanding of the words PREMs, PROMs and that 
of satisfaction by clinicians may hinder the appropriate use and reporting of new 
tools in the area of patient experience.  Unless clinicians themselves are prepared 
to develop and advocate the traditional thoughts of PREMs and that of the health 
service. The appreciation that to provide quality care is a continuum of patient 
experience alongside safety and effectiveness to ensure patient centred care is 
delivered. A shift of understanding in whether a service was 'good' or 'bad' is a 
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very different concept to understanding the experience of living with a disease. 
This has to be the focus of experience moving forward in the NHS.  
As previously discussed there are a vast number of PROMs and national patient 
surveys being used daily to capture organisation change, but how is this person-
centred? In COPD, this life-limiting condition, understanding the experience of 
living with the disease and the potential modifications that can be undertaken in 
partnership with health related quality of life measurements can for clinicians 
support and measure intervention, thus giving the clinicians evidence to support 
clinical expertise focussing on the patient rather than the focus on the money, 
length of stay or number of acute admissions avoided.  The misunderstanding of 
terminology is not just isolated to junior nurses and staff many senior clinicians 
have to have a greater understanding of the use of PREMs in clinical practice.  
It is hoped that this thesis will help inform this direction. 
8.5. Future Direction for Research 
 
The underlying aim of the study was to generate an instrument that was developed 
for COPD patients by COPD patients ensuring that the language used in the final 
COPD PREM-9 was able to be understood by the COPD population and that 
patients were able to relate to the underlying construct of the experience of 
patients living with COPD. The first direction of the COPD PREM-9 is to undertake 
a reliability and validity study of the final 9 items, although the items were 
examined for reliability and validity and identified as having a unidimensional fit to 
the Rasch. An exploratory study of the 9 items in a different cohort of COPD 
patients recruited through the same means including a test-re-test design method 
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would support the validity of the final instrument. This would allow the COPD 
PREM-9 to be used and generate further interest and testing its use more widely.  
Further work needs to be completed in the instructions and recommendations to 
compliment the use of the COPD PREM-9. These include making a series  
of levels according to a score range, and narrative with a list of recommendations 
and advice if a patient scores a high score indicating a bad experience and 
strategies and advice on how potentially this could be lowered increasing the 
patients experience. Future work with patients and healthcare professionals in  
a series of workshops is planned.   
The majority of participants in the testing and validation of the PREM COPD-9 
were white British with English as their first language. Validation of the PREM 
COPD-9 in other languages and cultures would entail translation of the instrument. 
However, as the  COPD PREM-9 was developed in the UK for European or 
international use would need a review of the items within this as for some EU 
countries the term General Practitioner is not known, and other meanings such  
a 'family doctor or physician' are more common terms. The view of future testing 
and translation of the new instrument into other languages and its validity testing is 
needed and I suspect welcomed.  
This instrument is on a journey and although the journey end point for its initial 
development has been completed, the roll out and embedding the instrument into 
practice has just begun. The next stage in the instrument’s longevity is to 
undertake a further reliability study which includes testing the COPD PREM-9 in a 
different cohort of people living with COPD. These would be recruited with 
participants who did not participate in Studies A and B. This would be undertaken 
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as a research study using a similarly sized recruitment pool, further assessing 
construct validity and reliability with participants. However, there are issues around 
the time and recruitment of these participants. Further concern with the roll out 
would also include ‘control’ over the possible number of ongoing studies which 
would have also been suggested in larger, discrete COPD populations using 
different severities of COPD, and translation and diffusion in different languages. 
However, these developments would be completed within a controlled way 
ensuring appropriateness which includes ensuring intellectual property and 
copyright remain within the PREM expert group and working in partnership to 
develop these potential studies further. But the instrument would not be made 
‘public’ until appropriate publication of the development of items and subsequent 
development and testing were published and referenced. The vision is for the 
instrument to be free to access and it is hoped a website would be created for 
healthcare professionals to utilise and download it, thereby sharing information 
and further research on the COPD PREM-9 as its vision develops.  
Further work is also needed with COPD patients and respiratory experts to review 
the advice and criteria on the total scoring of the instrument along with further 
research in testing the instrument in the advice areas to gain a greater 
understanding of whether the instrument is sensitive enough to detect change 
and/or be a useful benchmark or quality indicator in COPD. An example of this 
would be to undertake a study using the instrument as an outcome measure pre- 
and post- pulmonary rehabilitation, of which a number of quality of life and 
outcome measures are already used. But a short experience measure has not 
been undertaken and has the potential to add individual dialogue with the clinician 
and patient on areas that potentially the patient scores highly (bad experience). 
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Responsiveness of COPD PREM-9 was assessed in the validation of the 
instrument using a patient’s self-report of change in their general health. 
Responsiveness of a questionnaire to change is an important psychometric 
property for assessing benefit to ‘intervention’ for a change in experience.  
The COPD PREM-9 must go through further rigorous testing to explore its 
sensitivity to change and responsiveness to intervention before being accepted as 
a tool used as an outcome measure used in routine care. However, after further 
testing it should be appropriate for use in studies of a wide range of treatment 
areas including nurse-led intervention in education and self management 
techniques, along with pulmonary rehabilitation and possibly drug trials. Further 
research is also needed in using the PREM COPD-9 alongside other widely used 
outcome measures in these areas too. Suggested complimentary instruments 
could include the CAT, St Georges Respiratory Questionnaire and the COPD 
questionnaire.  
The COPD PREM-9 also needs to be explored further larger populations  
in specific younger population even though the study had a variety of age groups 
the mean was 71 years and further exploration of the working COPD population is 
needed. 
8.6. Reflection on the Thesis process 
 
The Nursing and Midwifery Council (NMC) encourages nurses to reflect on 
individual areas in order to ensure that there are examples of evidence which are 
evaluated and concise, enabling nurses to maintain high quality patient-centred 
care (RCN, 2011). The NMC code of professional conduct highlights two key 
points (NMC., 2008, p,6): 
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You must keep your knowledge and skills up to date throughout your 
working life 
You must take part in appropriate learning and practice activities that 
maintain and develop your competence and performance 
 
These two statements from the code underpin the acts upon how nurses learn and 
how experience underpins their own learning from this to undertake critical 
performance and demonstrate competency. Nurses practising in today's rapidly 
changing National Health Service  are increasingly responding to the need to 
evaluate and review services as well as  considering the political, social and 
organisational issues affecting evidence (Dhabi, 2003), even more evident in the 
background context discussed in Chapter One. As change happens daily, it is 
important for nurses to be able to analyse and respond to new challenges 
proactively. Having critical thinking and reflective skills has assisted me to 
challenge traditions and boundaries in the development of this instrument,  
to develop a tool that could support other nurses to deliver effective and cost-
efficient evidence-based patient care, exploring the key concepts in COPD care. 
Currently we are working in rapid change, and to understand fully the context of 
reflection and how the concept of my experience can be fully understood in its 
relationship to reflective practice is maintained within practice. The learning theory 
that underpins nursing practice is the backdrop of my everyday practice which has 
helped expand my critical thinking to develop a direction of work from what I have 
understood through my own experience of this thesis' journey. Chinn & Kramer, 
(2007, p.182) suggest that a theory is 
a creative and rigorous structuring of ideas that projects a tentative, 
purposeful and systematic view of phenomena 
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This suggests that ideas and learning are generated through the notion of 
experience and observation and are open to new evidence as insights emerge.  
As a critical reflective practitioner the process of reflection on my work is 
fundamental and therefore can be embedded into my learning process (Chinn  
& Kramer, 2008). The development of this thesis has enabled me to reflect upon 
how the experience in learning new skills such as the Rasch Model and the 
combination of statistics and words can work together to ensure that the value  
of experience can be approached or seen in many different ways, illustrating that 
nurses can use different models of developing and generating new ideas through 
the support of learning through reflection and action setting the scene for new 
concepts, models and behaviours. These can be related to how patients also can 
use experience in their interactions with healthcare staff and the impact of disease 
on quality of life. 
8.7. Concluding Remarks 
 
The work described in this thesis conveys the development and first validation of  
a new nine itemed experience instrument. In doing so, it has examined the 
research aim and objectives that underpinned this thesis, that qualitative 
descriptors can be used to develop an experience questionnaire in COPD. The 
COPD PREM-9 outlines that the recording of experience descriptors of living with 
COPD can be documented in a concise instrument that differs to commonly used 
outcome measures with COPD in clinical practice.   
The COPD PREM-9 was shown to have reliable and valid measurement 
properties in the measurement of experience in patients with COPD. It potentially 
has wide application in studies designed to assess experience in a range of 
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clinical settings such as pulmonary rehabilitation, and the potential to be used 
alongside other outcome measures in therapeutic studies, along with the potential 
to become a quality improvement tool. However, further work is needed to assess 
the application of the COPD PREM-9 in different clinical settings. This includes a 
further validation study of the final 9-item questionnaire with a different cohort of 
COPD patients across a broad spectrum of severities and demographics. 
Additional work is also need to support clinicians in the practicalities and guidance 
of the everyday application of the questionnaire. This will be done with clinical and 
patient engagement in a provision of suggested resources and instructions of 
‘areas’ to improve experience dependent on a total experience score. Further work 
and research is needed to examine and understand the individual patient clinical 
benefit that the COPD PREM-9 will have as an experience outcome to improve 
patient care, for example in areas such as pulmonary rehabilitation and COPD 
nurse-led case management, both of which provide COPD specific intervention 
aimed at improving the knowledge and confidence of COPD. Further ‘control’ of 
the instrument is also needed to work alongside potential researchers who may 
wish to use the instrument in ‘research’ and ‘clinical practice’ and work in 
partnership to collect questionnaire results to be used potentially in audit as a 
marker of quality or service development.  
Likewise, the impact of experience on different parts of a patient’s journey, and 
how this varies between different severities and age groups, is warranted. 
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EXECUTIVE SUMMARY 
The NECLES HIEC in collaboration with The Royal College of Physicians, British 
Thoracic Society, British Lung Foundation, Picker Institute, City University and Anglia 
Ruskin University collaborated in the development of a Patient Reported Experience 
Measure (PREM) for use in all Chronic Obstructive Pulmonary Disease patients 
(COPD).1 The PREM-COPD is a move away from traditional medical model 
questionnaires, to look at the patient journey with COPD and identify the principle 
moments of quality care and affective experiences which will then make it possible to 
benchmark future service provision.  
Our aim is to create a valid and reliable Patient Reported Experience Measure for 
patients with COPD and in doing so, provide a response to the Government’s White 
Paper “Equity and Excellence, Liberating the NHS”2 which puts the patient experience 
and patient outcomes as the metrics for quality improvements in healthcare.  
The experiences of a 64 patients with COPD across the community of North East 
London, North Central London and Essex (NECLES) region, with a range of severity 
and presentation and 19 patients with recent hospitalisation due to COPD related 
conditions were captured. The experiences for both groups were grouped and coded 
separately leading to the development of items pertaining to both patient groups.  
Twenty Affective (emotive or felt) responses were identified from patient responses. 
Negative Affective responses described by both the community and hospital patient 
groups included: scared; anxiety; worry; fear / frightened; frustration; annoyance / 
anger; confusion; embarrassment; surprise / shock. The negative Affective response 
“feeling depressed”, was only identified in the community group responses and guilt 
was only in the hospital group. 
Positive Affective responses identified for both groups were: gratitude; reassured and 
happy / enjoyment. Altruism, hope and acceptance were also mentioned in the 
community group. 
Self-motivation, control and respect were either Negative or Positive Affective 
responses according to their context with the first two only identified in the community 
group. 
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The community patient group experience centred around 5 categories:  
• “Journey to diagnosis” 
 This journey left patients frightened, frustrated, surprised and shocked  
• “Smoking” 
 Self-motivation and being scared by their diagnosis or the symptoms 
associated with COPD led some patients to give up smoking 
• “Usual care (communication, staff and managing routine care)” 
 Lack of, or poor communication, or the manner of communication with 
health professionals, left patients feeling frustrated, annoyed, confused 
and angry 
• “Exacerbation” 
 This can frighten, scare, confuse, frustrate and depress patients  
• “My everyday life” 
 The limitations of living with COPD are described as frustrating, annoying, 
worrying, depressing and embarrassing 
The “Hospital” patient experience pivoted around 5 categories:  
• Going to hospital 
• On arrival to hospital 
• On the ward 
• Discharge from hospital 
• Follow-up care 
Preliminary items from the Affective responses for both patient groups have been 
developed and will undergo pilot testing with the aim of establishing reliability and 
validity of the PREM-COPD. 
Completion of this testing will result in a sensitive and reliable PREM that can be used 
to measure self- defined important experiences of patients when using healthcare 
services. 
 
 
Roberts, M., Andrew, S., Walker, S., Hodson, M., & Hudson, R. 
(2012). Developing a patient reported experience measure for 
COPD. European Respiratory Journal, 40(56), P1464. 
Presented at ERS Conference Vienna 2012 
Abstract 
Introduction The patient experience and patient outcomes are metrics 
for quality improvements in healthcare. There is no currently available 
patient reported experience measure (PREM) for COPD. 
Study AimThe aim of the study is to create a valid and reliable PREM 
for patients with COPD. 
Methods Sixty four people with COPD across the community of North 
East London, North Central London and Essex and 19 with recent 
hospital experience were interviewed to capture their patient journey 
with COPD. Analysis of the interview data was by a two layer 
approach: content and then by affective (emotive or felt) responses. 
Results Eighteen different affective responses were described by 
patients and were grouped as positive, negative or ambivalent. 
Positive responses included: hope, gratitude, comfort/ reassured, 
acceptance, optimism, altruism, happy and respect. Negative 
responses included scared, anxiety, fear, frustration, worry, feeling 
depressed, denial and embarrassment. ‘Self-motivation ‘and control 
were contextual and could be either positive or negative. 
The community patient groups‘ experience centred around five 
categories identified in the content analysis: ‘Journey to Diagnosis‘; 
‘Smoking‘; ‘Usual Care‘; ‘Exacerbation (‘flare-up)‘ and ‘My Everyday 
Life‘. The hospital patient experience was categorised as: ‘Going to 
Hospital‘; ‘On Arrival to Hospital‘; ‘On the Ward‘; ‘Discharge from 
hospital‘ and ‘Follow-up care‘. Items based on patients ‘affective 
responses were generated from the categories to develop a PREM-
COPD scale. 
Conclusion Completion of the testing of the PREM-COPD will result 
in a valid and reliable instrument to be used to measure self-defined 
important patient experiences when using healthcare services. 
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NHS Patient Experience Framework 

In October 2011 the NHS National Quality Board (NQB) agreed on a working 
definition of patient experience to guide the measurement of patient experience 
across the NHS. This framework outlines those elements which are critical to the 
patients’ experience of NHS Services. 
	 Respect for patient-centred values, preferences, and 
expressed needs, including: cultural issues; the dignity, privacy and 
independence of patients and service users; an awareness of quality-of-life 
issues; and shared decision making;  
	 Coordination and integration of care across the health and social 
care system;  
	 Information, communication, and education on clinical status, 
progress, prognosis, and processes of care in order to facilitate autonomy, self-
care and health promotion; 
	 Physical comfort including pain management, help with activities of daily 
living, and clean and comfortable surroundings;  
	 Emotional support and alleviation of fear and anxiety about such issues 
as clinical status, prognosis, and the impact of illness on patients, their families 
and their finances; 
	 Welcoming the involvement of family and friends, on whom 
patients and service users rely, in decision-making and demonstrating 
awareness and accommodation of their needs as care-givers;  
	 Transition and continuity as regards information that will help patients 
care for themselves away from a clinical setting, and coordination, planning, 
and support to ease transitions; 
	 Access to care with attention for example, to time spent waiting for 
admission or time between admission and placement in a room in an in-patient 
setting, and waiting time for an appointment or visit in the out-patient, primary 
care or social care setting. 
This framework is based on a modified version of the Picker Institute 
Principles of Patient-Centred Care, an evidence based definition of a good
patient experience.   When using this framework the NHS is required under the
Equality Act 2010 to take account of its Public Sector Equality Duty including
eliminating discrimination, harassment and victimisation, promoting equality 
and fostering good relations between people.
Gateway reference number 17273 
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Development of a COPD 
Patient Reported Experience 
Measure (PREM) Stage 2
Matthew Hodson
Respiratory Nurse Consultant –
Homerton Hospital London 
Dr. Janelle Yorke
Supervisor 
Manchester University  
Expert Respiratory Group 
• Professor M Roberts
• Professor S Andrews
• Professor P Jones
• British Lung Foundation Representation 
• COPD National Audit Programme Manager 
Breathe Easy Group Patient Representation
Overview
PREM Stage 1 
PREM Stage 2 – Part A
▫ recruitment process & ethical clearance
▫ baseline demographics 
▫ hierarchical methods of item reduction
▫ understanding of the Rasch Model 
▫ item removal in Rasch
▫ summary of fit and decisions on items
 conclusion and final items
Introduction – Stage 1 
• Development of PREM Concept
• 83 Interview patients across the NECLES region 
on experience of living with COPD
• Thematic analysis and themes identified
▫ 20 Affective (emotive or felt) responses were identified
▫ 5 themes identified (journey to diagnosis, smoking, 
usual care, everyday life, exacerbation,information
provision)
Stage 2: COPD-PREM – initial item list
Part A PREM – Everyday life with COPD
▫ 40 Items into the 5 themes
▫ 38 Items into the Draft PREM COPD (2 removed)
Part B PREM – Hospital related care
▫ 14 Items
Stage 2
Ethical approval by Bloomsbury REC
COPD Patients recruited from (n = 174)
▫ London (n = 120) 
▫ Portsmouth (n = 19)
▫ Manchester (n = 15)
▫ Guernsey (n = 8) 
▫ Essex (n = 5)
▫ Norwich (n = 7) 
▫ Hospital and Breathe Easy Groups
Part A PREM - Demographics
Demographics:
▫174 participants
▫83 male and 91 female
▫Age (mean: 71years; SD: 9.1; range: 42 – 91) 
▫FEV1% (mean: 59%; SD: 21.9; range:11% - 92%)
▫FVC/FEV Ratio: (mean: 50%; SD: 20.4; range: 23-75%)
▫CAT Score (mean: 20; SD: 8.5; range: 2 – 40)
▫MRC: 1 = 4; 2 = 32; 3 = 53; 4 = 42; 5 = 31
PREM A – Item Reduction Protocol 
Hierarchical methods of item reduction:
▫ missing data at > 15%
▫ floor affect > 40%
▫ ceiling affect > 40% 
▫ gender bias* – Mann Whitney-U Test
▫ age correlation* – Spearman's Correlation 
▫ Item-item correlation  - r value > 0.80 
*p = < 0.01
Question 
No Question (Low Score Answer) Missing >15%
1 I am not shocked by my COPD diagnosis
2 I have come to terms with my diagnosis of COPD
3 I have given up smoking and I am confident that I will not start x
4 I want to stop smoking and I believe I can x
5 It was a relief to have a diagnosis for my symptoms x
6 I understand my diagnosis
7 I am confident that my GP will listen to my point of view
8 I am very pleased with health care workers 
9 I am happy with the length of time to see GP
10 I really enjoyed pulmonary rehabilitation x
11 I found pulmonary rehabilitation useful x
12 I understand my condition and this helps me to manage my fear
13 The information I have been given is consistent
14 I have enough information about my condition
15 I understand about my COPD tablets x
16 I am confused about how to use my COPD inhalers
17 I understand how my COPD treatments work
18 I don’t find going to a hospital outpatient clinic frustrating
19 I know how to use my inhaler properly
20 I have accepted the limitations to my lifestyle caused by COPD
21 I feel that I have good support from others 
22 Overall I am satisfied with my life
23 I am not depressed
24 Overall I am satisfied with the care given to me
25 I am not embarrassed to tell others about my condition
26 I feel that I am in control of my condition
27 I am motivated to keep going and to not give up
28 I am happy to talk about the future
29 I am not concerned about the future
30 I am not worried about the season
31 I keep going and try to enjoy my life
32 I am confident in a ‘flare up’ I have quick access to treatment
33 I do not feel anxious about my current health
34 I am not worried about the care I will get with 'flare-up'
35 I am not scared of getting a cold or an infection
36 I am not frightened of being breathless when I have a ‘flare-up’
37 I am not frightened to go to sleep 'flare-up'
38 I try not to panic  when I have a ‘flare up’ p = < 0.01
Floor > 40%
x
x
x
x
x
x
x
x
x
x
x
x
Age 
Correlation
x
x
x
x
x
x
x
R Value 
Q13
Q13
Q11
Q11
Q8
Items flagged for removal
Question No. Question (Low Score Answer) Item RemovedYes No
1 I am not shocked by my COPD diagnosis x
2 I have come to terms with my diagnosis of COPD x
3 I have given up smoking and I am confident that I will not start x
4 I want to stop smoking and I believe I can x
5 It was a relief to have a diagnosis for my symptoms x
6 I understand my diagnosis x
7 I am confident that my GP will listen to my point of view x
8 I am very pleased with health care workers x
9 I am happy with the length of time to see GP x
10 I really enjoyed pulmonary rehabilitation x
11 I found pulmonary rehabilitation useful x
12 I understand my condition and this helps me to manage my fear x
13 The information I have been given is consistent x
14 I have enough information about my condition x
15 I understand about my COPD tablets x
16 I am confused about how to use my COPD inhalers x
17 I understand how my COPD treatments work x
18 I don’t find going to a hospital outpatient clinic frustrating x
19 I know how to use my inhaler properly x
20 I have accepted the limitations to my lifestyle caused by COPD x
21 I feel that I have good support from others x
22 Overall I am satisfied with my life x
23 I am not depressed X
24 Overall I am satisfied with the care given to me x
25 I am not embarrassed to tell others about my condition x
26 I feel that I am in control of my condition x
27 I am motivated to keep going and to not give up x
28 I am happy to talk about the future x
29 I am not concerned about the future x
30 I am not worried about the season x
31 I keep going and try to enjoy my life x
32 I am confident in a ‘flare up’ I have quick access to treatment x
33 I do not feel anxious about my current health x
34 I am not worried about the care I will get with 'flare-up' x
35 I am not scared of getting a cold or an infection x
36 I am not frightened of being breathless when I have a ‘flare-up’ x
37 I am not frightened to go to sleep 'flare-up' x
38 I try not to panic  when I have a ‘flare up’ x
Professional Review (see no. 0)
Additional 3 items removed:
▫ 1 - not shocked by diagnosis
▫ 37 – not frightened to go to sleep during a flare-up
▫ 38 – try not to panic with a flare-up
Reasons: 
▫ Not general items of healthcare experience
▫ Poor spread across severity of COPD
▫ Patient feedback - confusing item (Q1) 
Items* entered into Rasch (see no. 1)
Question No Question (Low Score Answer) 
2 I have come to terms with my diagnosis of COPD
7 I am confident that my GP will listen to my point of view
9 I am happy with the length of time to see GP
14 I have enough information about my condition
16 I am confused about how to use my COPD inhalers
17 I understand how my COPD treatments work
20 I have accepted the limitations to my lifestyle caused by COPD
21 I feel that I have good support from others 
22 Overall I am satisfied with my life
26 I feel that I am in control of my condition
28 I am happy to talk about the future
32 I am confident in a ‘flare up’ I have quick access to treatment
34 I am not worried about the care I will get with 'flare-up'
*n= 13 
Item Location Person LocationItem fit Residual Person Fit Residual Chi Square Interactions PSI
Analysis Mean SD Mean SD Mean SD Mean SD Value df p
Initial: Run 0 0.29 -0.76 1.13 0.24 2.37 -0.25 1.50 87.81 26 0.000 0.80
Initial Summary of Statistics* 
*n= 13 
3 Items deleted due to mis-fit:
2 – ‘have come to terms with COPD’
9 – ‘happy with time taken to see GP’
16 – ‘confused about how to use inhalers’
Item Location Person Location
Item fit 
Residual
Person Fit 
Residual
Chi Square 
Interactions PSI
Analysis Mean SD Mean SD Mean SD Mean SD Value df p
Deleted Q16 DL16 0 0.20 -0.87 1.20 0.29 1.69 -0.28 1.60 56.9 24 0.000168 0.80
Deleted Q9 DL9 0 0.15 -0.94 1.30 0.30 1.22 -0.31 1.56 36 22 0.03 0.80
Deleted Q2 DL2* 0 0.15 -0.99 1.40 0.20 0.87 -0.52 2.38 22.2 20 0.328 0.77
Deleted Q22 DL22** 0 0.12 -1.01 1.49 0.36 0.95 -0.47 2.10 14.2 18 0.71 0.75
Deleted Q21 DL21*** 0 0.11 -0.99 1.50 0.43 1.10 -0.51 2.38 17.3 16 0.363 0.73
Summary of Statistics – Rasch Fit
10 item solution*
9 item solution**
8 item solution***
Individual Item Fit – 10 item solution
Person–Item Map – 10 item solution 
Individual Item Fit – 10 item solution
Deleted item 22
Individual Item Fit – 9 item solution
Person-Item map – 9 item solution
9 item fit
Individual Item Fit – 9 item solution
Deleted item 21
Individual Item Fit – 8 item solution
Person–Item map – 8 item solution 
Final 10, 9 or 8 items (see no. No 4) 
7 I am confident that my GP will listen to my point of view
Usual Care
/Primary Care
14 I have enough information about my condition
Usual Care 
/Information 
17 I understand how my COPD treatments work
Usual Care
/Treatments
20 I have accepted the limitations to my lifestyle caused by COPD
Everyday Life/ 
Physiology
21 I feel that I have good support from others Everyday Life
22 Overall I am satisfied with my life Everyday Life
26 I feel that I am in control of my condition Everyday Life/PR
28 I am happy to talk about the future
Everyday Life
/Palliative Care
32 I am confident in a ‘flare up’ I have quick access to treatment Exacerbation 
34 I am not worried about the care I will get with 'flare-up' Exacerbation 
Discussion Points 
• Need to decide which solution we use:
▫ 10 items    ICC 0.78
▫ 9 items      ICC: 0.78
▫ 8 items      ICC 0.77 
• Discuss process for Part B – Hospitalisation 
related questions
Error 
Plots 
MRC
10 Items
9 Items
8 Items
Correlations 
CAT Score* Anxiety* Depression*
Total 10 .46 .33 .46
Total 9 .42 .30 .41
Total 8 .44 .31 .42
*R value 
•Significant less than .001
Thank you …any questions?
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Data Collection tool v.1.1 (November 2012)  IRAS No:  
 
 
 
Study Centre   
Researcher Name / Contact   
 
Patient information Sheet given Yes   No  
Consent Form Signed  Yes   No  
 
 
Participant specific information  
 
Confirmed Diagnosis of COPD Yes   No  
Has the participant had a flare up in the last 3 months? Yes   No  
Did this require hospital admission? Yes   No  
  
 
Spirometry: Date undertaken: _____________ (within the last year)  
 
FEV1 % Predicted         % 
FVC        L                 % 
FEV/FVC ratio        % 
Severity   
 
 
 
Questionnaire Record  
 
Questionnaire  Score  
38 PREM-COPD Questionnaire   
CAT Score   
HAD Score  A=             D=   
MRC Score  
 
PREM – COPD Questionnaire  
 
38 PREM-COPD Questionnaire – Follow-up Received: 
Global Rate of Change   
 
Contact details: 
 
COPD PREM – Data Collection Tool        Study No:   
 
  
APPENDIX FIVE 
 Patient Reported Experience Measure – Stage II Version 1.3 (19/1/2012).                                             NHS REC No: 12/LO2022 1 
                                                                              
 
PATIENT INFORMATION SHEET  
 
The development of a patient reported experience measure in 
Chronic Obstructive Pulmonary Disease (COPD) 
 
1 Study Title 
 
The development of a patient reported experience measure in Chronic Obstructive Pulmonary 
Disease (COPD) – Stage II  
 
2 Invitation paragraph 
 
You are being invited  to take part in a research study. This study is part of Matthew 
Hodson’s Professional Doctorate in Nursing.  Before you decide it is important for you to 
understand why the research is being done and what it will involve.  Please take time to read 
the following information carefully. Talk to others such as family, carers or your GP about the 
study if you wish. Please also ask us if there is anything that you do not understand or you 
would like more information.  Take time to decide whether or not you wish to take part. This 
study has been approved by North West London - Bloomsbury Research Committee. 
 
3 What is the purpose of the study and why have I been chosen? 
 
The purpose of the research study is to develop a questionnaire. We want to find out about 
the experience of people who have been diagnosed with the lung condition chronic 
obstructive pulmonary disease (COPD). We recently interviewed over 80 people who live 
with COPD to learn about their experiences of  interaction with healthcare professionals or 
services regarding COPD; this may have been a local GP or respiratory nurse (Stage I). The 
purpose of the interviews are  to design a patient reported experience questionnaire that can 
inform services about how well you feel the services are running and find out what is 
important to you. A draft questionnaire of 52 items was developed from the interviews. We 
now wish to reduce and refine this item list to develop the final questionnaire.   
 
You have been chosen because you have a diagnosis of COPD and you have been in recent 
contact with a healthcare professional or been admitted to hospital because of your COPD.   
 
4 Do I have to take part? 
 
No.  It is up to you to decide whether or not to take part.  If you do, you will be given this 
information sheet to keep and be asked to sign a consent form. You are still free to withdraw 
at any time and without giving a reason.  A decision to withdraw at any time, or a decision not 
to take part, will not affect the standard of care you receive.  
 
5 What are the alternatives? 
 
If you decide that you do not wish to take part in this study, you are more than welcome keep 
this information sheet and to contact a member of the research team on 020 8510 5107.   
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6 What will happen to me if I take part? 
 
You will be asked to sign a consent form stating that you agree to completing the 
questionnaires either in the clinic with or without the researcher present. Or, you may take 
this information sheet, consent form and questionnaires  home with you to consider 
participation and complete the contact form (your  name and telephone number) so that the 
researcher (s) may contact you within 24-48 hours later to ascertain your interest in the 
study.  
 
If you choose this option and decide to take part, the researcher will request that you sign the 
consent form and return this with the completed questionnaires, using the stamped-
addressed envelope provided. The researcher will be available on the telephone to offer 
assistance in completing the questionnaires.  
 
7 What do I have to do? 
 
We ask all participants to complete and sign a consent form. Demographic data (Spirometry, 
age, gender, diagnosis, medications, previous hospital admissions, flare-up and smoking 
history) will be collected by the researcher from your medical notes.  
 
You will be requested to complete 4 questionnaires, including the 52 item list, quality of life 
questionnaire, and a questionnaire that assesses activity limitation due to breathlessness. 
Approximately 7 days later, you will be requested to repeat the 52 item list and to answer a 
single question asking if you think your health has changed since completing the first batch of 
questionnaires. You will be provided with a stamped-addressed envelope to return the 
completed questionnaire to the researcher.   
 
8 Will my taking part in this study be kept confidential? 
 
If you take part in the study you will be given a unique study number to ensure that none of 
your details will be known outside the research team.  All information which is collected about 
you during the course of the research will be kept strictly confidential.  If you consent to take 
part in the research the people conducting the study will abide by the Data Protection Act 
1998, and the rights you have under this Act.   
 
You also have the right to check the accuracy of data held about you and correct any errors.  
 
9 Expenses and payments: 
 
Unfortunately there is no reimbursement for taking part in this study. 
 
10 What are the other possible disadvantages and risks of taking part? 
 
We envisage that there are no disadvantages or risks to taking part in this study. But we 
hope that this study will help us to improve the care that people with COPD receive in the 
future.  
 
11 What happens if there is a problem? 
 
While answering the questionnaire if there are any particular issues please speak with your 
respiratory specialist [Insert Name of local collaborator] on [inset telephone no.] or we 
would advise that you speak directly to your GP. 
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We would not expect you to suffer any harm or injury because of your participation..  If you 
are harmed by taking part in this study, there is no special compensation arrangement. If you 
are harmed due to someone’s negligence, then you may have grounds for legal action but 
you may have to pay your legal costs. Regardless of this, if you wish to complain or have any 
concerns about any aspect of the way you have been approached or treated during the 
course of this study, please contact Matthew Hodson, NECLES Fellow on 020 8510 5107.  
  
Or, alternatively please contact Professor Roberts on Tel: 02078822161 NECLES COPD 
Clinical Lead  
 
If you have concerns about the way you have been treated by health care professionals or 
the healthcare system whilst treated for your COPD you should contact the Patient Advice 
and Liaison Service (PALS) for further advice and information on how to make a complaint 
can be found on the following website www.pals.nhs.uk or alternatively contact Matthew 
Hodson on 0208 510 5107. Or Matthew’s academic supervisor Dr. Sally Kiburn on 023 9284 
2847 
 
12 What are the side effects of any treatment received when taking part? 
 
There are no additional risks.  
 
13 What are the possible benefits of taking part? 
 
There are no direct benefits to taking part in this study what we hope to be able to achieve is 
that we can understand about the experience of people living with COPD that could help 
shape future service provision for future people with COPD in local communities.  
 
14 What happens when the research study stops? 
 
You will only be asked to complete the questionnaires twice.  
 
15 What if there is a problem and Contact Details for further information: 
 
Any complaint about the way you have been dealt with during the study or any possible harm 
you might suffer will be addressed.  
 
For Complaints or Further Information please contact: 
 
Matthew Hodson 
Nurse Consultant, Homerton Hospital - Tel:  020 8510 5107 
Or email: matthew.hodson@homerton.nhs.uk  
 
 
16 Who is organising and funding the research?   
 
The principle researcher is Matthew Hodson, who is undertaking the project as part of his 
work with the British Lung Foundation, and Doctorate Studies at University of Portsmouth.    
  
The funding for this project : UCL Partners in collaboration with Royal College of Physicians.  
 
Below are the contact details of the Clinical lead of the COPD work in NECLES if you wish to 
discuss the study with him. But if you do have any concerns please do not hesitate to discuss 
this Matthew Hodson.  
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Professor Mike Roberts 
NECLES COPD Clinical Lead    Tel: 0207882216  Email: c.m.roberts@qmul.ac.uk 
  
APPENDIX SIX 
  
CONSENT FORM  
 
Title of project:   
 
The development of a patient reported experience measure in  
Chronic Obstructive Pulmonary Disease (COPD) Stage 2 (PREM-COPD) 
 
 
Investigator:  Matthew Hodson  
1 copy for Patient, 1 for Investigator 
 
Version: 1.2 (19/1/2013)                       IRAS: 12/LO/2022    
Page 1 of 1 
 
Centre Number:     Study Number:                Patient Identification Number for this trial: 
 
                                                                 
Please initial box to indicate agreement 
 
 
1. 
I confirm that I have read and understand the information sheet dated 19.1.13 
(version1.3) for the above study. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily. 
 
 
 
2. 
I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights  
being affected. 
 
 
 
3. 
I agree for demographic data (including gender, age, severity of lung disease, 
medications, hospital information on flare up’s, smoking history and lung 
function results) to be used or collected by the research team from my hospital 
doctor and/or general practitioner.   
 
 
4. I agree to complete the questionnaires in the COPD pack and return an 
additional COPD pack a week later in the self addressed envelope to the 
research team. A unique number has been given to me indicated above.  
  
 
5.  I understand that relevant sections of my medical notes and data collected 
during the study, may be looked at by individuals from Homerton University 
Hospital and from regulatory authorities or from the NHS Trust, where it is 
relevant to my taking part in this research. I give permission for these 
individuals to have access to my records. 
 
6. 
 
I agree to take part in the above study. 
 
 
 
 
 
 
________________________ ________________                __________________ 
Name of Patient  Date Signature 
 
 
 
_________________________ ________________                __________________ 
Name of Person taking consent Date  Signature 
(if different from Investigator) 
 
 
_________________________ ________________                __________________ 
Investigator (if witnessed) Date  Signature 
 
  
APPENDIX SEVEN 
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Your name: Today’s date:
How is your COPD?Take the COPDAssessmentTest™ (CAT)
This questionnaire will help you and your healthcare professional measure the impact COPD (Chronic Obstructive
Pulmonary Disease) is having on your wellbeing and daily life.Your answers, and test score, can be used by you and
your healthcare professional to help improve the management of your COPD and get the greatest benefit from treatment.
For each item below, place a mark (X) in the box that best describes you currently. Be sure to only select one response
for each question.
Example: I am very happy I am very sad
TOTAL
SCORE
SCORE
COPDAssessmentTest and CAT logo is a trademark of the GlaxoSmithKline group of companies.
© 2009 GlaxoSmithKline. All rights reserved.
I never cough 0 1 2 3 4 5
0 1 2 3 4 5
0 1 2 3 4 5
0 1 2 3 4 5
0 1 2 3 4 5
0 1 2 3 4 5
0 1 2 3 4 5
0 1 2 3 4 5
I cough all the time
I have no phlegm (mucus)
in my chest at all
My chest is completely
full of phlegm (mucus)
My chest does not
feel tight at all
My chest feels
very tight
When I walk up a hill or
one flight of stairs I am
not breathless
When I walk up a hill or
one flight of stairs I am
very breathless
I am not limited doing
any activities at home
I am very limited doing
activities at home
I am confident leaving
my home despite my
lung condition
I am not at all confident
leavingmy home because
ofmy lung condition
I sleep soundly
I don’t sleep soundly
because of my lung
condition
I have lots of energy I have no energy at all
Global Rate of Change Questionnaire: v.1.0                                NHS REC No: 12/LO/2022 
Global Rate of Change                              Study No: 
 
My general health compared to last week is:       
 
 
No 
 
Global Rate of Change: 
 
 
 
1 
 
 
Much better 
 
 
2 
 
 
Somewhat better 
 
 
3  About he same 
 
 
4  Somewhat worse 
 
 
5  Much Worse  
 
 
Hospital Anxiety and Depression Scale (HADS) 
 
 
Study Number:         Date: 
 
Clinicians are aware that emotions play an important part in most illnesses. If your clinician 
knows about these feelings, he or she will be able to help you more. 
 
This questionnaire is designed to help your clinician to know how you feel. Read each item below 
and underline the reply which comes closest to how you have been feeling in the past week. 
Ignore the numbers printed at the edge of the questionnaire. 
 
Don’t take too long over your replies. Your immediate reaction to each item will probably be more 
accurate than a long, thought-out response.  
 
 
1. I feel tense or ‘wound up’ 
o Most of the time 
o A lot of the time 
o From time to time, occasionally 
o Not at all 
 
2. I still enjoy the things I used to enjoy 
o Definitely as much 
o Not quite so much 
o Only a little 
o Hardly at all 
 
3. I get a sort of frightened feeling as if 
something awful is about to happen 
o Very definitely and quite badly 
o Yes, but not too badly 
o A little, but it doesn’t worry me 
o Not at all 
 
4. I can laugh and see the funny side of  
things 
o As much as I always could 
o Not quite so much now 
o Definitely not so much now 
o Not at all  
 
5. Worrying thoughts go through my head 
o A great deal of the time 
o A lot of the time 
o Not too often 
o Very little 
 
6. I feel cheerful 
o Never 
o Not often 
o Sometimes 
o Most of the time 
 
7. I can sit at ease feel relaxed 
o Definitely 
o Usually 
o Not often 
o Not at all 
 
 
8. I feel as if I am slowed down 
o Nearly all the time 
o Very often 
o Sometimes 
o Not at all 
 
9. I get a sort of frightened feeling  
like “butterflies” in the stomach 
o Not at all 
o Occasionally 
o Quite often 
o Very often 
 
10. I have lost interest in my appearance 
o Definitely 
o I don’t take as much care as I should 
o I may not take quite as much care 
o I take just as much care as ever 
 
11. I feel restless as if I have to be on the move 
o Very much indeed 
o Quite a lot 
o Not very much 
o Not at all 
 
12. I look forward with enjoyment to things 
o As much as I ever did 
o Rather less than I used to 
o Definitely less than I used to 
o Hardly at all 
 
13. I get sudden feelings of panic 
o Very often indeed 
o Quite often 
o Not very often 
o Not at all 
 
14. I can enjoy a good book or radio or  
TV programme 
o Often 
o Sometimes 
o Not often 
o Very seldom  
 
A D 
 
3 
2 
1 
0 
 
 
    0 
    1 
    2 
    3 
 
 
 
3 
2 
1 
0 
 
 
     
    0 
    1 
    2 
    3 
 
 
3 
2 
1 
0  
 
 
    3 
    2 
    1 
    0 
 
 
0 
1 
2 
3 
A D 
 
    3 
    2 
    1 
    0 
 
 
 
0 
1 
2 
3 
 
 
    3 
    2 
    1 
    0 
 
  
3 
2 
1 
0 
 
 
    0 
    1 
    2 
    3  
 
 
3 
2 
1 
0 
 
 
     
    0 
    1 
    2 
    3 
MRC Scale: v1.0 – 03/03/12       NHS Rec No: 12/LO/2022 
 
                                                                                                                                                          
MRC DYSPNOEA SCALE                                                                       Study No:                                                           
 
 
Grade 
 
Degree of breathlessness related to activities: 
 
 
 
1 
 
 
Not troubled by breathlessness except on strenuous exercise 
 
2 
 
 
Short of breath when hurrying or walking up a slight hill 
 
 
3 
 
Walks slower than contemporaries on level ground because of 
breathlessness, or has to stop for breath when walking at own pace 
 
 
4 
 
Stops for breath after walking about 100 m or after a few 
minutes on level ground 
 
 
5 
 
Too breathless to leave the house, or breathless when 
dressing or undressing 
 
 
  
APPENDIX EIGHT 
 A Research Ethics Committee established by the Health Research Authority 
1 
 
 
 
National Research Ethics Service 
 
NRES Committee London - Bloomsbury 
HRA NRES Centre Manchester 
Barlow House 3rd Floor 
4 Minshull Street 
Manchester 
M1 3DZ 
 
Telephone: 0161 625 7815  
Facsimile: 0161 625 7299 
 
 
29 January 2013 
 
Mr Matthew Hodson 
Nurse Consultant - COPD 
Homerton University Hospital 
Homerton Row 
Hackney 
London 
E9 6SR 
 
 
Dear Mr Hodson 
 
Study title: Developing a Patient Reported Experience Measure for 
Chronic Obstructive Pulmonary Disease (PREM-COPD) - 
Stage II 
REC reference: 12/LO/2022 
IRAS project ID: 116806 
 
Thank you for your letter of 24 January 2013, responding to the Committee’s request for further 
information on the above research and submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by the Vice-Chair.  
 
We plan to publish your research summary wording for the above study on the NRES website, 
together with your contact details, unless you expressly withhold permission to do so.  
Publication will be no earlier than three months from the date of this favourable opinion letter.  
Should you wish to provide a substitute contact point, require further information, or wish to 
withhold permission to publish, please contact the Co-ordinator Dr Ashley Totenhofer, 
nrescommittee.london-bloomsbury@nhs.net.  
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting documentation 
as revised, subject to the conditions specified below. 
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Ethical review of research sites 
 
NHS sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to management 
permission being obtained from the NHS/HSC R&D office prior to the start of the study (see 
"Conditions of the favourable opinion" below). 
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start of the 
study. 
 
Management permission or approval must be obtained from each host organisation prior to the 
start of the study at the site concerned. 
 
Management permission ("R&D approval") should be sought from all NHS organisations 
involved in the study in accordance with NHS research governance arrangements. 
 
Guidance on applying for NHS permission for research is available in the Integrated Research 
Application System or at http://www.rdforum.nhs.uk.   
 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites ("participant identification centre"), guidance should be sought from 
the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation.  
 
Sponsors are not required to notify the Committee of approvals from host organisations 
 
It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable). 
 
Approved documents 
 
The final list of documents reviewed and approved by the Committee is as follows: 
  
Document    Version    Date    
Covering Letter    03 December 2012  
REC application  3.4  04 December 2012  
Protocol  Version 1.2  03 December 2012  
Evidence of insurance or indemnity  Zurich Municipal  20 July 2012  
Questionnaire: PREM-COPD  Version 1.3  03 December 2012  
Advertisement  Version 1.0     
Other: NECLES HIEC - PREM-COPD Final Report    22 February 2012  
Investigator CV  Sally Kilburn     
Investigator CV  Janelle Yorke     
Questionnaire: COPD Assessment Test  Validated     
Questionnaire: Hospital Anxiety and Depression Scale 
(HADS)  
Validated     
Questionnaire: Global Rate of Change Questionnaire  Validated     
Questionnaire: MRC Dsypnoea Scale  Validated     
Covering Letter    22 January 2012  
Investigator CV  Matthew Hodson - 2013     
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Participant Information Sheet  1.3  19 January 2013  
Participant Consent Form  1.2  19 January 2013  
Response to Request for Further Information    24 January 2013  
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research 
Ethics Committees in the UK. 
 
After ethical review 
 
Reporting requirements 
 
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
 Notifying substantial amendments 
 Adding new sites and investigators 
 Notification of serious breaches of the protocol 
 Progress and safety reports 
 Notifying the end of the study 
 
The NRES website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures. 
 
Feedback 
 
You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure.  If you wish to make your views known 
please use the feedback form available on the website. 
 
Further information is available at National Research Ethics Service website > After Review 
 
12/LO/2022                          Please quote this number on all correspondence 
 
We are pleased to welcome researchers and R & D staff at our NRES committee members’ 
training days – see details at http://www.hra.nhs.uk/hra-training/  
 
With the Committee’s best wishes for the success of this project. 
 
Yours sincerely 
 
Signed on behalf of: 
Reverend James Linthicum 
Chair 
 
Email: nrescommittee.london-bloomsbury@nhs.net  
 
Enclosures:  “After ethical review – guidance for 
   researchers” 
 
Copy to:  Mrs Linda Legrand - Homerton University Hospital 
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Dr Sally Kilburn – University of Portsmouth 
 
Dr Janelle Yorke – University of Manchester 
 
Professor Mike Roberts – Barts and the London School of Medicine and 
Dentistry 
 
Denise Teasdale – Portsmouth University    
 
 
 
 
 
 
 
 
 
 
  
APPENDIX NINE 
UPR 16 (2013) – November 2013                                                                      
 
FORM UPR16 
Research Ethics Review Checklist 
 
Please complete and return the form to Research Section, Quality Management 
Division, Academic Registry, University House, with your thesis, prior to 
examination 
 
 
 
Postgraduate Research Student (PGRS) Information 
 
 
Student ID: 
 
eco51458 
 
Candidate Name: 
 
 
Matthew Hodson 
 
Department: 
 
 
School of Health  
Sciences & Social Work 
 
First Supervisor: 
 
Dr. Sally Kilburn  
 
Start Date:  
(or progression date for Prof Doc students) 
 
 
September 2012 
 
 
Study Mode and Route: 
 
 
Part-time 
 
Full-time 
 
 
 
√ 
 
MPhil  
 
MD 
 
PhD 
 
 
 
 
 
 
 
 
 
Integrated Doctorate  
(NewRoute) 
 
Prof Doc (PD) 
 
 
 
 
√ 
 
 
Title of Thesis: 
 
The development of a patient reported experience measure in chronic obstructive 
pulmonary disease (COPD) 
 
 
Thesis Word Count:  
(excluding ancillary data) 
 
 
 
 
 
 
If you are unsure about any of the following, please contact the local representative on your Faculty Ethics 
Committee for advice.  Please note that it is your responsibility to follow the University’s Ethics Policy and any 
relevant University, academic or professional guidelines in the conduct of your study 
Although the Ethics Committee may have given your study a favourable opinion, the final responsibility for 
the ethical conduct of this work lies with the researcher(s). 
 
       
 
UKRIO Finished Research Checklist: 
(If you would like to know more about the checklist, please see your Faculty or Departmental Ethics 
Committee rep or see the online version of the full checklist at: http://www.ukrio.org/what-we-do/code-of-
practice-for-research/) 
 
 
a) Have all of your research and findings been reported accurately, honestly 
and within a reasonable time frame? 
 
 
YES  
 
 
b) Have all contributions to knowledge been acknowledged? 
 
 
YES 
 
 
c) Have you complied with all agreements relating to intellectual property, 
publication and authorship? 
 
YES 
 
 
 
d) Has your research data been retained in a secure and accessible form and 
will it remain so for the required duration?  
 
YES  
 
 
 
e) Does your research comply with all legal, ethical, and contractual 
requirements? 
 
 
YES  
 
*Delete as appropriate 
 
UPR 16 (2013) – November 2013                                                                      
 
          
 
Candidate Statement: 
 
 
I have considered the ethical dimensions of the above named research project, and have successfully 
obtained the necessary ethical approval(s) 
 
 
Ethical review number(s) from Faculty Ethics Committee (or from 
NRES/SCREC): 
 
 
NRES Committee London – 
Bloomsbury 
REC: 12/LO/2022 
 
 
 
Signed: 
(Student) 
 
Date: 26/09/2014  
 
If you have not submitted your work for ethical review, and/or you have answered ‘No’ to one or more of 
questions a) to e), please explain why this is so: 
 
 
 
 
 
 
 
 
 
 
 
Signed:  
(Student) 
 
 
Date: 
 
 
 


  
 
 
 
 
 
 
 
Dear Matt,  
 
Thank you for contacting us about your study into patient reported experience measures in 
COPD.  
 
You are welcome to invite our Breathe Easy members to take part in your study. I would 
also be happy to send out a communication on your behalf to let them know about it and 
tell them how to get in touch with you. 
 
The research protocol looks good and the patient information sheet is very clear. I think 
our group members will find it easy to understand.  
 
Please let me know if we can provide any further assistance.  
 
Kind regards, 
 
 
 
Bethany Bateman 
Stakeholder Engagement Manager 
 
T: 020 7688 5557 
M: 07792 767 356 
E: bethany.bateman@blf.org.uk  
 




  
APPENDIX TEN 
The development of a patient reported experience 
measure in COPD – using the Rasch Model
Matthew Hodson1 
Dr Janelle Yorke2 
Professor C Michael Roberts3
Professor Sharon Andrew4
Professor Paul Jones5
Introduction:
Experience of patients with chronic obstructive 
pulmonary disease (COPD) and their views on 
the quality of their healthcare is not currently 
captured in patient reported measures. 
Aim: 
To develop and validate a patient reported 
experience measure (PREM) to assess 
experiences of living with chronic obstructive 
pulmonary disease and perceived quality of 
healthcare provision. 
Method: 
Previous work with 83 COPD patients 
identi" ed 38 items for potential PREM 
inclusion. These, together with the COPD 
Assessment Test (CAT) and Hospital Anxiety & 
Depression Scale (HADS) were administered 
to patients with COPD. Items demonstrating 
signi" cant gender/age bias (p<0.05), # oor or 
ceiling e$ ects (at 40%), missing data >15%, 
or high item-item correlations (r>0.8) were 
removed. Rasch analysis was applied to the 
remaining items. 
Results: 
174 patients (Mean age 71, SD 9; 91 female; 
Mean FEV1% predicted 59, SD 21.9) were 
studied. 29 items were removed providing a 
9-item unidimensional scale ( χ2 p= 0.71) with 
a wide scaling range (logits from -0.1 to +0.2, 
Figure 2). 
These cover experiences of living with COPD 
(I feel that I am in control of my condition) 
and health care (I am concerned that my GP 
will not listen to my point of view). Internal 
consistency was good (PSI=0.75) and 
correlations between the PREM-COPD, CAT & 
HADS were moderate (r=0.42, 
r=0.30 respectively). 
Conclusion
The COPD-PREM demonstrated good internal 
reliability and showed a wide scaling range 
suggesting regardless of severity people with COPD 
can have good or bad experiences. There were 
low to moderate correlations with the CAT & HADS 
suggesting the PREM-COPD measures a di$ erent 
concept to health status. The COPD-PREM should 
provide a useful measure of patients’ experience 
with care that complements measures of health 
status and mood.
 
 
 
Academic Health Science Partnership
UCLPartners
Homerton University Hospital
NHS Foundation Trust
Copies of report could be obtained 
from Matthew Hodson: 
matthew.hodson@homerton.nhs.uk
1. ACERS Team, Homerton University Hospital, London UK
2. School of Nursing, Midwifery and Social Work, Manchester University, Manchester UK
3. Barts and The London School of Medicine and Dentistry, 
Queen Mary University of London
4. Faculty of Health, Social Care & Education, Anglia Ruskin University, Essex UK
5. Institute for Infection and Immunity, St George’s University of London, London UK
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Figure 1
Figure 2 Individual Item Fit for 9 Items
Three identi" ed themes with examples 
taken from the COPD PREM-9 Questionnaire
 Spearman’s rho correlation between 
total scores of the COPD PREM-9 and COPD 
Assessment Test (CAT) in 174 patients.
Person-item threshold distribution
I understand 
how my COPD 
treatments work
3
I am confused 
about how my COPD 
treatments work
1 2 3 4 5
USUAL CARE IN COPD - 
These questions relate to the everyday usual care given 
for your COPD
I feel that I am 
in control of 
my condition
6
I feel that I do not 
have any control 
over my condition
1 2 3 4 5
MY EVERYDAY LIFE WITH COPD 
These questions relate to your everyday life with COPD
I am con"dent 
that in a ‘#are up’ 
I have quick access 
to treatment like 
a rescue pack or 
access to my 
GP/nurse
I am worried 
that in a ‘#are up’ 
I do not have quick 
access to treatment 
like a rescue pack 
or access to my 
GP/nurse 
8 1 2 3 4 5
COPD EXACERBATION (Flare up)  
These questions relate to a "are up of your COPD
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high proportion of participants who had a better experience than others, 
scoring a 0 score on the 9 items overall.
Figure 3 shows there is a weak association (r = 0.42) demonstrating 
the PREM is measuring something di$ erent from impaired 
health status.
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CASP Screening Questions - Systematic Review  
(Adapted from CASP Critical Appraisal Skills Programme www.casp.net) 
 
Study: Giacomini, M., DeJean, D., Simeonov, D., & Smith, A. (2012). Experiences 
of living and dying with COPD: a systematic review and synthesis of the qualitative 
empirical literature. Ontario Health Technology Assessment Series, 12(13), 1–47 
 
Section A:  Are the results of the review valid?  
 
1. Did the review address a clearly focused question? X Yes Can’t tell No  
 
There was a clear research focused question focusing on the patient, carer and 
healthcare professional. The COPD population was being studied - but it wasn't that clear 
on the severity of population being studied.  There were clear inclusion and exclusion 
criteria set.  
The intervention was clear in terms of the papers needed to focus on experience in any 
aspect of COPD for example studies addressing topics other than the experiences of 
living or dying with COPD from the perspective of persons at risk, patients, health care 
providers, or informal carers were excluded from the study. 
 
The outcomes from the studies were clearly identified and summarised making a thematic 
account of pooled information.   
 
 
2. Did the authors look for the right type of papers? XYes Can’t tell No  
 
The main objective of the analysis was to review empirical qualitative research on the 
experiences of patients with chronic obstructive pulmonary disease (COPD), informal 
caregivers (“carers”), and health care providers—from the point of diagnosis, through daily 
living and exacerbation episodes, to the end of life. A wide variety of articles which 
addressed this objective were included in the systematic search with a clear PRISMA tree 
evident on the decisions to include or not include articles.  
 
The study designs were qualitative in nature with aims to explore or understand the 
experiences of living with COPD, and from the results of the systematic review useful 
themes were evident.  
 
 
Section B: What are the results?  
  
3. Do you think all the important, relevant X Yes Can’t tell No studies were 
included?  
 
A 10 year history was covered, Literature searches for studies published from January 1, 
2000 to November 2010 were  identified using OVID MEDLINE; ISI Web of Science; and 
 Cumulative Index to Nursing and Allied Health Literature (CINAHL). It was identified that 
the Titles and abstracts were reviewed by a single reviewer and, for those studies meeting 
the eligibility criteria, full-text articles were obtained. 
 
It was identified that a further 1 study was identified whilst undertaking the review, 
however there is no mention of any additional studies being reviewed through the 'grey 
literature' or a search for unpublished work and the systematic review also excluded non-
English language studies, so there is a potential that some studies with relevance could 
have been missed and not included overall.  
 
4. Did the review’s authors do enough to assess X Yes Can’t tell No the 
quality of the included studies?  
 
Full papers were retrieved and read by two investigators. Papers were grouped by broad 
topical focus and read closely by one investigator to generate a narrative summarizing the 
main findings under each topic. A second investigator reviewed the same papers, revised 
the narrative (by consensus with the first reviewer), and incorporated any relevant findings 
from papers in other topic groups (for example, some papers on smoking experiences 
also addressed day-to-day living issues). In all, each primary research paper was 
reviewed two to three times by at least two investigators. 
 
A synthesis was developed to relate the findings to the clinical trajectory of COPD, 
highlighting key patient, caregiver, and health care provider experiences reported at 
specific phases of the disease course. Drafts of the full report were presented sequentially 
to the Ontario Health Technology Advisory Committee, the Medical Advisory Secretariat, 
and the COPD Expert Panel for multidisciplinary feedback. 
 
A weakness of this systematic review is that it does not clearly identify areas of weakness 
of the papers identified. It was clear they were identified because of clinical relevance but 
the paper does not highlight many aspects about the papers themselves.  
 
 
5. If the results of the review have been combined, X Yes  Can’t tell No  
was it reasonable to do so?  
 
This paper makes a reference to a second investigator reviewing the same papers, and a 
revised narrative (by consensus with the first reviewer) completed for publication. This 
process I feel adds value to ensure that the themes which have been combined are 
appropriate and relevant to the research question. The review incorporates any relevant 
findings from papers in other topic areas which primarily are not concerned with the 
patient experience of living with COPD an example includes some of the papers reviewed 
were specifically on people's experience of smoking, but also addressed the day-to-day 
living with COPD, thereby appropriately combining. To ensure accuracy and improve 
quality each primary research paper was reviewed two to three times by the two 
investigators. 
 
 
6. What are the overall results of the review?  
 
The findings of the systematic review covered 4 broad categories of patient experiences 
over the course of COPD: diagnosis, living day-to-day, exacerbations, and the end of life. 
A fifth category addressed carer experiences - these categories were not dissimilar to the 
findings of Study One addressed within this thesis of our own work.  
 
As this review only explores qualitative results, no numerical data featured in the 
systematic review  
 
 
  
 
7. How precise are the results?  
 
It was difficult to quantify how precise the results were but the 5 themes identified were of 
high relevance and from a clinical perspective were appropriate and can be used within 
the clinical setting. The results were highly informative and gave the reader a 
comprehensive overview of the experiences of people living with COPD. 
A criticism however is the relevance of the papers to the classification of the disease or 
the number of years people had been living with COPD - therefore these results have 
been pooled together with little explanation and remain unclear from the literature how 
long someone had been living with the disease or the severity of their disease, along with 
other demographics such as age or gender.   
Section C:  Will the results help locally?  
 
8. Can the results be applied to the local population? X Yes Can’t tell No  
 
From my experience and reading of patient experience, this systematic review 
highlights some very interesting and key points into the experience of COPD. The 
themes identified give a clear message about 5 themes identified within the 
systematic review. These results can be applied to a local population.  
 
 
9. Were all important outcomes considered? X Yes Can’t tell No  
 
This systematic review has clearly answered the initial research question 'What do 
patients with COPD, their informal caregivers (“carers”), and health care providers 
experience over the course of COPD? The review clearly identified a significant number of 
papers within the literature on patient experience of COPD, identifying over 100 articles 
for inclusion. The authors identified the five themes which are relevant to current 
outcomes and topical subjects in COPD.  It addresses and quotes some powerful 
examples of these experiences of patients, which has now become saturated within the 
literature.  
 
This systematic review clearly identifies the need for improvement and the need for 
measurement as not much has changed over the 10 year period studied.     
 
 
10. Are the benefits worth the harms and costs? X Yes Can’t tell No  
 
This is an informative study that clearly identifies the harm that an incorrect 
diagnosis and the effects being diagnosed with COPD has on patients’ lives. The 
mostly negative experience is well documented and the results this has on people 
living with COPD throughout their lives is clearly evident, many resulting in high 
anxiety and depression with a high need for healthcare services.   
 
 CASP Screening Questions - Systematic Review  
(Adapted from CASP Critical Appraisal Skills Programme www.casp.net) 
 
Study: Disler, R. T., Green, A., Luckett, T., Newton, P. J., Currow, D., & Davidson, 
P. M. (2014). Experience of Advanced Chronic Obstructive Pulmonary Disease: 
Metasynthesis of Qualitative Research. Journal of Pain and Symptom 
Management. 
 
Section A:  Are the results of the review valid?  
 
1. Did the review address a clearly focused question? Yes X Can’t tell No  
 
A research question was not addressed specifically but a clear objective was stated which 
was to 'to increase understanding of the experience and ongoing needs of individuals 
living with COPD', however, the articles makes several references that the reason for 
metasynthesis is to answer 'complex research questions'. 
 
The population was not specially identified in the article except that the title and further 
reading makes reference to 'advanced COPD' but the objective does not support this 
suggesting that that it was looking at individuals with COPD', there are no reference to 
spirometry results of the articles chosen. There is a clear focus on how the metasynthesis 
was undertaken and the outcome of the study was clearly reviewed and understood. 
 
A further aim is also introduced as to 'increase the understanding of the experience and 
ongoing needs of individuals living with COPD and has unique potential for informing the 
coordination and responsiveness of services to the needs of individuals with COPD and 
their families'. 
 
 
2. Did the authors look for the right type of papers? X Yes Can’t tell No  
 
In total, twenty-two studies were included in the review. This was a variety of studies 
looking at the qualitative aspects of living with COPD. The appropriateness of study 
design or subjects however, was not commented on by the author of the articles that were 
included within the metasynthesis. But having reviewed the titles of the journals included, 
many were appropriate, however the severity of the COPD was difficult to gage as not all 
articles had 'severe' or 'advanced' in the title. But Disler does make a clear comment in the 
introduction that 'the clear benefit of this individual perspective, small sample sizes and 
inherent absence of generalisation limit the capacity to incorporate this information in 
policy, practice and research’. 
 
Section B: What are the results?  
  
3. Do you think all the important, relevant Yes Can’t tell No studies were 
included?  
 
Medline, PsychINFO, CINAHL, and Sociological Abstracts were searched for articles 
published between January 1990 and December 2012. Metasynthesis of qualitative data 
followed the principles of the Preferred Reporting Items for Systematic Reviews and Meta- 
Analyses (PRISMA). This is a reasonable data search and the appropriate databases 
were searched. However, there was no mention of searching the 'grey' literature or other 
forms of data collection, this potentially could have disadvantaged the review due to a 
number of known unpublished formal work not being included. 
   
The analysis focussed on twenty-two studies. Four hundred and twenty-two free codes 
were condensed into seven descriptive themes: better understanding of condition; 
breathlessness; fatigue; frailty; anxiety; social isolation; and loss of hope and maintaining 
meaning .These seven themes were condensed further into three analytical themes that 
described the experience and ongoing needs of individuals with COPD: the need for 
better understanding of condition; sustained symptom burden; and the unrelenting 
psychological impact of living with COPD. 
 
4. Did the review’s authors do enough to assess X Yes Can’t tell  No the 
quality of the included studies?  
 
The study was also undertaken with the supervision of a health informatics expert which 
adds value to the fact that only published work was reviewed. 
 
There was a good section examining the quality of the studies examined and clearly 
highlight that 'the majority of studies presented had clear aims, outlined the qualitative 
approach used and described data collection techniques. Studies did not consistently 
justify the qualitative research design.  Sampling techniques were assessed as having 
limited capacity to support generalizability to other contexts'  And makes suggestions 
that this is to be expected in small cohort qualitative research and was discussed as a 
limitation in most studies, however there were a number of different methods of data 
collection within the studies used such as interview, focus groups and open-ended 
questions.  
 
More importantly Disler et al. (2014) also evaluated for 'adherence, clarity of aims, 
justification of approach, procedural rigor, representativeness of the sample, interpretation 
of the data, reflexivity and evaluative rigor, and transferability of findings', key areas to 
ensure appropriate quality within a metasynthesis.  
 
5. If the results of the review have been combined, X Yes Can’t tell No  
was it reasonable to do so?  
 
The results within this metasynthesis have been combined and descriptive and 
analytical themes were developed through thematic synthesis and expert panel discussion 
of extracted primary quotes and not the primary data itself. This is helpful to get a 
good understanding of how the impact of the disease affects individuals living with 
COPD. The article gives a clear focus to the reason articles were chosen.  
 
6. What are the overall results of the review?  
 
An initial thematic synthesis of qualitative data was completed in three stages using 
electronic software (EPPI-Reviewer 4) for qualitative coding, also for quality purposes, 
independent investigators were also used. This process appears clear and the quality 
of this is well documented using appropriate software to support the handling of the 
data extracted and to make sense of the data through discussion and experts.  
 
The article has used an appropriate literature search and then followed the principles of 
the Preferred Reporting Items for Systematic Reviews and Meta- Analyses (PRISMA), 
which is commonly used method in this type of study. The overall results of the study 
highlight 3 main themes of living with COPD which are of high relevance and the script 
can be translated across the advanced COPD population.  
 
7. How precise are the results?  
 
It is difficult to quantify how precise the results were but the 3 themes identified were of 
high relevance and from a clinical perspective were appropriate and can be used further 
within the clinical setting. The results were highly informative and gave the reader a broad 
sense of the experience of living with COPD, generalised in this review format. 
A criticism, however, is the relevance of the papers to the classification of the disease or 
the number of years people had been living with COPD - therefore these results have 
been pooled together with little explanation and therefore remain unclear from the 
literature how long someone had been living with the disease or the severity of their 
disease, along with other demographics such as age or gender.   
Section C:  Will the results help locally?  
 
8. Can the results be applied to the local population?  x Yes Can’t tell No  
 
I believe that this study has through an appropriate research approach captured 
some key points which can be applied to the local population for clinicians, 
researchers and the general population and been able to apply these results to a 
local population to use as guidance to explore further the themes locally to 
improve or understand 'generally' the concerns of patients living with COPD.  
                                                                                                                                                                                                                                  
9. Were all important outcomes considered? x Yes Can’t tell No  
 
It was acknowledged that despite a number of medications and advancements in COPD, 
individuals living with advanced COPD continue to experience symptom burden and have 
high rates of health care utilization. 
 
Combining discrete qualitative studies has provided a useful perspective of the experience 
of living with COPD over the past two decades. 
 
Disler., et al (2014) makes good recommendation that future research and resources 
should focus on solutions through the development of consumer-driven interventions that 
address patients’ ongoing needs. 
 
10. Are the benefits worth the harms and costs? Yes Can’t tell No  
 
This is an informative study that clearly identifies the harm that an incorrect 
diagnosis and the effects being diagnosed with COPD has on patients’ lives. The 
mostly negative experience is well documented and the results this has on people 
living with COPD throughout their lives is clearly evident, many resulting in high 
anxiety and depression with a high need for healthcare services.   
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 Ref: Guidance for Industry Patient-reported outcome measures: Use on medical product 
development to support labelling claims. US Department of Health and Drug 
Administration RDA December 2009  
Conceptual Framework for the development of a Patient Reported Outcome (PRO) 
Instrument (FDA, 2009) 
Concept Iterative Process Map against COPD PREM 
development 
 
 
Identify 
Concepts 
and Develop 
Conceptual 
Framework 
 
a) Identify concepts and 
domains that are important to 
patients. 
  
b) Determine intended 
population and research 
application.  
 
c) Perform literature 
review/expert review. 
 
d) Hypothesize expected  
relationships among 
concepts. 
 
e) Document preliminary 
instrument development. 
 
a) the intended population for the development of the 
PREM was very clear from the start in that it focused 
on COPD patients of all severities. The concepts 
measured were drafted from the themes identified 
within the cognitive interviewing of patients and also 
supported by the literature review on patient 
experience, supported by expert opinion.   
b) The initial concept of the PREM was undertaken 
in two studies – the initial study was undertaken as a 
project, however, Study Two had robust and rigorous 
research applications. 
c) Two detailed literature reviews were undertaken 
first to review the published literature on COPD 
PREMS (none) and secondly a review of the 
experiences of living with COPD and interaction with 
healthcare.  
d) a formal hypothesis written – but verbal ones were 
evident i.e. we knew COPD pts report poor 
experience and understood where these lay i.e. 
diagnosis and end of life care. 
e) the concept of the preliminary instrument 
development was mapped and an ‘instrument’ 
protocol was developed                                                                                                                              
 
 
Create 
Instrument 
a) Generate items. 
 
b) Choose administration 
method recall period, and 
response scales. 
 
c) Draft instructions.  
 
d) Draft procedures for 
scoring and administration.  
 
e) Pilot test draft instrument.  
 
f) Refine instrument and 
procedures. 
 
a) Generation of items were undertaken in a robust 
and patient-centred manner using discovery 
interviews with the target population over 80 
patients, and thematic analysis of themes including 
expert and patient involvement. 40 items generated. 
b) Paper instrument handed out and, if possible, 
completed at point of initial contact. Follow-up one 
week after with global rate of change and PREM 
questionnaire. Likert scale of 0-5 chosen by expert 
panel. 
c) Patient information sheet also written on the use 
of the instrument and how to complete. i.e. 0 = good 
experience; 5 = bad experience. 
d) Research protocol including data collection 
methods and instructions were completed and 
agreed by expert panel and ethics board. The 
administration was self-administration. 
e) Testing of draft instrument with a number of 
COPD patients prior to formal testing. 
f) Two items were deleted at this stage as they were 
not understood by patients in a cognitive interviewing 
process and therefore the instrument was refined. 
No changes to the patient information sheet were 
needed. Refinement of the 38-item instrument was 
undertaken with item-reduction and Rasch analysis.    
 
 
  
a) Assess score reliability, 
validity, and ability to detect 
a) Content validity was undertaken with the items 
which were generated and also mapped against 
current literature on patient experience. Construct 
Assess 
Measurement 
Properties 
change.  
 
b) Evaluate administrative 
and respondent burden. 
 
c) Add, delete, or revise 
items. 
 
d) Identify meaningful 
differences in scores. Finalize 
instrument formats, scoring, 
procedures, and training 
materials. 
validity was measured through item-reduction 
following an expert review. Remaining items were 
entered into the Rasch  Model which mathematically 
analyses the total score - a series of tests were 
undertake in an detailed process to test reliability 
and validity of remaining items. Though the 
instrument hasn't been examined to detect change, a 
test-re-test design was examined. Further validity 
study needs exploring post thesis in a different group 
of patients.  
b) It was acknowledged that asking 38 items plus the 
additional outcome measures were long and wanted 
to reduce the emotional or cognitive strain on 
patients. Therefore, advice on reducing the length of 
the questionnaire, formatting and font size was 
critical. These aspects needed further review on the 
final 9-items PREM. 
c) There were several stages in which the instrument 
was modified, starting from its initial construction of 
items through the process and expert panel and 
patients were involved in the decisions until a final 13 
items were added into Rasch and then items were 
deleted due to the mathematical model and items not 
fitting a unidimensional model. 
d) As there was only one total score present in the 
construct of the questionnaire there was evidence in 
the Rasch analysis that there was a varying score of 
experience. Further work needs to be undertaken as 
set out in the FDA manual on the procedures and 
training materials for the instrument, including 
instructions on the use and advice/intervention on 
the final score. This will be completed as part of the 
expert group and further study.   
Criterion validity was difficult due to the fact that this 
is the first published instrument available and no 
‘gold standard’ as stated by FDA (though it is 
acknowledged that normally there is no ‘gold 
standard’ available)  
 
  
Modify 
Instrument 
a) Change concepts 
measured: 
 
- populations studied 
- research application 
  
- instrumentation 
 
- or method of administration 
a) The instrument throughout its development has 
also measured the appropriate population (COPD), 
there has been a wide consultation of the severity of 
COPD and this was evident in the FEV1 highlighted. 
Further work, however needs to be undertaken 
exploring the instrument with groups of patients with 
varying levels of severity.  
Further work is also needed to understand the 
instrument and adapt or translate for different 
languages; more evidence on content validity and 
other measurement properties will be needed. 
Therefore the instrument is only available in English. 
The concept of the instrument remained focused 
throughout the development; it is a way of capturing 
data on patients’ experience of living with COPD.  
The application and method of administration of the 
final COPD-PREM-9 is a short and focused 
instrument on experience of living with COPD; 
further work, however, will need to be undertaken on 
changing the instrument from paper to electronic, 
and understanding its use in areas such as clinics, 
pulmonary rehabilitation (PR) groups and a review of 
the order of the items.  
 
Conceptual Framework for the development of a Patient Reported Outcome (PRO) Instrument 
 
